<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>US7833737B2 - CA IX-specific inhibitors 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US7833737B2/en">
    <meta name="description" content="
     Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labeled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces. In an alternative mode of the invention, CA IX-specific inhibitors may be used therapeutically to target acidic conditions of a tumor, e.g., to increase pHe in order to enhance the efficacy of weak base chemotherapeutic drugs. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="CA IX-specific inhibitors 
       ">
    <meta name="DC.date" content="2007-10-30" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labeled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces. In an alternative mode of the invention, CA IX-specific inhibitors may be used therapeutically to target acidic conditions of a tumor, e.g., to increase pHe in order to enhance the efficacy of weak base chemotherapeutic drugs. 
   
   ">
    <meta name="citation_patent_application_number" content="US:11/929,536">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/94/b5/c1/f1945db619ca01/US7833737.pdf">
    <meta name="citation_patent_number" content="US:7833737">
    <meta name="DC.date" content="2010-11-16" scheme="issue">
    <meta name="DC.contributor" content="Claudiu Supuran" scheme="inventor">
    <meta name="DC.contributor" content="Andrea Scozzafava" scheme="inventor">
    <meta name="DC.contributor" content="Silvia Pastorekova" scheme="inventor">
    <meta name="DC.contributor" content="Jaromir Pastorek" scheme="inventor">
    <meta name="DC.contributor" content="Institute of Virology (Slovak Academy of Science)" scheme="assignee">
    <meta name="DC.relation" content="US:5610304" scheme="references">
    <meta name="DC.relation" content="US:6284923" scheme="references">
    <meta name="DC.relation" content="US:6034099" scheme="references">
    <meta name="citation_reference" content="Alterio et al., &quot;Carbonic Anhydrase Inhibitors: X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX,&quot; J. Am. Chem. Soc., 128: 8329-8335 (2006)." scheme="references">
    <meta name="citation_reference" content="Casey et al., &quot;Carbonic Anhydrase Inhibitors. Design of Selective, Membrane-Impermeant Inhibitors Targeting the Human Tumor-Associated Isozyme IX,&quot; J. Med Chem., 47: 2337-2347 (2004)." scheme="references">
    <meta name="citation_reference" content="Casini et al., &quot;Carbonic Anhydrase Inhibitors: Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects,&quot; J. Med. Chem., 43: 4884-4892 (2000)." scheme="references">
    <meta name="citation_reference" content="Cecchi et al., &quot;Carbonic Anhydrase Inhibitors. Design of Fluorescent Sulfonamides as Probes of Tumor-Associated Carbonic Anhydrase IX That Inhibit Isozyme IX-Mediated Acidification of Hypoxic Tumors,&quot; J. Med. Chem., 48: 4834-4841 (2005)." scheme="references">
    <meta name="citation_reference" content="Chegwidden et al., &quot;The Roles of Carbonic Anhydrase Isozymes in Cancer,&quot; Gene Families: Studies of DNA, RNA, Enzymes and Proteins, Proceedings of the International Isozymes, 10th, Beijing, China, Oct. 5-10, 1999, Meeting Date 1999, 157-169 (Xue, G. ed.: World Scientific Pub. Co.: 2001)." scheme="references">
    <meta name="citation_reference" content="Clare and Supuran, &quot;Carbonic anhydrase inhibitors. Part 61. Quantum Chemical QSAR of a group of benzenedisulfonamides,&quot; Eur. J. Med. Chem., 34: 463-474 (1999)." scheme="references">
    <meta name="citation_reference" content="Cuthbert et al., &quot;Bicarbonate-dependent chloride secretion in Calu-3 epithelia in response to 7,8-benzoquinoline,&quot; J Physiol., 551(Pt 1): 79-92 (Aug. 15, 2003)." scheme="references">
    <meta name="citation_reference" content="Dorwald F. A. (Side reactions in organic synthesis, 2005, Wiley, VCH, Weinheim, p. IX of Preface)." scheme="references">
    <meta name="citation_reference" content="Fischer et al., &quot;Acidic pH Inhibits Non-MHC-Restricted Killer Cell Functions,&quot; Clin. Immunol., 96(3): 252-263 (Sep. 2000)." scheme="references">
    <meta name="citation_reference" content="Franchi et al., &quot;Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Lipophillic Sulfonamides,&quot; Journal of Enzyme Inhibition and Medicinal Chemistry, 18(4): 333-338 (Aug. 2003)." scheme="references">
    <meta name="citation_reference" content="Fukumura et al., &quot;Hypoxia and Acidosis Independently Up-Regulate Vascular Endothelial Growth Factor Transcription in Brain Tumors in Vivo,&quot; Cancer Research, 61: 6020-6024 (Aug. 15, 2001)." scheme="references">
    <meta name="citation_reference" content="Garaj et al., &quot;Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties,&quot; Bioorganic &amp; Medicinal Chemistry Letters, 14: 5427-5433 (2004)." scheme="references">
    <meta name="citation_reference" content="Gerweck, L.E., &quot;Tumor pH: Implications for Treatment and Novel Drug Design,&quot; Seminars in Radiation Oncology, 8(3): 176-182 (Jul. 1998)." scheme="references">
    <meta name="citation_reference" content="Gruneberg et al., &quot;Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation,&quot; J. Med. Chem., 45(17): 3588-3602 (Abstract) (Aug. 15, 2002)." scheme="references">
    <meta name="citation_reference" content="Helmlinger et al., &quot;Acid Production in Glycolysis-impaired Tumors Provides New Insights into Tumor Metabolism,&quot; Clinical Cancer Research, 8: 1284-1291 (Apr. 2002)." scheme="references">
    <meta name="citation_reference" content="Hies et al., &quot;Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide Derivatives,&quot; J. Med. Chem., 46: 2187-2196 (2003)." scheme="references">
    <meta name="citation_reference" content="Ivanov et al., &quot;Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes,&quot; PNAS (USA) 95: 12596-12601 (Oct. 1998)." scheme="references">
    <meta name="citation_reference" content="Kaluz et al., &quot;Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hyposia-inducible Factor lalpha Stabilization: A Role for Phosphatidylinositol 3′Kinase,&quot; Cancer Research, 62: 4469-4477 (Aug. 1, 2002)." scheme="references">
    <meta name="citation_reference" content="Kaluz et al., &quot;Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hyposia-inducible Factor lalpha Stabilization: A Role for Phosphatidylinositol 3'Kinase,&quot; Cancer Research, 62: 4469-4477 (Aug. 1, 2002)." scheme="references">
    <meta name="citation_reference" content="Karumanchi et al., &quot;VHL tumor supressor regulates Cl-/HC03- exchange and Na+/H+ exchange activities in renal carcinoma cells,&quot; Physiol. Genomics, 5: 119-128 (2001)." scheme="references">
    <meta name="citation_reference" content="Karumanchi et al., &quot;VHL tumor supressor regulates Cl−/HC03− exchange and Na+/H+ exchange activities in renal carcinoma cells,&quot; Physiol. Genomics, 5: 119-128 (2001)." scheme="references">
    <meta name="citation_reference" content="Kato et al., &quot;Induction of 103-kDa Gelatinase/Type IV Collagenase by Acidic Culture Conditions in Mouse Metastatic Melanoma Cell Lines,&quot; J. Biol. Chem., 267(16): 11424-11430 (Jun. 5, 1992)." scheme="references">
    <meta name="citation_reference" content="Liu et al. &quot;BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities,&quot; Nucleic Acids Research, 00 (Database Issue): D1-D4 (2006)." scheme="references">
    <meta name="citation_reference" content="Matinez-Zaguilan et al., Acidic pH enhances the invasive behavior of human melanoma cells, Clin. Exp. Metastasis, 14: 176-186 (1996)." scheme="references">
    <meta name="citation_reference" content="Medina et al., &quot;Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells,&quot; Bioorg Med Chem Lett., 9(13): 1843-1846 (Jul. 5, 1999) Abstract." scheme="references">
    <meta name="citation_reference" content="Mekhall et al., &quot;HIF activation of pH-dependent nucleolar sequestration of VHL,&quot; Nature Cell Biology, 6(7): 642-647 (Jul. 2004)." scheme="references">
    <meta name="citation_reference" content="Newell et al., &quot;Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity,&quot; PNAS  (USA), 90: 1127-1131 (Feb. 1993)." scheme="references">
    <meta name="citation_reference" content="Newell et al., &quot;Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity,&quot; PNAS (USA), 90: 1127-1131 (Feb. 1993)." scheme="references">
    <meta name="citation_reference" content="Pastorek et al., &quot;Cloning and characterization of MN, a human tumor-associated protein witha domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,&quot; Oncogene, 9: 2877-2888 (1994)." scheme="references">
    <meta name="citation_reference" content="Pastorekova et al., &quot;Carbonic anhydrase Inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX,&quot; Bioorganic &amp; Medicinal Chemistry Letters, 14: 869-873 (2004)." scheme="references">
    <meta name="citation_reference" content="Potter and Harris, &quot;Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer,&quot; Br. J. Cancer, 89(1): 2-7 (Jul. 7, 2003)." scheme="references">
    <meta name="citation_reference" content="Potter and Harris, &quot;Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumor Hypoxia, Survival Pathway and Therapy Target,&quot; Cell Cycle, 3(2): 164-167 (Feb. 2004)." scheme="references">
    <meta name="citation_reference" content="Raghunand and Gillies, &quot;pH and chemotherapy,&quot; Noyartis Foundation Symposium, 240: 199-211 (2001)." scheme="references">
    <meta name="citation_reference" content="Robertson et al., &quot;Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion,&quot; Cancer Research, 64(17): 6160-6165 (Sep. 1, 2004)." scheme="references">
    <meta name="citation_reference" content="Scozzafava and Supuran, &quot;Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholylthiocarbonylsulfenylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II and IV,&quot;Bioorganic &amp; Medicinal Chemistry Letters, 10: 1117-1120 (2000)." scheme="references">
    <meta name="citation_reference" content="Scozzafava et al., &quot;Carbonic anhydrase inhibitors and activators and their use in therapy,&quot; Expert Opin. Ther. Pat., 16(12): 1627-1664 (2006)." scheme="references">
    <meta name="citation_reference" content="Scozzafava et al., &quot;Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties: Is the Tail More Important than the Ring?&quot; J. Med. Chem., 42: 2641-2650 (1999)." scheme="references">
    <meta name="citation_reference" content="Scozzafava et al., &quot;Carbonic Anhydrase Inhibitors: Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes,&quot; J. Med. Chem., 292-300 (Jan. 27, 2000)." scheme="references">
    <meta name="citation_reference" content="Sterling et al., &quot;A Transport Metabolon,&quot; J. Biol. Chem., 276(51): 47886-47894 (Dec. 21, 2001)." scheme="references">
    <meta name="citation_reference" content="Sterling et al., &quot;The Extracellular Component of a Transport Metabolon,&quot; J. Biol. Chem., 277(28): 25239-25246 (Jul. 12, 2002)." scheme="references">
    <meta name="citation_reference" content="Sterling et al., &quot;The functional anti physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II,&quot; Am. J. Physiol. Cell Phsiol., 283(5): C1522-C1529 (Nov. 2002)." scheme="references">
    <meta name="citation_reference" content="Stubbs et al., &quot;Causes and consequences of tumour acidity and implications for treatment,&quot; Mol. Med. Today, 6: 15-19 (Jan. 2000)." scheme="references">
    <meta name="citation_reference" content="Supuran and Clare, &quot;Carbonic anhydrase inhibitors. Part 24. A quantitative structure-activity relationship study of positively charged sulfonamide inhibitors,&quot; Eur. J. Med. Chem., 30: 687-696 (1995)." scheme="references">
    <meta name="citation_reference" content="Supuran and Clare, &quot;Carbonic anhydrase inhibitors-Part 57: Quantum chemical QSAR of a group of 1,3,4-thladizole- and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties,&quot; Eur. J. Med. Chem., 34: 41-50 (1999)." scheme="references">
    <meta name="citation_reference" content="Supuran and Clare, &quot;Carbonic anhydrase inhibitors—Part 57: Quantum chemical QSAR of a group of 1,3,4-thladizole- and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties,&quot; Eur. J. Med. Chem., 34: 41-50 (1999)." scheme="references">
    <meta name="citation_reference" content="Supuran and Scozzafava, &quot;Benzolamide is not a Membrane-impermeant Carbonic Anhydrase Inhibitor,&quot;Journal of Enzyme Inhibition and Medicinal Chemistry, 19(3): 269-273 (Jun. 2004)." scheme="references">
    <meta name="citation_reference" content="Supuran and Scozzafava, &quot;Carbonic Anhydrase Inhibitors: Aromatic Sulfonamides and Disulfonamides Act as Efficient Tumor Growth Inhibitors,&quot; J. Enzyme Inhib., 15(6): 597-610 (2000)." scheme="references">
    <meta name="citation_reference" content="Supuran and Scozzafava, &quot;Carbonic anhydrase inhibitors-Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?,&quot; Eur. J. Med. Chem., 35(9):867-874 (Sep. 2000)." scheme="references">
    <meta name="citation_reference" content="Supuran and Scozzafava, &quot;Carbonic anhydrase inhibitors—Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?,&quot; Eur. J. Med. Chem., 35(9):867-874 (Sep. 2000)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic Anhydrase Inhibitors,&quot; Medicinal Research Reviews, 23(2): 146-189 (Mar. 2003)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents?,&quot; Bioorganic &amp; Medicinal Chemistry, 9(3): 703-714 (Mar. 2001)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors-Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives,&quot; Eur. J. Med. Chem., 33: 739-751 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors—Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives,&quot; Eur. J. Med. Chem., 33: 739-751 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors-Part 49**: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I,&quot; Eur. J. Med. Chem., 33: 83-93 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors—Part 49**: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I,&quot; Eur. J. Med. Chem., 33: 83-93 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors-Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV,&quot; Eur. J. Med. Chem., 33: 577-594 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic anhydrase inhibitors—Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV,&quot; Eur. J. Med. Chem., 33: 577-594 (1998)." scheme="references">
    <meta name="citation_reference" content="Supuran et al., &quot;Carbonic Anhydrase: Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and In Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes,&quot; J. Enzyme Inhibition, 15(4): 381-401 (2000)." scheme="references">
    <meta name="citation_reference" content="Supuran, Casini and Scozzafava, &quot;Development of Sulfonamide Carbonic Anhydrase Inhibitors,&quot; &quot;Selective Inhibitors for Membrane-Associated CAs,&quot; Carbonic Anhydrase-Its Inhibitors and Activators, Supuran, C.T., Scozzafava, A., Conway, J.; Eds., CRC Press, Boca Raton (FL), USA (2004); pp. 121-124." scheme="references">
    <meta name="citation_reference" content="Supuran, Casini and Scozzafava, &quot;Development of Sulfonamide Carbonic Anhydrase Inhibitors,&quot; &quot;Selective Inhibitors for Membrane-Associated CAs,&quot; Carbonic Anhydrase—Its Inhibitors and Activators, Supuran, C.T., Scozzafava, A., Conway, J.; Eds., CRC Press, Boca Raton (FL), USA (2004); pp. 121-124." scheme="references">
    <meta name="citation_reference" content="Svastova et al., &quot;Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular p11,&quot; FEBS Letters, 577(3): 439-445 (Nov. 19, 2004)." scheme="references">
    <meta name="citation_reference" content="Tanaka et al., &quot;In situ detection of activated caspase-3 in apoptotic granule neurons in the developing cerebellum in slice cultures and in vivo,&quot; Developmental Brain Research, 121(2): 223-228 (2000)." scheme="references">
    <meta name="citation_reference" content="Taylor et al., &quot;Ligand discovery and virtual screening using the program LIDAEUS,&quot; British Journal of Pharmacology, 153: S55-S67 (2008)." scheme="references">
    <meta name="citation_reference" content="Teicher et al., &quot;A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies,&quot; Anticancer Research, 13: 1549-1556 (1993)." scheme="references">
    <meta name="citation_reference" content="Vullo et al., &quot;Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Anions,&quot; Journal of Enzyme Inhibition and Medicinal Chemistry, 18(5): 403-406 (Oct. 2003)." scheme="references">
    <meta name="citation_reference" content="Vullo et al., &quot;Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides,&quot; Bioorganic Medicinal Chemistry Letters, 13(6): 1005-1009 (Mar. 24, 2003)." scheme="references">
    <meta name="citation_reference" content="Wingo et al., &quot;The Catalytic Properties of Human Carbonic Anhydrase IX,&quot; Biochemical and Biophysical Research Communications, 288: 666-669 (2001)." scheme="references">
    <meta name="citation_reference" content="Winnum et al., &quot;Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors,&quot; J. Med. Chem. , 46(11): 2197-2204 (May 22, 2003)." scheme="references">
    <meta name="citation_reference" content="Winum et al., &quot;Carbonic Anhydrase IX: A New Druggable Target for the Design of Antitumor Agents,&quot; Medicinal Research Reviews, 28(3): 445-463 (2008)." scheme="references">
    <meta name="citation_reference" content="Wistrand and Lindqvist, &quot;Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide,&quot; In Carbonic Anhydrase-From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991)." scheme="references">
    <meta name="citation_reference" content="Wistrand and Lindqvist, &quot;Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide,&quot; In Carbonic Anhydrase—From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991)." scheme="references">
    <meta name="citation_reference" content="Workman and Stratford, &quot;The experimental development of bioreductive drugs and their role in cancer therapy,&quot; Cancer and Matastasis Reviews, 12: 73-82 (1993)." scheme="references">
    <meta name="citation_reference" content="Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Ciliary Epithelium, J. Membrane Biol., 162: 31-38 (1998)." scheme="references">
    <meta name="citation_reference" content="Wykoff et al., &quot;Hypoxia-inducible Expression of Tumor-associated Carbonic Anhydrases,&quot; Cancer Research, 60: 7075-7083 (Dec. 15, 2000)." scheme="references">
    <meta name="citation_reference" content="Yamagata et al., &quot;The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase,&quot; British Journal of Cancer, 77(11): 1726-1731 (1998)." scheme="references">
    <meta name="citation_reference" content="Zatovicova et al., &quot;Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX,&quot; Journal of Immunological Methods, 282: 117-134 (2003)." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            CA IX-specific inhibitors 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA81240377" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div num="p-0001" class="abstract style-scope patent-text">Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labeled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces. In an alternative mode of the invention, CA IX-specific inhibitors may be used therapeutically to target acidic conditions of a tumor, e.g., to increase pHe in order to enhance the efficacy of weak base chemotherapeutic drugs.</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">19</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0c/3a/d8/cc77127f2b71d7/US07833737-20101116-D00001.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/b2/3d/38/e84ec599e42213/US07833737-20101116-D00002.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/66/de/98/3ed26d9b4dff30/US07833737-20101116-D00003.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/51/c1/28/5eb14577dfe72b/US07833737-20101116-D00004.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f2/90/40/f81029b8e385cc/US07833737-20101116-D00005.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/fb/53/f0/3ecd5f2f7f2836/US07833737-20101116-D00006.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/48/2c/c3/00ef18409627ec/US07833737-20101116-D00007.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/4e/57/1a/38594160a17c5d/US07833737-20101116-D00008.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/58/b4/9a/dfe64876b42e47/US07833737-20101116-D00009.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/95/5d/f9/43c6616a7cbd9e/US07833737-20101116-D00010.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/68/42/e3/e922df27f6d685/US07833737-20101116-D00011.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/7e/a5/94/3171f7fad568c9/US07833737-20101116-D00012.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/49/37/0c/eaf914230f252e/US07833737-20101116-D00013.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/00/a5/b3/1f9efd07f79fb1/US07833737-20101116-D00014.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/9a/2d/d8/a1ae49e065c30a/US07833737-20101116-D00015.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/01/cd/e7/b4349c3217319e/US07833737-20101116-D00016.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/c8/d2/c0/c695fb00269e8f/US07833737-20101116-D00017.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/6b/b9/e2/8a83274a2d03f0/US07833737-20101116-D00018.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/e5/0a/a9/6507b4fe1e4411/US07833737-20101116-D00019.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/53"><a id="link" href="#" class="style-scope state-modifier">G01N33/53</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="G01N33/574"><a id="link" href="#" class="style-scope state-modifier">G01N33/574</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/16"><a id="link" href="#" class="style-scope state-modifier">A61K31/16</a></state-modifier>
                  <span class="description style-scope classification-tree">Amides, e.g. hydroxamic acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/18"><a id="link" href="#" class="style-scope state-modifier">A61K31/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Sulfonamides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/41"><a id="link" href="#" class="style-scope state-modifier">A61K31/41</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/415"><a id="link" href="#" class="style-scope state-modifier">A61K31/415</a></state-modifier>
                  <span class="description style-scope classification-tree">1,2-Diazoles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/4155"><a id="link" href="#" class="style-scope state-modifier">A61K31/4155</a></state-modifier>
                  <span class="description style-scope classification-tree">1,2-Diazoles non condensed and containing further heterocyclic rings</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/41"><a id="link" href="#" class="style-scope state-modifier">A61K31/41</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/425"><a id="link" href="#" class="style-scope state-modifier">A61K31/425</a></state-modifier>
                  <span class="description style-scope classification-tree">Thiazoles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/428"><a id="link" href="#" class="style-scope state-modifier">A61K31/428</a></state-modifier>
                  <span class="description style-scope classification-tree">Thiazoles condensed with carbocyclic rings</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/435"><a id="link" href="#" class="style-scope state-modifier">A61K31/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/44"><a id="link" href="#" class="style-scope state-modifier">A61K31/44</a></state-modifier>
                  <span class="description style-scope classification-tree">Non condensed pyridines; Hydrogenated derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/435"><a id="link" href="#" class="style-scope state-modifier">A61K31/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/47"><a id="link" href="#" class="style-scope state-modifier">A61K31/47</a></state-modifier>
                  <span class="description style-scope classification-tree">Quinolines; Isoquinolines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/495"><a id="link" href="#" class="style-scope state-modifier">A61K31/495</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/505"><a id="link" href="#" class="style-scope state-modifier">A61K31/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07D"><a id="link" href="#" class="style-scope state-modifier">C07D</a></state-modifier>
                  <span class="description style-scope classification-tree">HETEROCYCLIC COMPOUNDS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07D417/00"><a id="link" href="#" class="style-scope state-modifier">C07D417/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07D417/02"><a id="link" href="#" class="style-scope state-modifier">C07D417/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07D417/12"><a id="link" href="#" class="style-scope state-modifier">C07D417/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N"><a id="link" href="#" class="style-scope state-modifier">C12N</a></state-modifier>
                  <span class="description style-scope classification-tree">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N9/00"><a id="link" href="#" class="style-scope state-modifier">C12N9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N9/88"><a id="link" href="#" class="style-scope state-modifier">C12N9/88</a></state-modifier>
                  <span class="description style-scope classification-tree">Lyases (4.)</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/00"><a id="link" href="#" class="style-scope state-modifier">C12Q1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/527"><a id="link" href="#" class="style-scope state-modifier">C12Q1/527</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 11 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">US7833737B2</h2>
                  <p class="tagline style-scope patent-result">United States</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent ( having previously published pre-grant publication)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/94/b5/c1/f1945db619ca01/US7833737.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;inhibitor&quot;,&quot;activated&quot;,&quot;potent&quot;,&quot;membrane&quot;,&quot;specific&quot;]" data-before="20021126"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/US7833737B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Claudiu Supuran"><a id="link" href="#" class="style-scope state-modifier">Claudiu Supuran</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Andrea Scozzafava"><a id="link" href="#" class="style-scope state-modifier">Andrea Scozzafava</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Silvia Pastorekova"><a id="link" href="#" class="style-scope state-modifier">Silvia Pastorekova</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Jaromir Pastorek"><a id="link" href="#" class="style-scope state-modifier">Jaromir Pastorek</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Institute of Virology (Slovak Academy of Science)
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2005</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833734B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/222,986</div>
                <div class="style-scope application-timeline">Filing date: 2005-09-08</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2007</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8025865B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,652</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833514B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,601</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833738B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,774</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833739B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,816</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,536</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8628771B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/929,750</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application US11/929,536 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2003-11-26</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7550424B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from US10/723,795</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2007-10-30</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Institute of Virology (Slovak Academy of Science)"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Institute of Virology (Slovak Academy of Science)</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="priority style-scope application-timeline">2007-10-30</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority to US11/929,536</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2008-06-19</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20080145877A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US20080145877A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2010-11-16</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2010-11-16</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US7833737B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="reassignment style-scope application-timeline">2013-12-02</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Assigned to INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><iron-icon id="icon" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><overlay-tooltip positioning-target="#icon" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      <div class="description-item style-scope application-timeline">NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS).</div><div class="description-item style-scope application-timeline">Assignors: PASTOREK, JAROMIR, DR., PASTOREKOVA, SILVIA, DR.</div><template is="dom-repeat" class="style-scope application-timeline"></template>
    </div>
  </overlay-tooltip><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2023-11-26</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Expired - Fee Related</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (7)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (76)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (16)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;p=1&amp;u=/netahtml/PTO/srchnum.html&amp;r=1&amp;f=G&amp;l=50&amp;d=PALL&amp;s1=7833737.PN.">USPTO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patentcenter.uspto.gov/applications/11929536">USPTO PatentCenter</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=7833737">USPTO Assignment</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=7833737B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/patent/US/7833737/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/US7833737">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES38797297" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    
    <div num="p-0002" class="description-paragraph style-scope patent-text">This application is a continuation of copending U.S. application Ser. No. 11/222,986 (filed Sep. 8, 2005), which claims priority from U.S. Provisional Application Nos. 60/609,103 (filed on Sep. 9, 2004), and is a continuation-in-part of U.S. Ser. No. 10/723,795 (filed on Nov. 26, 2003), which was issued as U.S. Pat. No. 7,550,424 B2 on Jun. 23, 2009, which claims priority from U.S. Provisional Application Nos. 60/429,089 (filed on Nov. 26, 2002), 60/489,473 (filed on Jul. 22, 2003) and 60/515,140 (filed on Oct. 28, 2003). The above priority applications and parent U.S. application Ser. No. 11/222,986 are hereby incorporated by reference.</div>
    
    
    <heading class="style-scope patent-text">FIELD OF THE INVENTION</heading>
    <div num="p-0003" class="description-paragraph style-scope patent-text">The present invention is in the general area of medical genetics and in the fields of chemistry, biochemical engineering, and oncology. More specifically, it relates to the use of organic and inorganic compounds, preferably aromatic and heterocyclic sulfonamides, to treat preneoplastic and/or neoplastic diseases by specifically inhibiting the carbonic anhydrase activity of the oncoprotein now known alternatively as the MN protein, the MN/CA IX isoenzyme, the MN/G250 protein or simply MN/CA IX or CA IX or MN. The present invention also relates to methods of treating preneoplastic and/or neoplastic diseases characterized by MN/CA IX overexpression by administering cell membrane-impermeant, inhibitors of MN/CA IX, preferably pyridinium derivatives of aromatic and heterocyclic sulfonamides. The invention further concerns diagnostic/prognostic methods including imaging methods, for preneoplastic/neoplastic diseases, using the disclosed potent CA IX-specific inhibitors, and gene therapy with vectors conjugated to said inhibitors.</div>
    <heading class="style-scope patent-text">BACKGROUND OF THE INVENTION</heading>
    <div num="p-0004" class="description-paragraph style-scope patent-text">The instant inventors, Dr. Silvia Pastorekova and Dr. Jaromir Pastorek, with Dr. Jan Zavada [“Zavada et al.”], discovered MN/CA IX, a cancer related cell surface protein originally named MN. [73, 123; Zavada et al., U.S. Pat. No. 5,387,676 (Feb. 7, 1995).] Zavada et al., WO 93/18152 (published 16 Sep. 1993) and Zavada et al., WO 95/34650 (published 21 Dec. 1995) disclosed the discovery of the MN gene and protein and the strong association of MN gene expression and tumorigenicity led to the creation of methods that are both diagnostic/prognostic and therapeutic for cancer and precancerous conditions. Zavada et al. disclosed further aspects of the MN/CA IX protein and the MN/CA9 gene in Zavada et al., WO 00/24913 (published 4 May 2000).</div>
    <div num="p-0005" class="description-paragraph style-scope patent-text">Zavada et al. cloned and sequenced the MN cDNA and gene, and revealed that MN belongs to a carbonic anhydrase family of enzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and proton [66, 72]. MN protein (renamed to carbonic anhydrase IX, CA IX) is composed of an extracellular part containing a N-terminal proteoglycan-like region and a catalytically active carbonic anhydrase domain. It is anchored in the plasma membrane by a single transmembrane region and a short intracytoplasmic tail.</div>
    <div num="p-0006" class="description-paragraph style-scope patent-text">Expression of CA IX is restricted to only few normal tissues [74], but is tightly associated with tumors [123]. It is also regulated by cell density in vitro [52] and is strongly induced by tumor hypoxia both in vitro and in vivo [121]. Numerous clinical papers describe the value of CA IX as an indicator of poor prognosis. All CA IX-related studies performed so far support the assumption made in the original Zavada et al., U.S. Pat. No. 5,387,676 that CA IX is useful as a diagnostic and/or prognostic tumor marker and as a therapeutic target.</div>
    <div num="p-0007" class="description-paragraph style-scope patent-text">MN/CA IX consists of an N-terminal proteoglycan-like domain that is unique among the CAs, a highly active CA catalytic domain, a single transmembrane region and a short intracytoplasmic tail [66, 72, 74, 116]. CA IX is particularly interesting for its ectopic expression in a multitude of carcinomas derived from cervix uteri, ovarian, kidney, lung, esophagus, breast, colon, endometrial, bladder, colorectal, prostate, among many other human carcinomas, contrasting with its restricted expression in normal tissues, namely in the epithelia of the gastrointestinal tract [8, 11, 21, 35, 41, 48, 50, 51, 56, 66, 72, 74, 86, 110, 111, 113, 116, 121, 122].</div>
    <div num="p-0008" class="description-paragraph style-scope patent-text">Uemura et al. [112] reported in 1997 that the G250 antigen was identical to MN/CA IX, years after MN/CA IX had been discovered and sequenced by Zavada et al. {[73, 123]; see also Pastorek et al. [72] and Opavsky et al. [66]}. Uemura et al. [112] stated: “Sequence analysis and database searching revealed that G250 antigen is identical to MN a human tumor-associated antigen identified in cervical carcinoma (Pastorek et al., 1994).”</div>
    <div num="h-0003" class="description-paragraph style-scope patent-text">MN/<figure-callout id="9" label="CA" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">CA</a></figure-callout> 9 and MN/CA IX—Sequence Similarities</div>
    <div num="p-0009" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-C</figref> shows the full-length MN/CA9 cDNA sequence of 1522 base pairs (bps) [SEQ ID NO: 1], and the full-length MN/CA IX amino acid (aa) sequence of 459 aa [SEQ ID NO: 2]. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A-F</figref> provides the 10,898 bp genomic sequence of MN/CA9 [SEQ ID NO: 3].</div>
    <div num="p-0010" class="description-paragraph style-scope patent-text">Computer analysis of the MN cDNA sequence was carried out using DNASIS and PROSIS (Pharmacia Software packages). GenBank, EMBL, Protein Identification Resource and SWISS-PROT databases were searched for all possible sequence similarities. In addition, a search for proteins sharing sequence similarities with MN was performed in the MIPS databank with the FastA program [75].</div>
    <div num="p-0011" class="description-paragraph style-scope patent-text">The proteoglycan-like domain [aa 53-111; SEQ ID NO: 4] which is between the signal peptide and the CA domain, shows significant homology (38% identity and 44% positively) with a keratan sulphate attachment domain of a human large aggregating proteoglycan aggrecan [28].</div>
    <div num="p-0012" class="description-paragraph style-scope patent-text">The CA domain [aa 135-391; SEQ ID NO: 5] is spread over 265 aa and shows 38.9% amino acid identity with the human CA VI isoenzyme [5]. The homology between MN/CA IX and other isoenzymes is as follows: 35.2% with CA II in a 261 aa overlap [63], 31.8% with CA I in a 261 aa overlap [7], 31.6% with CA IV in a 266 aa overlap [65], and 30.5% with CA III in a 259 aa overlap [55].</div>
    <div num="p-0013" class="description-paragraph style-scope patent-text">In addition to the CA domain, MN/CA IX has acquired both N-terminal and C-terminal extensions that are unrelated to the other CA isoenzymes. The amino acid sequence of the C-terminal part, consisting of the transmembrane anchor and the intracytoplasmic tail, shows no significant homology to any known protein sequence.</div>
    <div num="p-0014" class="description-paragraph style-scope patent-text">The MN gene (MN/CA9 or CA9) was clearly found to be a novel sequence derived from the human genome. The overall sequence homology between the cDNA MN/CA9 sequence and cDNA sequences encoding different CA isoenzymes is in a homology range of 48-50% which is considered by ones in the art to be low. Therefore, the MN/CA9 cDNA sequence is not closely related to any CA cDNA sequences.</div>
    <div num="p-0015" class="description-paragraph style-scope patent-text">Very few normal tissues have been found to express MN protein to any significant degree. Those MN-expressing normal tissues include the human gastric mucosa and gallbladder epithelium, and some other normal tissues of the alimentary tract. Paradoxically, MN gene expression has been found to be lost or reduced in carcinomas and other preneoplastic/neoplastic diseases in some tissues that normally express MN, e.g., gastric mucosa.</div>
    <div num="h-0004" class="description-paragraph style-scope patent-text">CA IX, Hypoxia and Acidification of Extracellular Environment</div>
    <div num="p-0016" class="description-paragraph style-scope patent-text">Strong association between CA IX expression and intratumoral hypoxia (either measured by microelectrodes, or detected by incorporation of a hypoxic marker pimonidazole, or by evaluation of extent of necrosis) has been demonstrated in the cervical, breast, head and neck, bladder and non-small cell lung carcinomas (NSCLC) [8, 11, 21, 35, 48, 56, 111, 122]. Moreover, in NSCLC and breast carcinomas, correlation between CA IX and a constellation of proteins involved in angiogenesis, apoptosis inhibition and cell-cell adhesion disruption has been observed, possibly contributing to strong relationship of this enzyme to a poor clinical outcome [8]. Hypoxia is linked with acidification of extracellular milieu that facilitates tumor invasion and CA IX is believed to play a role in this process via its catalytic activity [86]. Thus, inhibition of MN/CA IX by specific inhibitors is considered to constitute a novel approach to the treatment of cancers in which CA IX is expressed.</div>
    <div num="p-0017" class="description-paragraph style-scope patent-text">Acidic extracellular pH (pHe) has been associated with tumor progression via multiple effects including up-regulation of angiogenic factors and proteases, increased invasion, and impaired immune functions [86, 124, 125, 130, 132]. In addition, it can influence the uptake of anticancer drugs and modulate the response of tumor cells to conventional therapy [86, 126]. Acidification of the tumor microenvironment was generally assigned to accumulation of lactic acid excessively produced by glycolysis and poorly removed by inadequate tumor vasculature. A high rate of glycolysis is especially important for hypoxic cells that largely depend on anaerobic metabolism for energy generation. However, experiments with glycolysis-deficient cells indicate that production of lactic acid is not the only mechanism leading to tumor acidity. The deficient cells produce only diminished amounts of lactic acid, but form acidic tumors in vivo [134, 144]. A comparison of the metabolic profiles of the glycolysis-impaired and parental cells revealed that CO<sub class="style-scope patent-text">2</sub>, in addition to lactic acid, is a significant source of acidity in tumors [127]. That data indicates that carbonic anhydrases could contribute to the acidification of the tumor microenvironment.</div>
    <div num="p-0018" class="description-paragraph style-scope patent-text">The CA IX isoform is identified herein as the best candidate for the role in acidifying the tumor microenvironment. First, CA IX is an integral plasma membrane protein with an extracellularly exposed enzyme active site [66, 72]. Second, CA IX has a very high catalytic activity with the highest proton transfer rate among the known CAs [116]. Third, CA IX is present in few normal tissues, but its ectopic expression is strongly associated with many frequently occurring tumors. Finally, CA IX level dramatically increases in response to hypoxia via a direct transcriptional activation of CA9 gene by HIF-1 [121], and its expression in tumors is a sign of poor prognosis [136]. Taken together, CA IX is herein considered to have all the qualities necessary to control tumor pH. That concept is supported by the proof provided herein that CA IX has the capacity to acidify extracellular pH.</div>
    <div num="h-0005" class="description-paragraph style-scope patent-text">CAIs</div>
    <div num="p-0019" class="description-paragraph style-scope patent-text">Teicher et al. [106] reported that acetazolamide—the prototypical CA inhibitor (CAI)—functions as a modulator in anticancer therapies, in combination with different cytotoxic agents, such as alkylating agents; nucleoside analogs; platinum derivatives, among other such agents, to suppress tumor metastasis and to reduce the invasive capacity of several renal carcinoma cell lines (Caki-1, Caki-2, ACHN, and A-498). Such studies demonstrate that CAIs may be used in the management of tumors that overexpress one or more CA isozymes. It was hypothesized that the anticancer effects of acetazolamide (alone or in combination with such drugs) might be due to the acidification of the intratumoral environment ensuing after CA inhibition, although other mechanisms of action of this drug were not excluded [20]. Chegwidden et al. 2001 hypothesized that the in vitro inhibition of growth in cell cultures, of human lymphoma cells with two other potent, clinically used sulfonamide CAIs, methazolamide and ethoxzolamide, is probably due to a reduced provision of bicarbonate for nucleotide synthesis (HCO<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">−</sup> is the substrate of carbamoyl phosphate synthetase II) as a consequence of CA inhibition [20].</div>
    <div num="p-0020" class="description-paragraph style-scope patent-text">All the six classical CAIs (acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, and dichlorophenamide) used in clinical medicine or as diagnostic tools, show some tumor growth inhibitory properties [18, 78, 101, 102].</div>
    <div num="p-0021" class="description-paragraph style-scope patent-text">The inventors, Dr. Claudia Supuran and Dr. Andrea Scozzafava, reported the design and in vitro antitumor activity of several classes of sulfonamide CAIs, shown to act as nanomolar inhibitors against the classical isozymes known to possess critical physiological roles, such as CA I, CA II and CA IV. Those compounds were also shown to exert potent inhibition of cell growth in several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines, with GI<sub class="style-scope patent-text">50 </sub>values of 10-75 nM in some cases [77, 91, 92, 100].</div>
    <div num="p-0022" class="description-paragraph style-scope patent-text">Wingo et al. reported that three classic sulfonamide drugs (acetozolamide, ethoxzolamide and methoxzolamide) inhibited CA IX carbonic anhydrase activity with values of K<sub class="style-scope patent-text">I </sub>in the nanomolar range [116]. However, until the present invention, no systematic structure-activity relationship study of sulfonamide inhibition of CA IX, alone or in comparison to other CA isozymes had been performed.</div>
    <div num="p-0023" class="description-paragraph style-scope patent-text">Certain pyridinium derivatives of aromatic/heterocyclic sulfonamides have shown nanomolar affinities both for CA II, as well as CA IV, and more importantly, they were unable to cross the plasma membranes in vivo [17].</div>
    <div num="p-0024" class="description-paragraph style-scope patent-text">Sterling et al. [85] investigated the functional and physical relationship between the downregulated in adenoma bicarbonate transporter and CA II, by using membrane-impermeant sulfonamide inhibitors (in addition to the classical inhibitors such as acetazolamide), which could clearly discriminate between the contribution of the cytosolic and membrane-associated isozymes in these physiological processes.</div>
    <div num="h-0006" class="description-paragraph style-scope patent-text">CAS</div>
    <div num="p-0025" class="description-paragraph style-scope patent-text">Carbonic anhydrases (CAs) form a large family of genes encoding zinc metalloenzymes of great physiological importance. As catalysts of reversible hydration of carbon dioxide, these enzymes participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, formation of aqueous humor, cerebrospinal fluid, saliva and gastric acid [reviewed in Dodgson et al. (27)]. CAs are widely distributed in different living organisms. In higher vertebrates, including humans, 14 different CA isozymes or CA-related proteins (CARP) have been described, with very different subcellular localization and tissue distribution [40, 93, 95, 94, 102]. Basically, there are several cytosolic forms (CA I-III, CA VII), four membrane-bound isozymes (CA IV, CA IX, CA XII and CA XIV), one mitochondrial form (CA V) as well as a secreted CA isozyme, CA VI [40, 93, 94, 95, 102].</div>
    <div num="p-0026" class="description-paragraph style-scope patent-text">It has been shown that some tumor cells predominantly express only some membrane-associated CA isozymes, such as CA IX and CA XII [2, 67, 68, 78, 87, 93, 95]. Occasionally, nuclear localization of some isoenzymes has been noted [64, 69, 70]. Not much is presently known about the cellular localization of the other isozymes.</div>
    <div num="p-0027" class="description-paragraph style-scope patent-text">CAs and CA-related proteins show extensive diversity in their tissue distribution, levels, and putative or established biological functions [105]. Some of the CAs are expressed in almost all tissues (CA II), while the expression of others appears to be more restricted (e.g., CA VI and CA VII in salivary glands [32, 69, 71]. The CAs and CA-related proteins also differ in kinetic properties and susceptibility to inhibitors [82].</div>
    <div num="p-0028" class="description-paragraph style-scope patent-text">Most of the clinically used sulfonamides mentioned above are systemically acting inhibitors showing several undesired side effects due to inhibition of many of the different CA isozymes present in the target tissue/organ (14 isoforms are presently known in humans) [93, 94, 95, 102]. Therefore, many attempts to design and synthesize new sulfonamides were recently reported, in order to avoid such side effects [13, 17, 42, 62, 80, 99, 100]. At least four CA isozymes (CA IV, CA IX, CA XII and CA XIV) are associated to cell membranes, with the enzyme active site generally oriented extracellularly [93, 94, 95, 102]. Some of these isozymes were shown to play pivotal physiological roles (such as for example CA IV and XII in the eye, lungs and kidneys, CA IX in the gastric mucosa and many tumor cells) [3, 18, 22, 29, 49, 67, 68, 83, 93, 94, 95, 102], whereas the function of other such isozymes (CA XIV) is for the moment less well understood [93, 95]. Due to the extracellular location of these isozymes, if membrane-impermeant CA inhibitors (CAIs) could be designed, only membrane-associated CAs would be affected.</div>
    <div num="p-0029" class="description-paragraph style-scope patent-text">The first approach towards introducing the membrane-impermeability to CAIs from the historical point of view was that of attaching aromatic/heterocyclic sulfonamides to polymers, such as polyethyleneglycol, aminoethyldextran, or dextran [39, 60, 107]. Such compounds, possessing molecular weights in the range of 3.5-99 kDa, prepared in that way, showed indeed membrane-impermeability due to their high molecular weights, and selectively inhibited in vivo only CA IV and not the cytosolic isozymes (primarily CA II), being used in several renal and pulmonary physiological studies [39, 60, 107]. Due to their macromolecular nature, such inhibitors could not be developed as drugs/diagnostic tools, since in vivo they induced potent allergic reactions [39, 60, 93, 95, 107]. A second approach for achieving membrane-impermeability is that of using highly polar, salt-like compounds. Only one such sulfonamide has until recently been used in physiological studies, QAS (quaternary ammonium sulphanilamide), which has been reported to inhibit only extracellular CAs in a variety of arthropods (such as the crab <i class="style-scope patent-text">Callinectes sapidus</i>) and fish [57]. The main draw-back of QAS is its high toxicity in higher vertebrates [57].</div>
    <div num="p-0030" class="description-paragraph style-scope patent-text">Enzyme activity of carbonic anhydrases (including that of CA IX) can be efficiently blocked by sulfonamide inhibitors. That fact has been therapeutically exploited in diseases caused by excessive activities of certain CA isoforms (e.g. CA II in glaucoma). There is also an experimental evidence that sulfonamides may block tumor cell proliferation and invasion in vitro and tumor growth in vivo, but the targets of those sulfonamides have not been identified yet. However, the sulfonamides available so far indiscriminately inhibit various CA isoenzymes (14 are presently known in humans) that are localized in different subcellular compartments and play diverse biological roles. This lack of selectivity compromises the clinical utilization of these compounds (due to undesired side effects caused by concurrent inhibition of many CA isoforms) and represents a main drawback also for the sulfonamide application against CA IX in anticancer therapy.</div>
    <div num="p-0031" class="description-paragraph style-scope patent-text">Thus, there is a need in the art for membrane-impermeant, potent CA IX inhibitors, which would become doubly selective inhibitors for CA IX. The inventors have previously made and described some of the membrane-impermeant molecules described here; however, they were characterized only for their ability to inhibit CA I, CA II and CA IV. While others have studied effects of selective inhibition of extracellular CA by membrane impermeant agents in retinal prigmented epithelia or muscle [34, 120], these agents have not been characterized for their ability to inhibit CA IX. Since CA IX is one of the few extracellular carbonic anhydrases, a membrane-impermeant selective inhibitor of CA IX would be doubly selective for this enzyme and thereby avoid side effects associated with nonspecific CA inhibition.</div>
    <heading class="style-scope patent-text">SUMMARY OF THE INVENTION</heading>
    <div num="p-0032" class="description-paragraph style-scope patent-text">The inventors have shown that MN/CA IX contributes to acidification of extracellular pH in hypoxia but not in normoxia. MN/CA IX-selective sulfonamides are shown to reduce the medium acidification and to bind only to hypoxic cells containing the wild type MN/CA IX. MN/CA IX's contributing to the acidification of the hypoxic extracellular milieu is considered to have important implications for the development of cancer. The disclosed experimental results indicate that hypoxia up-regulates both the expression level and enzyme activity of MN/CA IX, that is, hypoxia activates the CA catalytic activity of MN/CA IX. That is a very important finding because intratumoral hypoxia is a clinically relevant factor increasing aggressiveness of tumor cells and reducing success of therapy.</div>
    <div num="p-0033" class="description-paragraph style-scope patent-text">The invention concerns in one aspect diagnostic/prognostic and therapeutic methods for preneoplastic/neoplastic disease associated with abnormal MN/CA IX expression, comprising the use of MN/CA IX-specific inhibitors which bind preferentially to the activated form of the CA domain of MN/CA IX, and not to the inactive form of the CA domain of MN/CA IX. Preferred inhibitors according to the methods of the invention are activated MN/CA IX-specific inhibitors which are labeled, and which can be used to identify regions of hypoxic MN/CA IX expression, and not non-hypoxic MN/CA IX expression. Exemplary activated MN/CA IX-specific inhibitors include the sulfonamide Compounds 5, 6, 39 and 92, whose structures are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 4A and 8A</figref>.</div>
    <div num="p-0034" class="description-paragraph style-scope patent-text">Further, MN/CA IX-specific inhibitors which are useful according to the methods of the invention may comprise any molecules that preferentially bind only the activated form of the CA domain of MN/CA IX, and not the inactive form of the CA domain of MN/CA IX. Such molecules may be organic or inorganic, preferably organic molecules. Such organic molecules may be sulfonamides or antibodies which selectively bind the activated form of the CA domain of MN/CA IX. Preferred organic molecules include monoclonal antibodies which specifically bind the activated form of the CA domain of MN/CA IX.</div>
    <div num="p-0035" class="description-paragraph style-scope patent-text">In one aspect, the invention concerns a diagnostic/prognostic method for a preneoplastic/neoplastic disease associated with abnormal MN/CA IX expression, comprising determining whether MN/CA IX is activated in a vertebrate sample, comprising a) contacting said sample with a specific inhibitor of activated MN/CA IX, and b) detecting or detecting and quantifying binding of said specific inhibitor of activated MN/CA IX in said sample; wherein binding of said inhibitor to said MN/CA IX indicates that said MN/CA IX is activated, preferably wherein said activated MN/CA IX is hypoxia-activated.</div>
    <div num="p-0036" class="description-paragraph style-scope patent-text">Preferably, said specific inhibitor of activated MN/CA IX is an MN/CA IX-specific sulfonamide or an MN/CA IX-specific antibody. Preferably said specific sulfonamide inhibitor of activated MN/CA IX is an aromatic sulfonamide or a heterocyclic sulfonamide. Alternatively, said sulfonamide specific inhibitor of activated MN/CA IX is a membrane-impermeant pyridinium derivative of an aromatic sulfonamide or a membrane-impermeant pyridinium derivative of a heterocyclic sulfonamide. Also preferably, said MN/CA IX-specific sulfonamide is selected from the group consisting of Compounds 1-92, whose structures are shown in Tables 2 and 3, and/or <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 4 and 8A</figref>. Further preferably, said MN/CA IX-specific sulfonamide is selected from the group consisting of <figure-callout id="5" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="39" label="Compounds" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="92" label="Compounds" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 5, 6, 39, or 92. Said specific inhibitor of activated MN/CA IX can be conjugated to a label or a visualizing means, preferably fluorescein isothiocyanate, wherein said detecting or detecting and quantifying binding comprises detecting or detecting and quantifying said label or said visualizing means on cells in said sample, and wherein said detecting or said detecting and quantifying at a level above that for a control sample is indicative of hypoxic precancerous or cancerous cells that abnormally express activated MN/CA IX in said sample. Said method may further comprise detecting the binding of an antibody that specifically binds to a domain of the MN/CA IX protein other than the carbonic anhydrase domain.</div>
    <div num="p-0037" class="description-paragraph style-scope patent-text">Another exemplary method that is diagnostic or diagnostic and prognostic for precancer and/or cancer comprises contacting a mammalian sample with a MN/CA IX-specific inhibitor conjugated to a label or a visualizing means, and detecting or detecting and quantifying binding of said MN/CA IX-specific inhibitor to cells in said sample by detecting or detecting and quantifying said label or said visualizing means on cells in said sample, wherein said detection or said detection and quantitation at a level above that for a control sample is indicative of precancerous or cancerous cells that overexpress MN/CA IX in said sample. Such a method can be of particular diagnostic and prognostic importance by detecting or detecting and quantitating MN/CA IX activated by hypoxic conditions. Hypoxia combined with MN/CA IX overepression indicates that the mammal from whom the sample was taken is considered to have a poorer prognosis, and decisions on treatment for said mammal are made in view of the presence of said hypoxic conditions.</div>
    <div num="p-0038" class="description-paragraph style-scope patent-text">MN/CA IX as a hypoxia marker is useful in general in making therapeutic decisions. For example, a cancer patient whose tumor is known to express MN/CA IX at an abnormally high level would not be a candidate for certain kinds of chemotherapy and radiotherapy, but would be a candidate for hypoxia-selective chemotherapy.</div>
    <div num="p-0039" class="description-paragraph style-scope patent-text">In one embodiment of the invention, MN/CA IX-specific inhibitors are used in methods that aid in selecting patient therapy, for example, in a method wherein the inhibitor's binding to activated MN/CA IX is detectable at a level above that for a control sample, and hypoxia-selective therapy is selected. Preferably such hypoxia-selective therapy comprises the use of drugs that are toxic only under hypoxic conditions, for example, wherein the therapy comprises the use of tirapazamine or AQ4N. In another embodiment of the invention, the inhibitor's binding to activated MN/CA IX is not detectable at a level above that for a control sample, and the therapy consequently selected is radiotherapy and/or non-hypoxia-selective chemotherapy.</div>
    <div num="p-0040" class="description-paragraph style-scope patent-text">In another aspect, the invention concerns a method of imaging hypoxic tissues in a patient, comprising a) administering to said patient a specific inhibitor of activated MN/CA IX, said inhibitor linked to an imaging agent; and b) detecting the binding of said inhibitor. Said specific inhibitor of activated MN/CA IX is preferably an MN/CA IX-specific sulfonamide or an MN/CA IX-specific antibody. More preferably, said MN/CA IX-specific sulfonamide is an aromatic or a heterocyclic sulfonamide, and said MN/CA IX-specific antibody is a monoclonal antibody.</div>
    <div num="p-0041" class="description-paragraph style-scope patent-text">Still another aspect of the invention concerns a method of therapy for a preneoplastic/neoplastic disease associated with hypoxic tissues, comprising administering a specific inhibitor of activated MN/CA IX, preferably an MN/CA IX-specific sulfonamide. Preferably, said specific inhibitor of activated MN/CA IX is an aromatic sulfonamide or a heterocyclic sulfonamide. Alternatively, said specific inhibitor of activated MN/CA IX is preferably a membrane-impermeant pyridinium derivative of an aromatic sulfonamide or a membrane-impermeant pyridinium derivative of a heterocyclic sulfonamide. More preferably, said MN/CA IX-specific sulfonamide is selected from the group consisting of Compounds I-92. Most preferably, said MN/CA IX-specific sulfonamide is selected from the group consisting of <figure-callout id="5" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="39" label="Compounds" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="92" label="Compounds" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 5, 6, 39, or 92.</div>
    <div num="p-0042" class="description-paragraph style-scope patent-text">Said specific inhibitor of activated MN/CA IX can also be an MN/CA IX-specific antibody, alone or conjugated to a toxic and/or cytostatic agent; preferably said MN/CA IX-specific antibody is a monoclonal antibody.</div>
    <div num="p-0043" class="description-paragraph style-scope patent-text">In another embodiment of the invention, the method of therapy comprises the use of a specific inhibitor of activated MN/CA IX conjugated to a vector comprising a gene that expresses a cytotoxic protein. Said vector may further comprise a MN/CA9 promoter or MN/CA9 promoter fragment, and/or one or more hypoxia response elements.</div>
    <div num="p-0044" class="description-paragraph style-scope patent-text">In still another embodiment of the invention, the method of therapy comprises the use of a specific inhibitor of activated MN/CA IX to modulate the efficiency of chemotherapeutic drugs whose uptake or activity is pH-dependent.</div>
    <div num="p-0045" class="description-paragraph style-scope patent-text">The instant invention is related to (1) the recognition that certain carbonic anhydrase inhibitors (CAIs), preferably sulfonamides, selectively target the cancer-related, hypoxia-induced MN/CA IX; (2) the use of such CAIs, preferably sulfonamides, as lead compounds for the design and synthesis of MN/CA IX-specific inhibitors; (3) the employment of said MN/CA IX-specific inhibitors for anticancer therapy based upon the inhibition of MN/CA IX-mediated acidification of tumor microenvironments; and (4) the use of the specificity of potent MN/CA IX-specific inhibitors for diagnostic/prognostic methods including imaging methods, such as scintigraphy, and for gene therapy. The invention is particularly directed to the use of MN/CA IX-specific inhibitors for the development of drugs possessing anticancer properties and to modulate conventional chemotherapy for preneoplastic and neoplastic disease characterized by MN/CA IX expression, particularly MN/CA IX overexpression.</div>
    <div num="p-0046" class="description-paragraph style-scope patent-text">In one aspect, the invention concerns methods of treating a mammal for a pre-cancerous or cancerous disease, wherein said disease is characterized by overexpression of MN/CA IX protein, comprising administering to said mammal a therapeutically effective amount of a composition comprising a compound, wherein said compound is selected from the group consisting of organic and inorganic molecules, and wherein said compound is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay to determine the K<sub class="style-scope patent-text">I </sub>of a compound inhibiting the enzymatic activity of MN/CA IX, wherein if said inhibition constant K<sub class="style-scope patent-text">I </sub>is determined to be less than about 50 nanomolar, said compound is determined be a potent inhibitor of MN/CA IX enzymatic activity; and wherein said compound is not selected from the group consisting of acetazolamide, ethoxzolamide, methazolamide and cyanate. Said mammal is preferably human, and said K<sub class="style-scope patent-text">I </sub>is preferably less than about 35 nanomolar, more preferably less than about 25 nanomolar, and still more preferably less than about 10 nanomolar. Exemplary enzymatic screening assays that can be used to determine the K<sub class="style-scope patent-text">I </sub>of a compound inhibiting the enzymatic activity of MN/CA IX are described below under “Enzyme Assays” in the Materials and Methods section, and also described in references cited in Table 1, which are hereby incorporated by reference.</div>
    <div num="p-0047" class="description-paragraph style-scope patent-text">Such methods can also be framed as methods of treating precancer and/or cancer, or inhibiting the growth of precancerous and/or cancerous cells in a mammalian subject, wherein said precancer and cancer are characterized by the overexpression of MN/CA IX. Said methods can also be framed as inhibiting the growth of such precancerous or cancerous mammalian cells overexpressing MN/CA IX comprising contacting said cells with a MN/CA IX-specific inhibitor of this invention.</div>
    <div num="p-0048" class="description-paragraph style-scope patent-text">The MN/CA IX-specific inhibitors of this invention can be administered in a therapeutically effective amount, preferably dispersed in a physiologically acceptable nontoxic liquid vehicle. Different routes of administration may be preferred depending on the site or type of preneoplastic/neoplastic disease, for example, solid or non-solid tumor or metastasis. In general, parenteral administration would be preferred to avoid undesired effects of systemic treatment, for example, those that could be occasioned by binding of the inhibitors to the gastrointestinal mucosa. Injection into or into the vicinity of the preneoplastic/neoplastic disease would be generally preferred. For example, such injections could be intravenous, intraperitoneal, rectal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intramedullary, intralesional, intradermal, among other routes of injection. Also, other modes of administration, for example, by suppository or topically, can be used as would be appropriate to the target disease. The pharmaceutical formulation would be designed in accordance with known standards as suitable for the route of administration.</div>
    <div num="p-0049" class="description-paragraph style-scope patent-text">Said MN/CA IX-specific inhibitors are preferably organic, more preferably aromatic or heterocyclic, and still more preferably an aromatic sulfonamide or a heterocyclic sulfonamide. Said aromatic sulfonamide may be a substituted aromatic sulfonamide, wherein said aromatic sulfonamide comprises an aromatic ring structure bearing a sulfonamide moiety bonded to said ring structure and optionally bearing one or more substituents independently selected from the group consisting of halogeno, nitro, and an alkylamino group, wherein the alkyl radical of said alkylamino group comprises 1 to 4 carbon atoms.</div>
    <div num="p-0050" class="description-paragraph style-scope patent-text">Preferably the MN/CA IX-specific inhibitors of this invention are more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of a carbonic anhydrase selected from the group consisting of CA I, CA II and CA IV. More preferably, the MN/CA IX-specific inhibitors are more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of at least two carbonic anhydrases selected from the group consisting of CA I, CA II and CA IV. Still more preferably, the MN/CA IX-specific inhibitors are more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of each of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    <div num="p-0051" class="description-paragraph style-scope patent-text">However, since CA II is a particularly abundant and significant CA, that is cytosolic, it is important when the MN/CA IX-specific inhibitors of this invention are not membrane-impermeant, that they may be more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of CA II. Exemplary enzymatic screening assays to determine the K<sub class="style-scope patent-text">I </sub>of CA II inhibitors are described below under “Enzyme Assays” in the Materials and Methods section, and also described in references cited in Table 1, which are hereby incorporated by reference.</div>
    <div num="p-0052" class="description-paragraph style-scope patent-text">Exemplary and preferred aromatic sulfonamide or heterocyclic sulfonamide MN/CA IX-specific inhibitors of this invention are selected from the group consisting of Compounds 1-26 shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref>, and their FITC-derivatives. Exemplary preferred aromatic sulfonamide MN/CA IX-specific aromatic sulfonamides are <figure-callout id="1" label="Compounds" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> 1, 6, and 23-26. A preferred aromatic sulfonamide MN/CA IX-specific inhibitor can be that wherein a halogen atom is bonded to at least one carbon atom in the aromatic ring of said aromatic sulfonamide. Particularly preferred aromatic sulfonamide MN/CA IX-specific inhibitors are selected from the group consisting of <figure-callout id="5" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="6" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> 5 and 6, and the FITC-derivative of <figure-callout id="5" label="Compound" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 5, Compound 92 (whose structure is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8A</figref>). Particularly preferred heterocyclic sulfonamide MN/CA IX-specific inhibitors are <figure-callout id="14" label="Compounds" filenames="US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="15" label="Compounds" filenames="US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="21" label="Compounds" filenames="US07833737-20101116-D00012.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="22" label="Compounds" filenames="US07833737-20101116-D00012.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 14, 15, 21 and 22.</div>
    <div num="p-0053" class="description-paragraph style-scope patent-text">Preferred heterocyclic sulfonamide MN/CA IX-specific inhibitors can be substituted heterocyclic sulfonamides, wherein said substituted heterocyclic sulfonamide comprises a heterocyclic ring structure bearing a sulfonamide moiety bonded to said ring structure and optionally bearing one or more substituents independently selected from a group consisting of halogeno, nitro, and an alkylamino group, wherein the alkyl radical of said alkylamino group comprises 1 to 4 carbon atoms. Preferred heterocyclic sulfonamide MN/CA IX-specific inhibitors may be halogenated.</div>
    <div num="p-0054" class="description-paragraph style-scope patent-text">Further preferred methods of treating mammals for pre-cancerous or cancerous disease, wherein said disease is characterized by overexpression of MN/CA IX protein, comprise administering to said mammal membrane-impermeant MN/CA IX-specific inhibitors. A therapeutically effective amount of such a membrane-impermeant MN/CA IX-specific inhibitor can be administered in a composition comprising the membrane-impermeant compound, wherein said membrane-impermeant inhibitor compound is selected from the group consisting of organic and inorganic molecules, and wherein said membrane-impermeant compound is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay.</div>
    <div num="p-0055" class="description-paragraph style-scope patent-text">Such a membrane-impermeant MN/CA IX specific inhibitor compound is preferably organic, and more preferably a pyridinium derivative of an aromatic sulfonamide or a pyridinium derivative of a heterocyclic sulfonamide. Such membrane-impermeant MN/CA IX-specific inhibitor compounds are preferably more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of a carbonic anhydrase selected from the group consisting of CA I, CA II and CA IV, and still more preferably more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of at least two carbonic anhydrases selected from the group consisting of CA I, CA II and CA IV. Further more preferably, said membrane-impermeant MN/CA IX-specific inhibitor compounds are more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of each of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV. Since both MN/CA IX and CA IV are membrane bound CAs, it is particularly important that the membrane-impermeant MN/CA IX-specific inhibitor compounds are more potent inhibitors of MN/CA IX enzymatic activity than of the enzymatic activity of CA IV.</div>
    <div num="p-0056" class="description-paragraph style-scope patent-text">Exemplary enzymatic screening assays that can be used to determine the K<sub class="style-scope patent-text">I </sub>of a compound inhibiting the enzymatic activity of CA IV are described below under “Enzyme Assays” in the Materials and Methods section, and also in references cited in Table 1, which are hereby incorporated by reference.</div>
    <div num="p-0057" class="description-paragraph style-scope patent-text">Preferred membrane-impermeant MN/CA IX-specific inhibitor compounds that are pyridinium derivatives of aromatic sulfonamides are selected from the group consisting of sulfanilamide, homosulfanilamide and 4-aminoethyl-benzenesulfonamide. Preferred pyridinium derivatives of aromatic sulfonamides can have the general formula of:</div>
    <div num="p-0058" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00001" num="00001" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/37/9e/db/19df9c01e13419/US07833737-20101116-C00001.png" class="style-scope patent-text"><img id="EMI-C00001" he="23.28mm" wi="60.96mm" file="US07833737-20101116-C00001.TIF" alt="Figure US07833737-20101116-C00001" img-content="chem" img-format="tif" width="244" height="93" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/37/9e/db/19df9c01e13419/US07833737-20101116-C00001.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US07833737-20101116-C00001.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US07833737-20101116-C00001.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div num="p-0059" class="description-paragraph style-scope patent-text">wherein</div>
    <div num="p-0060" class="description-paragraph style-scope patent-text">n is 0, 1, or 2;</div>
    <div num="p-0061" class="description-paragraph style-scope patent-text">R2, R3, R4 and R6 are each independently selected from the group consisting of hydrogen, alkyl moieties comprising from 1 to 12 carbon atoms, and aryl moieties. Further preferred pyridinium derivatives of aromatic sulfonamides are Compounds 27-70 shown in Table 2. Exemplary preferred pyridinium derivatives of aromatic sulfonamides are <figure-callout id="39" label="Compounds" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> 39, 55, 58, 59 and 70. Particularly preferred is <figure-callout id="39" label="Compound" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 39 shown in Table 2 and <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8A</figref>.</div>
    <div num="p-0062" class="description-paragraph style-scope patent-text">When said MN/CA IX-specific inhibitors are membrane-impermeant pyridinium derivatives of a heterocyclic sulfonamides, a preferred compound is a pyridinium derivative of aminobenzolamide.</div>
    <div num="p-0063" class="description-paragraph style-scope patent-text">Preferred MN/CA IX-specific inhibitor compounds that are pyridinium derivatives of heterocyclic sulfonamides may have the general formula of:</div>
    <div num="p-0064" class="description-paragraph style-scope patent-text">
      <chemistry id="CHEM-US-00002" num="00002" class="style-scope patent-text">
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/9b/a9/1b/d3a9e0abc12bf4/US07833737-20101116-C00002.png" class="style-scope patent-text"><img id="EMI-C00002" he="21.51mm" wi="70.27mm" file="US07833737-20101116-C00002.TIF" alt="Figure US07833737-20101116-C00002" img-content="chem" img-format="tif" width="281" height="86" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/9b/a9/1b/d3a9e0abc12bf4/US07833737-20101116-C00002.png"></a></div>
        <attachments class="style-scope patent-text">
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US07833737-20101116-C00002.CDX" class="style-scope patent-text"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US07833737-20101116-C00002.MOL" class="style-scope patent-text"> </attachment>
        </attachments>
      </chemistry>
    </div>
    <div num="p-0065" class="description-paragraph style-scope patent-text">wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl moieties comprising from 1 to 12 carbon atoms, and aryl moieties. Further preferred pyridinium derivatives of heterocyclic sulfonamides are Compounds 71-91 shown in Table 3.</div>
    <div num="p-0066" class="description-paragraph style-scope patent-text">In another aspect, this invention concerns methods of inhibiting tumor growth in a patient having a tumor, the cells of which tumor are characterized by overexpression of MN/CA IX protein, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound, wherein said compound is selected from the group consisting of organic and inorganic molecules, and wherein said compound is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay as outlined above.</div>
    <div num="p-0067" class="description-paragraph style-scope patent-text">In another therapeutic aspect of the invention, the MN/CA IX-specific inhibitors can be conjugated to radioisotopes for administration. Also, the MN/CA IX-specific inhibitors can be administred concurrently and/or sequentially with radiation and/or with a therapeutically effective amount in a physiologically acceptable formulation of one or more of the following compounds selected from the group consisting of: conventional anticancer drugs, chemotherapeutic agents, different inhibitors of cancer-related pathways, bioreductive drugs, MN/CA IX-specific antibodies and MN/CA IX-specific antibody fragments that are biologically active. Preferably said MN/CA IX-specific antibodies and/or MN/CA IX-specific antibody fragments are humanized or fully human, and may be attached to a cytotoxic entity.</div>
    <div num="p-0068" class="description-paragraph style-scope patent-text">In another therapeutic aspect, this invention concerns methods of treating a mammal for a precancerous or cancerous disease, wherein said disease is characterized by overexpression of MN/CA IX protein, comprising administering to said mammal a therapeutically effective amount in a physiologically acceptable formulation of a vector conjugated to a potent MN/CA IX-specific inhibitor, wherein said vector expresses a wild-type gene that is absent from or mutated in a MN/CA IX expressing cell, that is precancerous or cancerous, and wherein the wild type gene product has an anticancer effect in said cell; or wherein said vector comprises a gene that expresses a cytotoxic protein. An exemplary wild-type gene would be the von Hippel-Lindau gene known to be directly involved in the constitutive expression of MN/CA IX in renal cell carcinoma.</div>
    <div num="p-0069" class="description-paragraph style-scope patent-text">Preferably said vector comprises a MN/CA IX promoter or a MN/CA IX promoter fragment, wherein said promoter or promoter fragment comprises one or more hypoxia response elements (HREs), and wherein said promoter or promoter fragment is operably linked to said wild-type gene or to said gene that expresses a cytotoxic protein. Preferably the MN/CA IX-specific inhibitor conjugated to the vector has a K<sub class="style-scope patent-text">I </sub>as determined in a CO<sub class="style-scope patent-text">2 </sub>saturation assay to be less than about 50 nM, more preferably less than about 35 nM, still more preferably less than about 25 nM and still further more preferably less than about 10 nM. Preferably, said potent MN/CA IX inhibitor is not selected from the group consisting of acetazolamide, ethoxzolamide, methazolamide and cyanate.</div>
    <div num="p-0070" class="description-paragraph style-scope patent-text">Brown, J. M. [16] points out at <figure-callout id="157" label="page" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">page</a></figure-callout> 157 that “solid tumours are considerably less well oxygenated than normal tissues. This leads to resistance to radiotherapy and anticancer chemotherapy, as well as predisposing to increased tumour metastases.” Brown explains how tumor hypoxia can be exploited in cancer treatment. One strategy to exploit tumor hypoxia for cancer treatment proposed by Brown [16] is to use drugs that are toxic only under hypoxic conditions. Exemplary and preferred drugs that could be used under that strategy include tirapazamine and AQ4N, a di-N-oxide analogue of mitozantrome.</div>
    <div num="p-0071" class="description-paragraph style-scope patent-text">A second mode of exploiting hypoxia proposed by Brown [16] is by gene therapy strategies developed to take advantage of the selective induction of HIF-1. Brown notes that a tumor-specific delivery system can be developed wherein a promoter that is highly responsive to HIF-1 would drive the expression of a conditionally lethal gene under hypoxic but not normoxic conditions. The MN/CA IX promoter is just such a promoter highly responsive to hypoxia, as well as MN/CA IX promoter fragments comprising one or more HREs. “Expression of an enzyme not normally found in the human body could, under the control of a hypoxia-responsive promoter [the MN/CA IX promoter], convert a nontoxic pro-drug into a toxic drug in the tumour.” [Brown [16], page 160.] Exemplary is the use of the bacterial cytosine deaminase, which converts the nontoxic 5-fluorocytosine to the anticancer drug 5-fluorouracil (5FU) cited by Brown to Trinh et al. [109].</div>
    <div num="p-0072" class="description-paragraph style-scope patent-text">Ratcliffe et al., U.S. Pat. Nos. 5,942,434 and 6,265,390 explain how anti-cancer drugs become activated under hypoxia [119], but that the use of a drug activation system, wherein the enzyme that activates the drug is significantly increased under hypoxia, results in much enhanced therapeutic effect.</div>
    <div num="p-0073" class="description-paragraph style-scope patent-text">This invention further concerns methods for imaging tumors and/or metastases that express MN/CA IX in a patient comprising the administration of a MN/CA IX-specific inhibitor linked to an imaging agent to said patient. A preferred imaging method would encompass scintigraphy.</div>
    <div num="p-0074" class="description-paragraph style-scope patent-text">The assays of this invention are both diagnostic and/or prognostic, i.e., diagnostic/prognostic. The term “diagnostic/prognostic” is herein defined to encompass the following processes either individually or cumulatively depending upon the clinical context: determining the presence of disease, determining the nature of a disease, distinguishing one disease from another, forecasting as to the probable outcome of a disease state, determining the prospect as to recovery from a disease as indicated by the nature and symptoms of a case, monitoring the disease status of a patient, monitoring a patient for recurrence of disease, and/or determining the preferred therapeutic regimen for a patient. The diagnostic/prognostic methods of this invention are useful, for example, for screening populations for the presence of neoplastic or pre-neoplastic disease, determining the risk of developing neoplastic disease, diagnosing the presence of neoplastic and/or pre-neoplastic disease, monitoring the disease status of patients with neoplastic disease, and/or determining the prognosis for the course of neoplastic disease.</div>
    <div num="p-0075" class="description-paragraph style-scope patent-text">The present invention is useful for treating and for screening the presence of a wide variety of preneoplastic/neoplastic diseases including carcinomas, such as, mammary, colorectal, urinary tract, ovarian, uterine, cervical, endometrial, squamous cell and adenosquamous carcinomas; head and neck cancers; mesodermal tumors, such as, neuroblastomas and retinoblastomas; sarcomas, such as osteosarcomas and Ewing's sarcoma; and melanomas. Of particular interest are gynecological cancers including ovarian, uterine, cervical, vaginal, vulval and endometrial cancers, particularly ovarian, uterine cervical and endometrial cancers. Also of particular interest are cancers of the breast, of gastrointestinal tract, of the stomach including esophagus, of the colon, of the kidney, of the prostate, of the liver, of the urinary tract including bladder, of the lung, and of the head and neck. Gynecologic cancers of particular interest are carcinomas of the uterine cervix, endometrium and ovaries; more particularly such gynecologic cancers include cervical squamous cell carcinomas, adenosquamous carcinomas, adenocarcinomas as well as gynecologic precancerous conditions, such as metaplastic cervical tissues and condylomas.</div>
    <div num="p-0076" class="description-paragraph style-scope patent-text">The invention provides methods and compositions for evaluating the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such an assay can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The assays can also be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy and/or radiation therapy. It can further be used to monitor cancer chemotherapy and tumor reappearance.</div>
    <div num="p-0077" class="description-paragraph style-scope patent-text">The presence of MN antigen can be detected and/or quantitated using a number of well-defined diagnostic assays. Those in the art can adapt any of the conventional immunoassay formats to detect and/or quantitate MN antigen as herein disclosed. The immunoassays of this invention can be embodied in test kits which comprise the potent MN/CA IX-specific inhibitors of this invention, appropriately labeled and/or linked to a visualizing means, as known in the art. Such test kits can be in solid phase formats, but are not limited thereto, and can also be in liquid phase format, and can be based on immunohistochemical assays, ELISAS, particle assays, radiometric or fluorometric assays either unamplified or amplified, using, for example, avidin/biotin technology, among other assay formats.</div>
    <div num="p-0078" class="description-paragraph style-scope patent-text">Exemplary MN/CA IX-specific inhibitors of the invention are shown herein to treat transfected cells that constitutively express MN/CA IX compared to non-transfected cells with no MN/CA IX expression. The exemplary MN/CA IX-specific inhibitors are shown to inhibit acidification of extracellular pH induced by MN/CA IX in cell cultures exposed to hypoxia.</div>
    <div num="p-0079" class="description-paragraph style-scope patent-text">Further, labeled exemplary MN/CA IX-specific inhibitors, such as labeled sulfonamides, for example, conjugated to fluorescein isothiocyanate (FITC), are shown to bind to the surface of MN/CA IX transfected cells, and not to control cells, only in hypoxia but not in normoxia. Those experiments confirm that MN/CA IX-specific inhibitors, such as the sulfonamide compounds described herein, can specifically target MN/CA IX under conditions characteristic of intratumoral microenvironments.</div>
    <div num="p-0080" class="description-paragraph style-scope patent-text">The MN/CA IX-specific inhibitors of this invention can be used diagnostically and prognostically for precancer and cancer, and to determine the status of a patient, and therapeutically, individually or in different combinations with conventional therapeutic regimens to treat precancers and/or cancer. The MN/CA IX-specific inhibitors may also be used in cancer research.</div>
    <div num="p-0081" class="description-paragraph style-scope patent-text">More particularly for treating precancer and/or cancer, the MN/CA IX-specific inhibitors of this invention can be used to hinder cancer expansion and/or progression by blocking MN/CA IX activity. The MN/CA IX-specific inhibitors can be conjugated to radioisotopes for radiotherapy. The MN/CA IX-specific inhibitors can be combined with MN/CA IX-specific antibodies and a variety of conventional therapeutic drugs, different inhibitors of cancer-related pathways, bioreductive drugs, and/or radiotherapy, wherein different combinations of treatment regimens with the MN/CA IX-specific inhibitors of this invention may increase overall treatment efficacy. Particularly, the MN/CA IX-specific inhibitors of this invention may be combined with therapy using MN/CA IX-specific antibodies and/or MN/CA IX-specific antibody fragments, preferably humanized MN/CA IX-specific antibodies and/or biologically active fragments thereof, and more preferably fully human MN/CA IX-specific antibodies and/or fully human MN/CA IX-specific biologically active antibody fragments. Said MN/CA IX-specific antibodies and biologically active MN/CA IX-specific antibody fragments, preferably humanized and more preferably fully human, may be conjugated to a cytotoxic entity, for example, a cytotoxic protein, such as ricin A, among many other cytotoxic entities.</div>
    <div num="p-0082" class="description-paragraph style-scope patent-text">Still further, a MN/CA IX-specific inhibitor of this invention could be coupled to a vector for targeted delivery to MN/CA IX-specific expressing cells for gene therapy (for example, with the wild-type von Hippel-Lindau gene), or for effecting the expression of cytotoxic proteins, preferably wherein said vector comprises a MN/CA IX promoter or MN/CA IX promoter fragment comprising the MN/CA IX hypoxia response element (HRE) or a HRE of another gene, and more preferably wherein the MN/CA IX promoter or MN/CA IX promotor fragment comprises more than one HRE, wherein said HRE or HREs is or are either of MN/CA IX, and/or of other genes and/or of genetically engineered HRE consensus sequences in a preferred context.</div>
    <div num="p-0083" class="description-paragraph style-scope patent-text">Particularly, the MN/CA IX-specific inhibitors of this invention can be used diagnostically/prognostically to detect precancerous and/or cancerous cells by binding to MN/CA IX, preferably to MN/CA IX activated by hypoxic conditions, wherein said MN/CA IX specific inhibitors are coupled to a label or to some visualizing means. Such detection, particularly of hypoxic conditions, and MN/CA IX overexpression, can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Further the MN/CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can be used for imaging tumors and/or metastases that express MN/CA IX.</div>
    <div num="p-0084" class="description-paragraph style-scope patent-text">The MN/CA IX-specific inhibitors of this invention can also be used in basic and pre-clinical research. For example, the MN/CA IX-specific inhibitors can be used to study the regulation of MN/CA IX enzyme activity, to study the role of MN/CA IX in tumor growth and metabolism, and to study the role of MN/CA IX in response to treatment by drugs, radiation, inhibitors and other therapeutic regimens.</div>
    <div num="p-0085" class="description-paragraph style-scope patent-text">Further provided are screening assays for compounds that are useful for inhibiting the growth of a vertebrate, preferably mammalian, more preferably human, preneoplastic or neoplastic cell that abnormally expresses MN protein. Said screening assays comprise tests for the inhibition of the enzymatic activity of MN by said compounds. Additional assays provided herein test said compounds for their cell membrane impermeance.</div>
    <div num="p-0086" class="description-paragraph style-scope patent-text">Aspects of the instant invention disclosed herein are described in more detail below.</div>
    <heading class="style-scope patent-text">REFERENCES</heading>
    <div num="p-0087" class="description-paragraph style-scope patent-text">The following references are cited throughout the application by numbers in italics keyed to the list below:
</div> <ul class="style-scope patent-text"> <li id="ul0001-0001" num="0087" class="style-scope patent-text">1. Abbate et al., <i class="style-scope patent-text">J. Med. Chem., </i>45: 3583-3587 (2002).</li> <li id="ul0001-0002" num="0088" class="style-scope patent-text">2. Abbate et al., <i class="style-scope patent-text">J. Enz. Inhib. Med. Chem., </i>18: 303-308 (2003a).</li> <li id="ul0001-0003" num="0089" class="style-scope patent-text">3. Abbate et al., <i class="style-scope patent-text">Bioorg. Med. Chem. Lett., </i>13: In Press (2003b).</li> <li id="ul0001-0004" num="0090" class="style-scope patent-text">4. Abdine et al., <i class="style-scope patent-text">J. Assoc. Off. Anal. Chem., </i>61: 695-701 (1978).</li> <li id="ul0001-0005" num="0091" class="style-scope patent-text">5. Aldred et al., <i class="style-scope patent-text">Biochemistry, </i>30: 569-575 (1991).</li> <li id="ul0001-0006" num="0092" class="style-scope patent-text">6. Balaban et al., “Pyrylium Salts: Syntheses, Reactions and Physical Properties,” In <i class="style-scope patent-text">Advances in Heterocyclic Chemistry</i>, Katritzky, A. R., Ed., Academic Press, New York, pp. 8-360 (1982).</li> <li id="ul0001-0007" num="0093" class="style-scope patent-text">7. Barlow et al., <i class="style-scope patent-text">Nucl. Acids Res., </i>15: 2386 (1987).</li> <li id="ul0001-0008" num="0094" class="style-scope patent-text">8. Bartosova et al., <i class="style-scope patent-text">J. Pathol., </i>197: 314-321 (2002).</li> <li id="ul0001-0009" num="0095" class="style-scope patent-text">9. Bayer, A., <i class="style-scope patent-text">Ber. Dtsch. Chem. Ges., </i>43: 2337-2349 (1910).</li> <li id="ul0001-0010" num="0096" class="style-scope patent-text">10. Bayer and Piccard, Liebigs <i class="style-scope patent-text">Ann. Chem., </i>384: 208-223 (1911).</li> <li id="ul0001-0011" num="0097" class="style-scope patent-text">11. Beasley et al., <i class="style-scope patent-text">Cancer Res., </i>61: 5262-5267 (2001).</li> <li id="ul0001-0012" num="0098" class="style-scope patent-text">12. Behravan et al., <i class="style-scope patent-text">Eur. J. Biochem., </i>190: 351-357 (1990).</li> <li id="ul0001-0013" num="0099" class="style-scope patent-text">13. Borras et al., <i class="style-scope patent-text">Bioorg. Med. Chem., </i>7: 2397-2406 (1999).</li> <li id="ul0001-0014" num="0100" class="style-scope patent-text">14. Briganti et al., <i class="style-scope patent-text">Biochemistry, </i>36: 10384-10392 (1997).</li> <li id="ul0001-0015" num="0101" class="style-scope patent-text">15. Briganti et al., <i class="style-scope patent-text">Inorg. Chim. Acta.: </i>275-276, 295-300 (1998).</li> <li id="ul0001-0016" num="0102" class="style-scope patent-text">16. Brown, J. M., “Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies,” <i class="style-scope patent-text">Molecular Medicine Today, </i>6: 157-162 (April 2000).</li> <li id="ul0001-0017" num="0103" class="style-scope patent-text">17. Casini et al., <i class="style-scope patent-text">J. Med. Chem., </i>43: 4488-4892 (2000).</li> <li id="ul0001-0018" num="0104" class="style-scope patent-text">18. Casini et al., <i class="style-scope patent-text">Curr. Cancer Drug Targets, </i>2: 55-75 (2002).</li> <li id="ul0001-0019" num="0105" class="style-scope patent-text">19. a) Casini et al., <i class="style-scope patent-text">Bioorg. Med. Chem. Lett., </i>13: 841-845 (2003).</li> <li id="ul0001-0020" num="0106" class="style-scope patent-text"> b) Casini et al., <i class="style-scope patent-text">Biorg. Med. Chem. Lett., </i>13: 2763-2769 (2003).</li> <li id="ul0001-0021" num="0107" class="style-scope patent-text">20. Chegwidden et al., “The Roles of carbonic anhydrase isozymes in cancer,” <i class="style-scope patent-text">Gene Families Studies of DNA, RNA, Enzymes and Proteins</i>, Xue et al., Eds., World Scientific, Singapore, pp. 157-169 (2001).</li> <li id="ul0001-0022" num="0108" class="style-scope patent-text">21. Chia et al., <i class="style-scope patent-text">J. Clin. Oncol., </i>19: 3660-3668 (2001).</li> <li id="ul0001-0023" num="0109" class="style-scope patent-text">22. Chirica et al., <i class="style-scope patent-text">Biochim. Biophys. Acta, </i>1544: 55-63 (2001).</li> <li id="ul0001-0024" num="0110" class="style-scope patent-text">23. Clare and Supuran, <i class="style-scope patent-text">Eur. J. Med., Chem.: </i>32: 311-319 (1997).</li> <li id="ul0001-0025" num="0111" class="style-scope patent-text">24. Clare and Supuran, <i class="style-scope patent-text">Eur. J. Med. Chem., </i>34: 463-474 (1999).</li> <li id="ul0001-0026" num="0112" class="style-scope patent-text">25. Cuthbert et al., <i class="style-scope patent-text">J. Physiol., </i>551 (Pt. 1) 79-92, (2003).</li> <li id="ul0001-0027" num="0113" class="style-scope patent-text">26. Dinculescu and Balaban, <i class="style-scope patent-text">Rev. Roum. Chem., </i>25: 1505-1528 (1980).</li> <li id="ul0001-0028" num="0114" class="style-scope patent-text">27. Dodgson et al., <i class="style-scope patent-text">The Carbonic Anhydrases</i>, Plenum Press, New York-London, pp. 398 (1991).</li> <li id="ul0001-0029" num="0115" class="style-scope patent-text">28. Doege et al., <i class="style-scope patent-text">J. Biol. Chem., </i>266: 894-902 (1991).</li> <li id="ul0001-0030" num="0116" class="style-scope patent-text">29. Elleby et al., <i class="style-scope patent-text">Eur. J. Biochem., </i>268: 1613-1619 (2001).</li> <li id="ul0001-0031" num="0117" class="style-scope patent-text">30. Ferraroni et al., <i class="style-scope patent-text">Biochemistry, </i>41: 6237-6244 (2002a).</li> <li id="ul0001-0032" num="0118" class="style-scope patent-text">31. Ferraroni et al., <i class="style-scope patent-text">Inorg. Chim. Acta, </i>339: 135-144 (2002b).</li> <li id="ul0001-0033" num="0119" class="style-scope patent-text">32. Fleming et al., <i class="style-scope patent-text">J. Clin. Invest., </i>96: 2907-2913 (1995).</li> <li id="ul0001-0034" num="0120" class="style-scope patent-text">33. Franchi et al., <i class="style-scope patent-text">J. Enz. Inhib. Med. Chem., </i>18: 333-338 (2003).</li> <li id="ul0001-0035" num="0121" class="style-scope patent-text">34. Geers and Gros, <i class="style-scope patent-text">Physiol. Rev. </i>80:681-715 (2000).</li> <li id="ul0001-0036" num="0122" class="style-scope patent-text">35. Giatromanolaki et al., <i class="style-scope patent-text">Cancer Res., </i>61: 7992-7998 (2001).</li> <li id="ul0001-0037" num="0123" class="style-scope patent-text">36. Gomaa, Z. S., <i class="style-scope patent-text">Biomed. Chromatogr., </i>7: 134-135 (1993).</li> <li id="ul0001-0038" num="0124" class="style-scope patent-text">37. Gruneberg et al., <i class="style-scope patent-text">Angew. Chem. Int. Ed., </i>40: 389-393 (2001).</li> <li id="ul0001-0039" num="0125" class="style-scope patent-text">38. Hakansson et al., <i class="style-scope patent-text">J. Mol. Biol., </i>227: 1192-1204 (1992).</li> <li id="ul0001-0040" num="0126" class="style-scope patent-text">39. Heming et al., <i class="style-scope patent-text">J. Appl. Physiol., </i>61: 1849-1856 (1986).</li> <li id="ul0001-0041" num="0127" class="style-scope patent-text">40. Hewett-Emmett, D., “Evolution and distribution of the carbonic anhydrase gene families,” In <i class="style-scope patent-text">The Carbonic Anhydrases—New Horizons</i>, Chegwidden et al., Eds., Birkhauser Verlag: Basel, Switzerland, pp. 29-78 (2000).</li> <li id="ul0001-0042" num="0128" class="style-scope patent-text">41. Höckel and Vaupel, <i class="style-scope patent-text">J. Natl. Cancer Inst., </i>93: 266-276 (2001).</li> <li id="ul0001-0043" num="0129" class="style-scope patent-text">42. Ilies et al., <i class="style-scope patent-text">Bioorg. Med. Chem., </i>8: 2145-2155 (2000).</li> <li id="ul0001-0044" num="0130" class="style-scope patent-text">43. Ilies et al., <i class="style-scope patent-text">J. Med. Chem., </i>46: 2187-2196 (2003).</li> <li id="ul0001-0045" num="0131" class="style-scope patent-text">44. Khalifah, R. G., <i class="style-scope patent-text">J. Biol. Chem., </i>246: 2561-2573 (1971).</li> <li id="ul0001-0046" num="0132" class="style-scope patent-text">45. Khalifah et al., <i class="style-scope patent-text">Biochemistry, </i>16: 2241-2247 (1977).</li> <li id="ul0001-0047" num="0133" class="style-scope patent-text">46. Kim et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>122: 12125-12134 (2000).</li> <li id="ul0001-0048" num="0134" class="style-scope patent-text">47. Kim et al., <i class="style-scope patent-text">J. Am. Chem. Soc., </i>123: 9620-9627 (2001).</li> <li id="ul0001-0049" num="0135" class="style-scope patent-text">48. Koukourakis et al., <i class="style-scope patent-text">Clin. Cancer Res., </i>7: 3399-3403 (2001).</li> <li id="ul0001-0050" num="0136" class="style-scope patent-text">49. Krungkrai et al., <i class="style-scope patent-text">Int. J. Parasitol., </i>31: 661-668 (2001).</li> <li id="ul0001-0051" num="0137" class="style-scope patent-text">50. Liao et al., <i class="style-scope patent-text">Am. J. Pathol., </i>145: 598-609 (1994).</li> <li id="ul0001-0052" num="0138" class="style-scope patent-text">51. Liao et al., <i class="style-scope patent-text">Cancer Res., </i>57: 2827-2831 (1997).</li> <li id="ul0001-0053" num="0139" class="style-scope patent-text">52. Lieskovska et al., <i class="style-scope patent-text">Neoplasma, </i>46: 17-24 (1999).</li> <li id="ul0001-0054" num="0140" class="style-scope patent-text">53. Lindskog and Coleman, <i class="style-scope patent-text">Proc. Natl. Acad. Sci</i>. (USA) 70: 2505-2508 (1964).</li> <li id="ul0001-0055" num="0141" class="style-scope patent-text">54. Lindskog et al., “Structure-function relations in human carbonic anhydrase II as studied by site-directed mutagenesis,” in <i class="style-scope patent-text">Carbonic anhydrase—From biochemistry and genetics to Physiology and clinical medicine</i>, Botre et al., Eds., VCH, Weinheim, pp. 1-13 (1991)].</li> <li id="ul0001-0056" num="0142" class="style-scope patent-text">55. Lloyd et al., <i class="style-scope patent-text">Genes. Dev., </i>1: 594-602 (1987).</li> <li id="ul0001-0057" num="0143" class="style-scope patent-text">56. Loncaster et al., <i class="style-scope patent-text">Cancer Res., </i>61: 6394-6399 (2001).</li> <li id="ul0001-0058" num="0144" class="style-scope patent-text">57. Maren, T. H., <i class="style-scope patent-text">Physiol. Rev., </i>47: 595-781 (1967).</li> <li id="ul0001-0059" num="0145" class="style-scope patent-text">58. Maren, T. H., “Benzolamide—a renal carbonic anhydrase inhibitor,” In <i class="style-scope patent-text">Orphan Drugs</i>, Karch, T. E., Ed., M. Dekker, New York, pp. 89-115 (1982).</li> <li id="ul0001-0060" num="0146" class="style-scope patent-text">59. Maren et al., <i class="style-scope patent-text">Mol. Pharmacol., </i>44: 901-906 (1993).</li> <li id="ul0001-0061" num="0147" class="style-scope patent-text">60. Maren et al., <i class="style-scope patent-text">J. Pharmacol. Exp. Ther., </i>280: 98-104 (1997).</li> <li id="ul0001-0062" num="0148" class="style-scope patent-text">61. Mendelsohn and Lippman, “Growth Factors,” pp. 114-133, IN: DeVita et al. (eds.), <i class="style-scope patent-text">Cancer: Principles and Practice of Oncology </i>(4<sup class="style-scope patent-text">th </sup>Ed.; Lippincott; Philadelphia, 1993).</li> <li id="ul0001-0063" num="0149" class="style-scope patent-text">62. Mincione et al., <i class="style-scope patent-text">Eur. J. Pharm. Sci., </i>9: 185-199 (1999).</li> <li id="ul0001-0064" num="0150" class="style-scope patent-text">63. Montgomery et al., <i class="style-scope patent-text">Nucl. Acids. Res., </i>15: 4687 (1987).</li> <li id="ul0001-0065" num="0151" class="style-scope patent-text">64. Mori et al., <i class="style-scope patent-text">Gastroenterol., </i>105: 820-826 (1993).</li> <li id="ul0001-0066" num="0152" class="style-scope patent-text">65. Okuyama et al., <i class="style-scope patent-text">PNAS </i>(USA) 89: 1315-1319 (1992).</li> <li id="ul0001-0067" num="0153" class="style-scope patent-text">66. Opavsky et al., <i class="style-scope patent-text">Genomics, </i>33: 480-487 (1996).</li> <li id="ul0001-0068" num="0154" class="style-scope patent-text">67. Owa and Nagasu, <i class="style-scope patent-text">Exp. Opin. Ther. Patents, </i>10: 1725-1740 (2000).</li> <li id="ul0001-0069" num="0155" class="style-scope patent-text">68. Owa et al., <i class="style-scope patent-text">J. Med. Chem., </i>42: 3789-3799 (1999).</li> <li id="ul0001-0070" num="0156" class="style-scope patent-text">69. Parkkila et al., <i class="style-scope patent-text">Gut, </i>35: 646-650 (1994).</li> <li id="ul0001-0071" num="0157" class="style-scope patent-text">70. Parkkilla et al., <i class="style-scope patent-text">Histochem. J., </i>27: 133-138 (1995).</li> <li id="ul0001-0072" num="0158" class="style-scope patent-text">71. Parkkila et al., <i class="style-scope patent-text">Hepatology, </i>24: 104 (1996).</li> <li id="ul0001-0073" num="0159" class="style-scope patent-text">72. Pastorek et al., <i class="style-scope patent-text">Oncogene, </i>9: 2788-2888 (1994).</li> <li id="ul0001-0074" num="0160" class="style-scope patent-text">73. Pastorekova et al., <i class="style-scope patent-text">Virology, </i>187: 620-626 (1992).</li> <li id="ul0001-0075" num="0161" class="style-scope patent-text">74. Pastorekova et al., <i class="style-scope patent-text">Gastroenterology, </i>112: 398-408 (1997).</li> <li id="ul0001-0076" num="0162" class="style-scope patent-text">75. Pearson and Lipman, <i class="style-scope patent-text">PNAS </i>(USA), 85: 2444 (1988).</li> <li id="ul0001-0077" num="0163" class="style-scope patent-text">76. Pocker and Stone, <i class="style-scope patent-text">Biochemistry, </i>6: 668-678 (1967).</li> <li id="ul0001-0078" num="0164" class="style-scope patent-text">77. Scozzafava and Supuran, <i class="style-scope patent-text">Bioorg. Med. Chem. Lett., </i>10: 1117-1120(2000).</li> <li id="ul0001-0079" num="0165" class="style-scope patent-text">78. Scozzafava et al., <i class="style-scope patent-text">Curr. Med. Chem., </i>10: 925-953 (2003).</li> <li id="ul0001-0080" num="0166" class="style-scope patent-text">79. Scozzafava et al., <i class="style-scope patent-text">J. Med. Chem., </i>42: 2641-2650 (1999).</li> <li id="ul0001-0081" num="0167" class="style-scope patent-text">80. Scozzafava et al., <i class="style-scope patent-text">J. Med. Chem., </i>42: 3690-3700 1999)</li> <li id="ul0001-0082" num="0168" class="style-scope patent-text">81. Scozzafava et al., <i class="style-scope patent-text">J. Med. Chem., </i>43: 292-300 (2000).</li> <li id="ul0001-0083" num="0169" class="style-scope patent-text">82. Sly and Hu, <i class="style-scope patent-text">Annu. Rev. Biochem., </i>64: 375-401 (1995).</li> <li id="ul0001-0084" num="0170" class="style-scope patent-text">83. Smith and Ferry, <i class="style-scope patent-text">FEMS Microbiol. Rev., </i>24: 335-366 (2000).</li> <li id="ul0001-0085" num="0171" class="style-scope patent-text">84. Steiner et al., <i class="style-scope patent-text">Eur. J. Biochem., </i>59: 253-259 (1975).</li> <li id="ul0001-0086" num="0172" class="style-scope patent-text">85. Sterling et al., <i class="style-scope patent-text">Am. J. Physiol</i>.-<i class="style-scope patent-text">Cell Physiol., </i>283: C1522-C1529 (2002).</li> <li id="ul0001-0087" num="0173" class="style-scope patent-text">86. Stubbs et al., <i class="style-scope patent-text">Mol. Med. Today, </i>6: 15-19 (2000).</li> <li id="ul0001-0088" num="0174" class="style-scope patent-text">87. Supuran, C. T., <i class="style-scope patent-text">Opin. Investig. Drugs, </i>12: 283-287 (2003).</li> <li id="ul0001-0089" num="0175" class="style-scope patent-text">88. Supuran and Clare, <i class="style-scope patent-text">Eur J. Med. Chem., </i>30: 687-696 (1995).</li> <li id="ul0001-0090" num="0176" class="style-scope patent-text">89. Supuran and Clare, <i class="style-scope patent-text">Eur J. Med. Chem., </i>33: 489-500 (1998).</li> <li id="ul0001-0091" num="0177" class="style-scope patent-text">90. Supuran and Clare, <i class="style-scope patent-text">Eur. J. Med. Chem., </i>34: 41-50 (1999).</li> <li id="ul0001-0092" num="0178" class="style-scope patent-text">91. Supuran and Scozzafava, <i class="style-scope patent-text">J. Enzyme Inhib., </i>15: 597-610 (2000a).</li> <li id="ul0001-0093" num="0179" class="style-scope patent-text">92. Supuran and Scozzafava, <i class="style-scope patent-text">Eur. J. Med. Chem., </i>35: 867-874 (2000b).</li> <li id="ul0001-0094" num="0180" class="style-scope patent-text">93. Supuran and Scozzafava, <i class="style-scope patent-text">Exp. Opin. Ther. Patents, </i>10: 575-600 (2000c).</li> <li id="ul0001-0095" num="0181" class="style-scope patent-text">94. Supuran and Scozzafava, <i class="style-scope patent-text">Curr. Med. Chem.</i>-<i class="style-scope patent-text">Imm., Endoc. Metab. Agents, </i>1: 61-97 (2001).</li> <li id="ul0001-0096" num="0182" class="style-scope patent-text">95. Supuran and Scozzafava, <i class="style-scope patent-text">Exp. Opin. Ther. Patents, </i>12: 217-242 (2002).</li> <li id="ul0001-0097" num="0183" class="style-scope patent-text">96. Supuran et al., <i class="style-scope patent-text">Eur. J. Med. Chem., </i>33: 577-594 (1998a).</li> <li id="ul0001-0098" num="0184" class="style-scope patent-text">97. Supuran et al., <i class="style-scope patent-text">Eur. J. Med. Chem., </i>33: 739-752 (1998b).</li> <li id="ul0001-0099" num="0185" class="style-scope patent-text">98. Supuran et al., <i class="style-scope patent-text">J. Enz. Inhib., </i>15: 381-401 (2000a).</li> <li id="ul0001-0100" num="0186" class="style-scope patent-text">99. Supuran et al., <i class="style-scope patent-text">J. Med. Chem., </i>35: 309-321 (2000b).</li> <li id="ul0001-0101" num="0187" class="style-scope patent-text">100. Supuran et al., <i class="style-scope patent-text">Bioorg. Med. Chem., </i>9: 703-714 (2001a).</li> <li id="ul0001-0102" num="0188" class="style-scope patent-text">101. Supuran et al., <i class="style-scope patent-text">Curr. Med. Chem.</i>-<i class="style-scope patent-text">Imm. Endoc. Metab. Agents, </i>1: 61-97 (2001b)</li> <li id="ul0001-0103" num="0189" class="style-scope patent-text">102. Supuran et al., <i class="style-scope patent-text">Med. Res. Rev., </i>23: 146-189 (2003).</li> <li id="ul0001-0104" num="0190" class="style-scope patent-text">103. Svastova et al., <i class="style-scope patent-text">Experimental Cell Research, </i>290: 332-345, (2003).</li> <li id="ul0001-0105" num="0191" class="style-scope patent-text">104. Symington, <i class="style-scope patent-text">J. Biol. Chem., </i>267: 25744 (1992).</li> <li id="ul0001-0106" num="0192" class="style-scope patent-text">105. Tashian, R. E., <i class="style-scope patent-text">Adv. in Genetics, </i>30: 321-356 (1992).</li> <li id="ul0001-0107" num="0193" class="style-scope patent-text">106. Teicher et al., <i class="style-scope patent-text">Anticancer Research, </i>13: 1549-1556 (1993).</li> <li id="ul0001-0108" num="0194" class="style-scope patent-text">107. Tinker et al., <i class="style-scope patent-text">J. Pharmacol. Exp. Ther., </i>218: 600-607 (1981).</li> <li id="ul0001-0109" num="0195" class="style-scope patent-text">108. Toma and Balaban, <i class="style-scope patent-text">Tetrahedron, Suppl. </i>7: 27-34 (1966).</li> <li id="ul0001-0110" num="0196" class="style-scope patent-text">109. Trinh et al., <i class="style-scope patent-text">Cancer Res., </i>55: 4808-4812 (1995).</li> <li id="ul0001-0111" num="0197" class="style-scope patent-text">110. Turner, et al., <i class="style-scope patent-text">Hum. Pathol., </i>28: 740-744 (1997).</li> <li id="ul0001-0112" num="0198" class="style-scope patent-text">111. Turner et al., <i class="style-scope patent-text">Br. J. Cancer, </i>86: 1276-1282 (2002).</li> <li id="ul0001-0113" num="0199" class="style-scope patent-text">112. Uemura et al. [<i class="style-scope patent-text">J. Urology, </i>1571 (4 Supp.): 377 (Abstract 1475) (Apr. 16, 1997)]</li> <li id="ul0001-0114" num="0200" class="style-scope patent-text">113. Vermylen et al., <i class="style-scope patent-text">Eur. Respir. J., </i>14: 806-811 (1999);</li> <li id="ul0001-0115" num="0201" class="style-scope patent-text">114. Vullo et al., <i class="style-scope patent-text">Bioorg. Med. Chem. Lett., </i>13: 1005-1009 (2003a).</li> <li id="ul0001-0116" num="0202" class="style-scope patent-text">115. Vullo et al. <i class="style-scope patent-text">J. Enz. Inhib. Med. Chem., </i>18: 403-406 (2003b).</li> <li id="ul0001-0117" num="0203" class="style-scope patent-text">116. Wingo et al., <i class="style-scope patent-text">Biochem. Biophys. Res. Comm., </i>288: 666-669 (2001).</li> <li id="ul0001-0118" num="0204" class="style-scope patent-text">117. Winum et al. <i class="style-scope patent-text">J. Med. Chem., </i>46: 2197-2204 (2003).</li> <li id="ul0001-0119" num="0205" class="style-scope patent-text">118. Wistrand and Lindqvist, “Design of carbonic anhydrase inhibitors and the relationship between the pharmacodymanics and pharmacokinetics of acetazolamide,” In <i class="style-scope patent-text">Carbonic Anhydrase—From Biochemistry and Genetics to Physiology and Clinical Medicine</i>, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991).</li> <li id="ul0001-0120" num="0206" class="style-scope patent-text">119. Workman and Stratford, <i class="style-scope patent-text">Cancer and Metastasis Reviews, </i>12: 73-82(1993)</li> <li id="ul0001-0121" num="0207" class="style-scope patent-text">120. Wu et al., <i class="style-scope patent-text">J. Membr. Biol. </i>162: 31-38 (1998).</li> <li id="ul0001-0122" num="0208" class="style-scope patent-text">121. Wykoff et al., <i class="style-scope patent-text">Cancer Research, </i>60: 7075-7083 (2000).</li> <li id="ul0001-0123" num="0209" class="style-scope patent-text">122. Wykoff et al., <i class="style-scope patent-text">Am. J. Pathol., </i>158: 1011-1019 (2001).</li> <li id="ul0001-0124" num="0210" class="style-scope patent-text">123. Zavada et al., <i class="style-scope patent-text">Int. J. Cancer, </i>54: 268-274 (1993).</li> <li id="ul0001-0125" num="0211" class="style-scope patent-text">124. Fischer et al., <i class="style-scope patent-text">Clin. Immunol., </i>96: 252-263 (2000).</li> <li id="ul0001-0126" num="0212" class="style-scope patent-text">125. Fukumura et al., <i class="style-scope patent-text">Cancer Res., </i>61: 6020-6024 (2001).</li> <li id="ul0001-0127" num="0213" class="style-scope patent-text">126. Gerweck et al., <i class="style-scope patent-text">Semin. Radiat. Oncol., </i>8: 176-182 (1998).</li> <li id="ul0001-0128" num="0214" class="style-scope patent-text">127. Helmlinger et al., <i class="style-scope patent-text">Clin. Cancer Res., </i>8: 1284-1291 (2002).</li> <li id="ul0001-0129" num="0215" class="style-scope patent-text">128. Ivanov et al., <i class="style-scope patent-text">Proc. Natl. Acad. Sci</i>. (USA), 95: 12596-12601 (1998).</li> <li id="ul0001-0130" num="0216" class="style-scope patent-text">129. Kaluz et al., <i class="style-scope patent-text">Cancer Res., </i>62: 4469-4477 (2002).</li> <li id="ul0001-0131" num="0217" class="style-scope patent-text">130. Kato et al., <i class="style-scope patent-text">J. Biol. Chem., </i>267: 11424-11430 (1992).</li> <li id="ul0001-0132" num="0218" class="style-scope patent-text">131. Karumanchi et al., <i class="style-scope patent-text">Physiol. Genomics, </i>5: 119-128 (2001).</li> <li id="ul0001-0133" num="0219" class="style-scope patent-text">132. Martinez-Zaguilan et al., <i class="style-scope patent-text">Clin. Exp. Metastasis, </i>14: 176-186(1996).</li> <li id="ul0001-0134" num="0220" class="style-scope patent-text">133. Mekhail et al., <i class="style-scope patent-text">Nature Cell Biol., </i>6: 642-647 (2004).</li> <li id="ul0001-0135" num="0221" class="style-scope patent-text">134. Newell et al., <i class="style-scope patent-text">Proc. Natl. Acad. Sci</i>. (USA), 90: 1127-1131 (1993).</li> <li id="ul0001-0136" num="0222" class="style-scope patent-text">135. Pastorekova et al., <i class="style-scope patent-text">Bioorg. Med. Chem. Lett., </i>14: 869-873 (2004).</li> <li id="ul0001-0137" num="0223" class="style-scope patent-text">136. Potter and Harris, <i class="style-scope patent-text">Br. J. Cancer, </i>89: 2-7 (2003).</li> <li id="ul0001-0138" num="0224" class="style-scope patent-text">137. Raghunand and Gillies, <i class="style-scope patent-text">Novartis Found Symp., </i>240: 199-211 (2001).</li> <li id="ul0001-0139" num="0225" class="style-scope patent-text">138. Robertson et al., <i class="style-scope patent-text">Cancer Research, </i>64: 6160-6165 (2004).</li> <li id="ul0001-0140" num="0226" class="style-scope patent-text">139. Semenza et al., <i class="style-scope patent-text">Nat. Rev. Cancer, </i>3: 721-732 (2003).</li> <li id="ul0001-0141" num="0227" class="style-scope patent-text">140. Sterling et al., <i class="style-scope patent-text">J. Biol. Chem., </i>276: 47886-47894 (2001).</li> <li id="ul0001-0142" num="0228" class="style-scope patent-text">141. Sterling et al., <i class="style-scope patent-text">J. Biol. Chem., </i>277: 25239-46 (2002).</li> <li id="ul0001-0143" num="0229" class="style-scope patent-text">142. Supuran et al., <i class="style-scope patent-text">Eur. J. Med. Chem., </i>33: 83-93 (1998).</li> <li id="ul0001-0144" num="0230" class="style-scope patent-text">143. Tanaka et al., <i class="style-scope patent-text">Brain Res Dev Brain Res, </i>121(2): 223-228 (2000).</li> <li id="ul0001-0145" num="0231" class="style-scope patent-text">144. Yamagata et al., <i class="style-scope patent-text">Br. J. Cancer, </i>77: 1726-1731 (1998).</li> <li id="ul0001-0146" num="0232" class="style-scope patent-text">145. Zatovicova et al., <i class="style-scope patent-text">J. Immunol. Methods, </i>282: 117-134 (2003).</li> <li id="ul0001-0147" num="0233" class="style-scope patent-text">146. Zavada et al., <i class="style-scope patent-text">Br. J. Cancer, </i>82: 1808-1813 (2000).</li> </ul>

    <heading class="style-scope patent-text">Abbreviations</heading>
    <div num="p-0088" class="description-paragraph style-scope patent-text">The following abbreviations are used herein:</div>
    <div num="p-0089" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00001" num="00001" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">aa</td>
                <td class="description-td style-scope patent-text">amino acid</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AAZ</td>
                <td class="description-td style-scope patent-text">acetazolamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">AE</td>
                <td class="description-td style-scope patent-text">anion exchanger</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ATCC</td>
                <td class="description-td style-scope patent-text">American Type Culture Collection</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ΔCA</td>
                <td class="description-td style-scope patent-text">deletion mutant of CA IX </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">lacking the catalytic domain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ΔPG</td>
                <td class="description-td style-scope patent-text">deletion mutant of CA IX lacking </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">the proteoglycan-like domain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">bp</td>
                <td class="description-td style-scope patent-text">base pairs</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">BRL</td>
                <td class="description-td style-scope patent-text">Bethesda Research Laboratories</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">BRZ</td>
                <td class="description-td style-scope patent-text">brinzolamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">BSA</td>
                <td class="description-td style-scope patent-text">bovine serum albumin</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CA</td>
                <td class="description-td style-scope patent-text">carbonic anhydrase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CAI</td>
                <td class="description-td style-scope patent-text">carbonic anhydrase inhibitor</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CAM</td>
                <td class="description-td style-scope patent-text">cell adhesion molecule</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CARP</td>
                <td class="description-td style-scope patent-text">carbonic anhydrase related protein</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Ci</td>
                <td class="description-td style-scope patent-text">curie</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">cm</td>
                <td class="description-td style-scope patent-text">centimeter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CNS</td>
                <td class="description-td style-scope patent-text">central nervous system</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">cpm</td>
                <td class="description-td style-scope patent-text">counts per minute</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">C-terminus</td>
                <td class="description-td style-scope patent-text">carboxyl-terminus</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">° C.</td>
                <td class="description-td style-scope patent-text">degrees centigrade</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">DCP</td>
                <td class="description-td style-scope patent-text">dichlorophenamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">DEAE</td>
                <td class="description-td style-scope patent-text">diethylaminoethyl</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">DMEM</td>
                <td class="description-td style-scope patent-text">Dulbecco modified Eagle medium</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ds</td>
                <td class="description-td style-scope patent-text">double-stranded</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">DZA</td>
                <td class="description-td style-scope patent-text">dorzolamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EDTA</td>
                <td class="description-td style-scope patent-text">ethylenediaminetetraacetate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EZA</td>
                <td class="description-td style-scope patent-text">ethoxzolamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">F</td>
                <td class="description-td style-scope patent-text">fibroblasts</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">FCS</td>
                <td class="description-td style-scope patent-text">fetal calf serum</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">FITC</td>
                <td class="description-td style-scope patent-text">fluorescein isothiocyanate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">HeLa cells; hypoxia</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">HIF</td>
                <td class="description-td style-scope patent-text">hypoxia inducible factor</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">IC</td>
                <td class="description-td style-scope patent-text">intracellular</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">kb</td>
                <td class="description-td style-scope patent-text">kilobase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">kbp</td>
                <td class="description-td style-scope patent-text">kilobase pairs</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">kd or kDa</td>
                <td class="description-td style-scope patent-text">kilodaltons</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K<sub class="style-scope patent-text">1</sub> </td>
                <td class="description-td style-scope patent-text">inhibition constant</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">KS</td>
                <td class="description-td style-scope patent-text">keratan sulphate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">LTR</td>
                <td class="description-td style-scope patent-text">long terminal repeat</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">M</td>
                <td class="description-td style-scope patent-text">molar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">mA</td>
                <td class="description-td style-scope patent-text">milliampere</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">MAb</td>
                <td class="description-td style-scope patent-text">monoclonal antibody</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ME</td>
                <td class="description-td style-scope patent-text">mercaptoethanol</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">MEM</td>
                <td class="description-td style-scope patent-text">minimal essential medium</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">min.</td>
                <td class="description-td style-scope patent-text">minute(s)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">mg</td>
                <td class="description-td style-scope patent-text">milligram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ml</td>
                <td class="description-td style-scope patent-text">milliliter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">mM</td>
                <td class="description-td style-scope patent-text">millimolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">MMC</td>
                <td class="description-td style-scope patent-text">mitomycin C</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">mmol</td>
                <td class="description-td style-scope patent-text">millimole</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">MZA</td>
                <td class="description-td style-scope patent-text">methazolamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">N</td>
                <td class="description-td style-scope patent-text">normal concentration; normoxia</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">NEG</td>
                <td class="description-td style-scope patent-text">negative</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ng</td>
                <td class="description-td style-scope patent-text">nanogram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">nm</td>
                <td class="description-td style-scope patent-text">nanometer</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">nM</td>
                <td class="description-td style-scope patent-text">nanomolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">nt</td>
                <td class="description-td style-scope patent-text">nucleotide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">N-terminus</td>
                <td class="description-td style-scope patent-text">amino-terminus</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ODN</td>
                <td class="description-td style-scope patent-text">oligodeoxynucleotide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ORF</td>
                <td class="description-td style-scope patent-text">open reading frame</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PA</td>
                <td class="description-td style-scope patent-text">Protein A</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PBS</td>
                <td class="description-td style-scope patent-text">phosphate buffered saline</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PCR</td>
                <td class="description-td style-scope patent-text">polymerase chain reaction</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PG</td>
                <td class="description-td style-scope patent-text">proteoglycan</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pHe</td>
                <td class="description-td style-scope patent-text">extracellular pH</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pI</td>
                <td class="description-td style-scope patent-text">isoelectric point</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PMA</td>
                <td class="description-td style-scope patent-text">phorbol 12-myristate 13-acetate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">POS</td>
                <td class="description-td style-scope patent-text">positive</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PVDF</td>
                <td class="description-td style-scope patent-text">polyvinylidene difluoride</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pVHL</td>
                <td class="description-td style-scope patent-text">von Hippel-Lindau tumor suppressor protein</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Py</td>
                <td class="description-td style-scope patent-text">pyrimidine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">QAS</td>
                <td class="description-td style-scope patent-text">quaternary ammonian sulfonilamide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">QSAR</td>
                <td class="description-td style-scope patent-text">quantitative structure-activity relationship(s)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RACE</td>
                <td class="description-td style-scope patent-text">rapid amplification of cDNA ends</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RCC</td>
                <td class="description-td style-scope patent-text">renal cell carcinoma</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RIA</td>
                <td class="description-td style-scope patent-text">radioimmunoassay</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RIP</td>
                <td class="description-td style-scope patent-text">radioimmunoprecipitation</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RIPA</td>
                <td class="description-td style-scope patent-text">radioimmunoprecipitation assay</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RNP</td>
                <td class="description-td style-scope patent-text">RNase protection assay</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">RT-PCT</td>
                <td class="description-td style-scope patent-text">reverse transcription polymerase chain reaction</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SAC</td>
                <td class="description-td style-scope patent-text">Staphylococcus aureus cells</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SAR</td>
                <td class="description-td style-scope patent-text">structure-activity relationship</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">sc</td>
                <td class="description-td style-scope patent-text">subcutaneous</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SDS</td>
                <td class="description-td style-scope patent-text">sodium dodecyl sulfate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SDS-PAGE</td>
                <td class="description-td style-scope patent-text">sodium dodecyl sulfate-polyacrylamide </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">gel electrophoresis</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SINE</td>
                <td class="description-td style-scope patent-text">short interspersed repeated sequence</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SP</td>
                <td class="description-td style-scope patent-text">signal peptide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">SP-RIA</td>
                <td class="description-td style-scope patent-text">solid-phase radioimmunoassay</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">TBE</td>
                <td class="description-td style-scope patent-text">Tris-borate/EDTA electrophoresis buffer</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">TC</td>
                <td class="description-td style-scope patent-text">tissue culture</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">TCA</td>
                <td class="description-td style-scope patent-text">trichloroacetic acid</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">TC media</td>
                <td class="description-td style-scope patent-text">tissue culture media</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">tk</td>
                <td class="description-td style-scope patent-text">thymidine kinase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">TM</td>
                <td class="description-td style-scope patent-text">transmembrane</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Tris</td>
                <td class="description-td style-scope patent-text">tris (hydroxymethyl) aminomethane</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">μCi</td>
                <td class="description-td style-scope patent-text">microcurie</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">μg</td>
                <td class="description-td style-scope patent-text">microgram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">μl</td>
                <td class="description-td style-scope patent-text">microliter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">μM</td>
                <td class="description-td style-scope patent-text">micromolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">Cell Lines</heading>
    <div num="p-0090" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00002" num="00002" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">BL21 (DE3) </td>
                <td class="description-td style-scope patent-text"> <i class="style-scope patent-text">Escherichia coli </i>strain described by Lindskog’s </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">group (for CA I, II expression)[Lindskog et al., </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">“Structure-function relations in human carbonic </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">anhydrase II as studied by site-directed mutagenesis,” </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">in Carbonic anhydrase - From biochemistry </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">and genetics to physiology and clinical medicine,</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Botre et al.,Eds., VCH, Weinheim, pp. 1-13 (1991)]</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">BL21-GOLD </td>
                <td class="description-td style-scope patent-text"> <i class="style-scope patent-text">Escherichia coli </i>strain (from Stratagene) used for </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(DE3)</td>
                <td class="description-td style-scope patent-text">CA IX expression)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">HeLa</td>
                <td class="description-td style-scope patent-text">cell line derived from human cervical adenocarcinoma; </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">cells normally express endogenous CA IX</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">HeLa-ΔCA</td>
                <td class="description-td style-scope patent-text">HeLa cells stably transfected with recombinant </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">plasmids to contain ΔCA but not CA IX under </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">normoxia, and express both proteins under hypoxia, </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">which apparently form mixed oligomers </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">(composed of both CA IX and ΔCA)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">HeLa-mock</td>
                <td class="description-td style-scope patent-text">HeLa cells cotransfected with empty pSG5C and pSV2 </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">neo plasmids as negative controls</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MDCK</td>
                <td class="description-td style-scope patent-text">cell line derived from normal canine tubular </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">kidney epithelium; cells do not express endogenous </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CA IX</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MDCK-CA IX</td>
                <td class="description-td style-scope patent-text">MDCK cells stably transfected with recombinant </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">plasmids to express CA IX constitutively</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MDCK-mock</td>
                <td class="description-td style-scope patent-text">MDCK cells cotransfected with empty pSG5C and </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">pSV2 neo plasmids as negative controls</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SiHa</td>
                <td class="description-td style-scope patent-text">cell line derived from human cervical squamous cell</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">carcinoma; cells normally express endogenous CA IX</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">Nucleotide and Amino Acid Sequence Symbols</heading>
    <div num="p-0091" class="description-paragraph style-scope patent-text">The following symbols are used to represent nucleotides herein:</div>
    <div num="p-0092" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00003" num="00003" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Base Symbol</td>
                <td class="description-td style-scope patent-text">Meaning</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">A</td>
                <td class="description-td style-scope patent-text">adenine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">C</td>
                <td class="description-td style-scope patent-text">cytosine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">G</td>
                <td class="description-td style-scope patent-text">guanine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T</td>
                <td class="description-td style-scope patent-text">thymine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">U</td>
                <td class="description-td style-scope patent-text">uracil</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">I</td>
                <td class="description-td style-scope patent-text">inosine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M</td>
                <td class="description-td style-scope patent-text">A or C</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">R</td>
                <td class="description-td style-scope patent-text">A or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">W</td>
                <td class="description-td style-scope patent-text">A or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">S</td>
                <td class="description-td style-scope patent-text">C or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Y</td>
                <td class="description-td style-scope patent-text">C or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">K</td>
                <td class="description-td style-scope patent-text">G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">V</td>
                <td class="description-td style-scope patent-text">A or C or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">A or C or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">D</td>
                <td class="description-td style-scope patent-text">A or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">B</td>
                <td class="description-td style-scope patent-text">C or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">N/X</td>
                <td class="description-td style-scope patent-text">A or C or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0093" class="description-paragraph style-scope patent-text">There are twenty main amino acids, each of which is specified by a different arrangement of three adjacent nucleotides (triplet code or codon), and which are linked together in a specific order to form a characteristic protein. A three-letter or one-letter convention is used herein to identify said amino acids, as, for example, in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> as follows:</div>
    <div num="p-0094" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00004" num="00004" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">3 Ltr.</td>
                <td class="description-td style-scope patent-text">1 Ltr.</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Amino acid name</td>
                <td class="description-td style-scope patent-text">Abbrev.</td>
                <td class="description-td style-scope patent-text">Abbrev.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Alanine</td>
                <td class="description-td style-scope patent-text">Ala</td>
                <td class="description-td style-scope patent-text">A</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Arginine</td>
                <td class="description-td style-scope patent-text">Arg</td>
                <td class="description-td style-scope patent-text">R</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Asparagine</td>
                <td class="description-td style-scope patent-text">Asn</td>
                <td class="description-td style-scope patent-text">N</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Aspartic Acid</td>
                <td class="description-td style-scope patent-text">Asp</td>
                <td class="description-td style-scope patent-text">D</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Cysteine</td>
                <td class="description-td style-scope patent-text">Cys</td>
                <td class="description-td style-scope patent-text">C</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glutamic Acid</td>
                <td class="description-td style-scope patent-text">Glu</td>
                <td class="description-td style-scope patent-text">E</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glutamine</td>
                <td class="description-td style-scope patent-text">Gln</td>
                <td class="description-td style-scope patent-text">Q</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glycine</td>
                <td class="description-td style-scope patent-text">Gly</td>
                <td class="description-td style-scope patent-text">G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Histidine</td>
                <td class="description-td style-scope patent-text">His</td>
                <td class="description-td style-scope patent-text">H</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Isoleucine</td>
                <td class="description-td style-scope patent-text">Ile</td>
                <td class="description-td style-scope patent-text">I</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Leucine</td>
                <td class="description-td style-scope patent-text">Leu</td>
                <td class="description-td style-scope patent-text">L</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Lysine</td>
                <td class="description-td style-scope patent-text">Lys</td>
                <td class="description-td style-scope patent-text">K</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Methionine</td>
                <td class="description-td style-scope patent-text">Met</td>
                <td class="description-td style-scope patent-text">M</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Phenylalanine</td>
                <td class="description-td style-scope patent-text">Phe</td>
                <td class="description-td style-scope patent-text">F</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Proline</td>
                <td class="description-td style-scope patent-text">Pro</td>
                <td class="description-td style-scope patent-text">P</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Serine</td>
                <td class="description-td style-scope patent-text">Ser</td>
                <td class="description-td style-scope patent-text">S</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Threonine</td>
                <td class="description-td style-scope patent-text">Thr</td>
                <td class="description-td style-scope patent-text">T</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Tryptophan</td>
                <td class="description-td style-scope patent-text">Trp</td>
                <td class="description-td style-scope patent-text">W</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Tyrosine</td>
                <td class="description-td style-scope patent-text">Tyr</td>
                <td class="description-td style-scope patent-text">Y</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Valine</td>
                <td class="description-td style-scope patent-text">Val</td>
                <td class="description-td style-scope patent-text">V</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Unknown or other</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">X</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    
    
    <description-of-drawings class="style-scope patent-text">
      <heading class="style-scope patent-text">BRIEF DESCRIPTION OF THE FIGURES</heading>
      <div num="p-0095" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-C</figref> provides the nucleotide sequence for MN/CA IX full-length cDNA [SEQ ID NO: 1]. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> A-C also sets forth the predicted amino acid sequence [SEQ ID NO: 2] encoded by the cDNA.</div>
      <div num="p-0096" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A-F</figref> provides a 10,898 bp complete genomic sequence of MN/CA9 [SEQ ID NO: 3]. The base count is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. The 11 exons are in general shown in capital letters, but <figure-callout id="1" label="exon" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is considered to begin at position 3507 as determined by RNase protection assay.</div>
      <div num="p-0097" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref> provides an exon-intron map of the human MN/CA9 gene. The positions and sizes of the exons (numbered, cross-hatched boxes), Alu repeat elements (open boxes) and an LTR-related sequence (first unnumbered stippled box) are adjusted to the indicated scale. The exons corresponding to individual MN/CA IX protein domains are enclosed in dashed frames designated PG (proteoglycan-like domain), CA (carbonic anhydrase domain), TM (transmembrane anchor) and IC (intracytoplasmic tail). Below the map, the alignment of amino acid sequences illustrates the extent of homology between the MN/CA IX protein PG region (aa 53-111) [SEQ ID NO: 4] and the human aggrecan (aa 781-839) [SEQ ID NO: 5].</div>
      <div num="p-0098" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref> A-B shows the chemical structures of the 26 different sulfonamide compounds tested in Example 1.</div>
      <div num="p-0099" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref> shows the scheme for the general synthesis of compounds 71-91 of Example 3 (Scheme 1).</div>
      <div num="p-0100" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> shows the scheme for the reaction between a pyrylium salt and an amine (Scheme 2), as described in Example 3.</div>
      <div num="p-0101" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7</figref> (discussed in Example 4) illustrates the CA IX-mediated acidification of the extracellular pH in hypoxia. Values of pHe [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A</figref>] and lactate [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7B</figref>] concentrations are shown in histograms (mean values and standard deviations) for cells grown in the constant medium volumes, maintained in normoxia (N, 21% O<sub class="style-scope patent-text">2</sub>) or exposed to hypoxia (H, 2% O<sub class="style-scope patent-text">2</sub>) for 48 hours. The cells tested were CA IX-transfected MDCK cells and mock-transfected controls for comparison. Five independent experiments with three different clones of the transfectants and three parallel dishes for each clone were performed.</div>
      <div num="p-0102" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref> (discussed in Example 5) shows sulfonamide inhibition and binding to hypoxic MDCK-CA IX cells. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8A</figref> shows the chemical structures of the CA IX-selective inhibitors used in Examples 5-8: Compound 6 [4-(2-aminoethyl)-benzenesulfonamide], Compound 39 [4-(2,4,6-trimethylpyridinium-N-methylcarboxamido)-benzensulfonamide perchlorate], and Compound 92 [FITC derivative of homosulfanilamide (Compound 5)]. [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8B</figref>] The sulfonamides were added to MDCK-CA IX cells just before the cells were transferred to hypoxia, and pHe was measured 48 hours later. At least three independent experiments with three parallel dishes per sample were performed for each inhibitor. Data are expressed as differences between the pH values (ΔpH) measured in the untreated versus treated cells and include the standard deviations.</div>
      <div num="p-0103" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9</figref> (discussed in Example 6) shows the expression and acidification capability of the CA IX deletion mutants. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9A</figref> is a schematic drawing of the domain composition of the wild-type (wt) CA IX with the amino acid positions indicating an extent of deletions in the N-terminal PG domain (ΔPG) and the central CA domain (ΔCA): SP, signal peptide; PG, proteoglycan-like region; CA, carbonic anhydrase domain; TM, transmembrane anchor; IC, intracytoplasmic tail. [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9B</figref>] Extracellular pH and production of lactate in the transfected MDCK cells. At least three independent experiments were performed using three clonal cell lines for each transfected variant with at least three parallel dishes. Data are expressed as mean differences in the pH values (ΔpH) and in the lactate concentrations (Δmg/ml), respectively.</div>
      <div num="p-0104" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref> (discussed in Example 7) shows treatment of the tumor cells by <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 sulfonamide [FITC derivative of homosulfanilamide (Compound 5)]. HeLa and SiHa cervical carcinoma cells were incubated for 48 hours in normoxia and hypoxia, respectively, either in the absence or in the presence of 1 mM of the <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 sulfonamide. Mean differences in the pH values determined in the treated versus control dishes are shown on the histogram with indicated standard deviations. The experiment was repeated three times using at least three parallel dishes for each sample.</div>
      <div num="p-0105" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11</figref> (discussed in Example 8) illustrates ectopic expression of ΔCA mutant in HeLa cells. Values of pHe in the culture media of HeLa cells transfected with ΔCA in comparison to the mock-transfected controls. Data represent mean differences in the pH values and corresponding standard deviations. The experiment was repeated three times with three different clones of the transfected HeLa, each having at least three parallel dishes.</div>
    </description-of-drawings>
    
    
    <heading class="style-scope patent-text">DETAILED DESCRIPTION</heading>
    <div num="p-0106" class="description-paragraph style-scope patent-text">The novel methods of the present invention comprise inhibiting the growth of tumor cells which overexpress MN protein with compounds that inhibit the enzymatic activity of MN protein. Said compounds are organic or inorganic, preferably organic, more preferably sulfonamides. Still more preferably, said compounds are pyridinium derivatives of aromatic or heterocyclic sulfonamides. These preferred pyridinium derivatives of sulfonamides are likely to have fewer side effects than other compounds in three respects: they are small molecules, they are membrane-impermeant, and they are specific potent inhibitors of the enzymatic activity of the tumor-associated MN/CA IX protein.</div>
    <div num="p-0107" class="description-paragraph style-scope patent-text">The use of oncoproteins as targets for developing new cancer therapeutics is considered conventional by those of skill in the art. [See, e.g., Mendelsohn and Lippman [61]. However, the application of such approaches to MN is new. In comparison to other tumor-related molecules (e.g. growth factors and their receptors), MN has the unique property of being differentially expressed in preneoplastic/neoplastic and normal tissues, which are separated by an anatomic barrier.</div>
    <div num="p-0108" class="description-paragraph style-scope patent-text">The pyridinium derivatives of sulfonamides of the present invention can be formed, for example, by creating bonds between pyrylium salts and aromatic or heterocyclic sulfonamide reagents, as described below. The aromatic or heterocyclic sulfonamide portion of a pyridinium salt of a sulfonamide compound can be called the “head,” and the pyridinium portion can be called the “tail.”</div>
    <div num="p-0109" class="description-paragraph style-scope patent-text">It can be appreciated by those of skill in the art that various other types of linkages can couple the pyridinium portion with the sulfonamide portion. It can further be appreciated that alternate methods, in addition to those disclosed herein, can be used to make the pyridinium derivatives of the present invention.</div>
    <div num="p-0110" class="description-paragraph style-scope patent-text">As used herein, “cancerous” and “neoplastic” have equivalent meanings, and “precancerous” and “preneoplastic” have equivalent meanings.</div>
    <div num="p-0111" class="description-paragraph style-scope patent-text">As used herein, the term “aromatic” when applied to sulphonamide structures means “comprising an aromatic ring, without an additional heterocyclic ring.” The term “heterocyclic” when applied to sulphonamide structures means “comprising a heterocyclic ring, with or without an additional aromatic ring.”</div>
    <div num="p-0112" class="description-paragraph style-scope patent-text">As used herein, the term “alkyl”, alone or in combination, refers to a straight-chain or branched-chain alkyl radical containing from 1 to 12, preferably from 1 to 6 and more preferably from 1 to 4, carbon atoms. Examples of such radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, decyl and the like.</div>
    <div num="p-0113" class="description-paragraph style-scope patent-text">The term “aryl”, alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl, amido, mono and dialkyl substituted amino, mono and dialkyl substituted amido and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 4-acetamidophenyl, 2-methyl-3-acetamidophenyl, 2-methyl-3-aminophenyl, 3-methyl-4-aminophenyl, 2-amino-3-methylphenyl, 2,4-dimethyl-3-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, 3-amino-1-naphthyl, 2-methyl-3-amino-1-naphthyl, 6-amino-2-naphthyl, 4,6-dimethoxy-2-naphthyl and the like.</div>
    <div num="p-0114" class="description-paragraph style-scope patent-text">Preferred sulfonamides of the present invention are aromatic and heterocyclic sulfonamides. The structures of representative sulfonamides of this group, designated 1-26, are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref>.</div>
    <div num="p-0115" class="description-paragraph style-scope patent-text">More preferred sulfonamides of the present invention are pyridinium derivatives of aromatic sulfonamides and have the general formula (A) below,</div>
    <div num="p-0116" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00003" num="00003" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4e/50/15/729d4ee91f924c/US07833737-20101116-C00003.png" class="style-scope patent-text"><img id="EMI-C00003" he="25.74mm" wi="69.51mm" file="US07833737-20101116-C00003.TIF" alt="Figure US07833737-20101116-C00003" img-content="chem" img-format="tif" width="278" height="103" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4e/50/15/729d4ee91f924c/US07833737-20101116-C00003.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US07833737-20101116-C00003.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00003" attachment-type="mol" file="US07833737-20101116-C00003.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
wherein n is 0, 1, or 2; and R2, R3, R4 and R6 are each independently selected from the group consisting of hydrogen, alkyls and aryls. The structures of representative sulfonamides of this group, designated 27 through 70, are shown as derivatives of the general structure (A), in Table 2.
</div>
    <div num="p-0117" class="description-paragraph style-scope patent-text">Alternatively, more preferred sulfonamides of the present invention are pyridinium derivatives of heterocyclic sulfonamides and have the general formula (B) below, wherein said pyridinium derivative of a heterocyclic sulfonamide has the general formula of:</div>
    <div num="p-0118" class="description-paragraph style-scope patent-text"> <chemistry id="CHEM-US-00004" num="00004" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/13/f6/89/5ed1a66dc47769/US07833737-20101116-C00004.png" class="style-scope patent-text"><img id="EMI-C00004" he="26.59mm" wi="73.41mm" file="US07833737-20101116-C00004.TIF" alt="Figure US07833737-20101116-C00004" img-content="chem" img-format="tif" width="294" height="106" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/13/f6/89/5ed1a66dc47769/US07833737-20101116-C00004.png"></a></div> <attachments class="style-scope patent-text"> <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US07833737-20101116-C00004.CDX" class="style-scope patent-text"> </attachment> <attachment idref="CHEM-US-00004" attachment-type="mol" file="US07833737-20101116-C00004.MOL" class="style-scope patent-text"> </attachment> </attachments> </chemistry> <br class="style-scope patent-text">
wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyls and aryls. The structures of representative sulfonamides of this group, designated 71 through 91, are shown as derivatives of the general structure (B), in Table 3.
</div>
    <div num="p-0119" class="description-paragraph style-scope patent-text">Representative sulfonamide derivatives of the group of compounds represented by the general formulas (A) and (B) have CA IX inhibitory activity, and are potentially useful therapeutically as anticancer agents in treating MN-associated tumors.</div>
    <div num="p-0120" class="description-paragraph style-scope patent-text">Further, biologic activity of the identified sulfonamides will be tested in vitro by inhibition of the carbonic anhydrase enzymatic activity of the MN protein, by effects on cell morphology and growth characteristics of MN-related tumor cells (HeLa) and of control cells [104]. In vivo screening will be carried out in nude mice that have been injected with HeLa cells.</div>
    <div num="p-0121" class="description-paragraph style-scope patent-text">It can be appreciated by those of skill in the art that various other CA IX-specific inhibitors can be useful according to the methods of the invention, and may comprise any molecules that preferentially bind only the activated form of the CA domain of CA IX, and not the inactive form of the CA domain of CA IX. Such molecules may be organic or inorganic, preferably organic molecules. Such organic molecules may be antibodies, preferably monoclonal antibodies, which selectively bind the activated form of the CA domain of CA IX. For example, monoclonal antibodies have been described which specifically recognize the epitope of caspases that is characteristic of the activated form of those proteases [143]. Therefore, activation of the CA domain of CA IX could theoretically be detected both indirectly from tumor cell samples and directly in situ, immunocytochemically.</div>
    <heading class="style-scope patent-text">Representative Sulfonamide Inhibitors of CA IX</heading>
    <div num="p-0122" class="description-paragraph style-scope patent-text">The sulfonamides investigated in Example 1 for the inhibition of the tumor-associated isozyme CA IX, of types 1-26 are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4A-B</figref>. Compounds 1-6, 11-12, 20 and 26 are commercially available, whereas 7-10 [43], 13-19 [24, 90, 97] and 21-25 [79] were prepared as reported earlier. The six clinically used compounds were also assayed. For Example 2 compounds (pyridinium derivatives of aromatic sulfonamides), reaction of sulfanilamide, homosulfanilamide or 4-(2-aminoethyl)-benzenesulfonamide with 2,6-di-, 2,4,6-<figure-callout id="2" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="4" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">tri-or</a></figure-callout> </a></figure-callout> </a></figure-callout> 2,3,4,6-tetrasubstituted pyrylium salts afforded the pyridinium salts 27-70 investigated here, by the general Bayer—Piccard synthesis [9, 10, 97].</div>
    <div num="p-0123" class="description-paragraph style-scope patent-text">As described in Example 3, a series of positively-charged sulfonamides, designated here as compounds 71-91, were obtained by reaction of aminobenzolamide (5-(4-aminobenzenesulfonylamino)-1,3,4-thiadiazole-2-sulfonamide) with tri-/tetra-substituted pyrilium salts possessing alkyl-, aryl-or combinations of alkyl and aryl groups at the pyridinium ring (described below). Three of these compounds (71, 75, and 87) have been described elsewhere [25, 85]; all other compounds of this series are new.</div>
    <heading class="style-scope patent-text">Heterocyclic Sulfonamide Inhibitors of CA IX</heading>
    <heading class="style-scope patent-text">Synthesis of Pyridinium Derivatives of Aminobenzolamide</heading>
    <div num="p-0124" class="description-paragraph style-scope patent-text">Chemistry: Reaction of aminobenzolamide (5-(4-aminobenzenesulfonylamino)-1,3,4-thiadiazole-2-sulfonamide) [97] with 2,6-di-, 2,4,6-<figure-callout id="2" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="3" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="4" label="tri-or" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">tri-or</a></figure-callout> </a></figure-callout> </a></figure-callout> 2,3,4,6-tetrasubstituted pyrylium salts afforded the pyridinium salts 71-91 investigated here, by the general synthesis of such derivatives with nucleophiles (<figure-callout id="1" label="Scheme" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Scheme</a></figure-callout> 1 as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>) [6, 26, 108].</div>
    <div num="p-0125" class="description-paragraph style-scope patent-text">Preparation of compounds: A large number of positively-charged sulfonamides, prepared by reaction of amino-sulfonamides with pyrylium salts [23, 88, 89] were recently reported by this group, and generally tested as inhibitors of the “classical” isozymes CA I, II and IV [81, 96, 97, 98]. Based on QSAR studies on several series of CA inhibitors, including some positively-charged derivatives [23, 88, 89], it emerged that the enhancement of CA inhibitory activity is correlated with increased positive charges on the heterocyclic/aromatic ring incorporated in such molecules, as well as with “long” inhibitor molecules per se (i.e., molecules extending on the direction passing through the Zn(II) ion of the enzyme, the sulfonamide nitrogen atom and the long axis of the inhibitor) [23, 88, 89]. It appeared thus of interest to try to explore this result, designing positively-charged, long sulfonamide CAIs. Thus, we thought of attaching substituted-pyridinium moieties to an already potent and long-molecule CAI suitable for reaction with pyrylium salts, i.e., aminobenzolamide [97]. Indeed, this compound acts as a very potent CAI against <figure-callout id="1" label="isozymes" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">isozymes</a></figure-callout> 1, II and IV (with inhibition constants in the low nanomolar range—see later in the text). The substitution pattern of the pyridinium ring was previously shown [81, 96, 97, 98] to be critical for the biological activity of this type of sulfonamide CAIs. Thus, a large series of 2,4,6-trialkylpyridinium-; 2,6-dialkyl-4-phenylpyridinium-; 2-alkyl-4,6-diphenylpyridinium-; 2,4,6-triphenylpyridinium-, together with various 2,6-disubstituted-pyridinium and 2,3,5,6-tetrasubstituted-pyridinium aminobenzolamide derivatives have been prepared by the reaction described in Scheme 1 (Shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>).</div>
    <div num="p-0126" class="description-paragraph style-scope patent-text">Although apparently simple, the reaction between a pyrylium salt and an amine, leading to pyridinium salts, is in reality a complicated process (<figure-callout id="2" label="Scheme" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Scheme</a></figure-callout> 2, shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref>), as established by detailed spectroscopic and kinetic data from Balaban's and Katritzky's groups [6, 26, 108]. Thus, the nucleophilic attack of a primary amine RNH<sub class="style-scope patent-text">2 </sub>on pyrylium cations generally occurs in the α position, with the formation of intermediates of type IV (depicted in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref>), which by deprotonation in the presence of bases lead to the 2-amino-tetradehydropyran derivatives V. In many cases the deprotonation reaction is promoted by the amine itself, when this is basic enough (this being the reason why in many cases one works at molar ratios pyrylium:amine of 1:2 when pyridinium salts are prepared by this method), or by external catalysts added to the reaction mixture, such as triethylamine [6, 26, 108]. The derivatives V are generally unstable, being tautomers with the ketodieneamines VI which are the key intermediates for the conversion of pyryliums into pyridiniums [6, 26, 108]. In acidic media, in the rate-determining step of the whole process, ketodieneamines VI may be converted to the corresponding pyridinium salts VII, although other products, such as vinylogous amides with diverse structures have also been isolated in such reactions [6, 26, 108]. A supplementary complication appears when the moiety substituting the 2-and/or 6-position(s) of the pyrylium ring is methyl, cases in which a concurrent cyclisation with formation of the anilines VIII in addition to the pyridinium salts VII, may take place too [6, 26, 108]. These concurrent reactions mentioned above are generally important when the amine to be converted into the pyridinium salt possesses weak nucleophilicity or basicity. This happens to be the case of aminobenzolamide. In fact, reaction of aminobenzolamide with several pyrylium salts, performed in a variety of conditions (different solvents, such as low molecular weight alcohols (MeOH, EtOH, i-PrOH); DMF; methylene chloride; acetonitrile; diverse molar ratios of the reagents; temperatures from 25 to 150° C.; reaction times between 15 min and 48 hours, etc) led only to the isolation of the unreacted raw materials. The only conditions which led to the formation of the pyridinium salts III (depicted in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>) were the following: anhydrous methanol in the presence of acetic anhydride as solvent and triethylamine as catalysts for the deprotonation of the intermediates IV. Acetic anhydride had the role of reacting with the water formed in the condensation reaction. This water may in fact act as a competitive nucleophile with aminobenzolamide when reacting with the pyrylium cation, and as a consequence the yields in pyridinium salts would dramatically be decreased. After the rapid formation of the ketodieneamine, catalyzed by triethylamine (and in the presence of the acetic anhydride as water scavenging agent), the cyclisation to the pyridinium ring (the rate-determining step) has been achieved by refluxation in the presence of acetic acid (2-5 hours). Still the yields were not always good, especially for the 2-methyl-containing derivatives.</div>
    <heading class="style-scope patent-text">Representative Sulfonamide Inhibitors of Activated CA IX</heading>
    <div num="p-0127" class="description-paragraph style-scope patent-text">In Examples 5 and 7 below, three exemplary CA IX-selective inhibitors tested for extracellular pH effects [<figure-callout id="6" label="Compounds" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="39" label="Compounds" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compounds</a></figure-callout> </a></figure-callout> 6, 39 and 92 (the FITC-derivative of Compound 5) as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8A</figref>] bind to CA IX preferentially under conditions of hypoxia. As indicated in Example 5, all three sulfonamides were able to reduce the extracellular acidification of MDCK-CA IX cells in hypoxia, and their effect on the normoxic pHe was negligible [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>]. The FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 was detected only in hypoxic MDCK-CA IX cells, but was absent from their normoxic counterparts and from the mock-transfected controls.</div>
    <div num="p-0128" class="description-paragraph style-scope patent-text">Exclusive binding of the FITC-conjugated <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 sulfonamide to the hypoxic cells that express activated CA IX (described in Example 7) offers an attractive possibility for the use of similar sulfonamide-based compounds for imaging purposes in vivo. Moreover, CA IX-selective sulfonamide derivatives may potentially serve as components of the therapeutic strategies designed to increase pHe in the tumor microenvironment and thereby reduce the tumor aggressiveness and the drug uptake [18, 86, 106, 126].</div>
    <div num="p-0129" class="description-paragraph style-scope patent-text">It is generally accepted that the reaction between CA and inhibitor occurs principally via a coordination of the ionized inhibitor to the zinc ion through the network of hydrogen bonds with amino acid residues of the active site, which effectively means that the inhibitor can efficiently bind only to active CA isoforms [102]. It cannot be excluded that hypoxia influences the conformation and hence the accessibility of the active site of CA IX, but this assumption warrants further studies.</div>
    <heading class="style-scope patent-text">Preparation of MN Proteins and/or Polypeptides</heading>
    <div num="p-0130" class="description-paragraph style-scope patent-text">The terms “MN/CA IX” and “MN/CA9” are herein considered to be synonyms for MN. Also, the G250 antigen is considered to refer to MN protein/polypeptide [112].</div>
    <div num="p-0131" class="description-paragraph style-scope patent-text">Zavada et al., WO 93/18152 and/or WO 95/34650 disclose the MN cDNA sequence shown herein in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-1C</figref> [SEQ ID NO: 1], the MN amino acid sequence [SEQ ID NO: 2] also shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-1C</figref>, and the MN genomic sequence [SEQ ID NO: 3] shown herein in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A-2F</figref>. The MN gene is organized into 11 exons and 10 introns.</div>
    <div num="p-0132" class="description-paragraph style-scope patent-text">The first thirty seven amino acids of the MN protein shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-1C</figref> is the putative MN signal peptide [SEQ ID NO: 6]. The MN protein has an extracellular domain [amino acids (aa) 38-414 of <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-1C</figref> [SEQ ID NO: 7], a transmembrane domain [aa 415-434; SEQ ID NO: 8] and an intracellular domain [aa 435-459; SEQ ID NO: 9]. The extracellular domain contains the proteoglycan-like domain [aa 53-111: SEQ ID NO: 4] and the carbonic anhydrase (CA) domain [aa 135-391; SEQ ID NO: 5].</div>
    <div num="p-0133" class="description-paragraph style-scope patent-text">The phrase “MN proteins and/or polypeptides” (MN proteins/polypeptides) is herein defined to mean proteins and/or polypeptides encoded by an MN gene or fragments thereof. An exemplary and preferred MN protein according to this invention has the deduced amino acid sequence shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref>. Preferred MN proteins/polypeptides are those proteins and/or polypeptides that have substantial homology with the MN protein shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref>. For example, such substantially homologous MN proteins/polypeptides are those that are reactive with the MN-specific antibodies, preferably the Mab M75 or its equivalent. The VU-M75 hybridoma that secretes the M75 Mab was deposited at the ATCC under HB 11128 on Sep. 17, 1992.</div>
    <div num="p-0134" class="description-paragraph style-scope patent-text">A “polypeptide” or “peptide” is a chain of amino acids covalently bound by peptide linkages and is herein considered to be composed of 50 or less amino acids. A “protein” is herein defined to be a polypeptide composed of more than 50amino acids. The term polypeptide encompasses the terms peptide and oligopeptide.</div>
    <div num="p-0135" class="description-paragraph style-scope patent-text">It can be appreciated that a protein or polypeptide produced by a neoplastic cell in vivo could be altered in sequence from that produced by a tumor cell in cell culture or by a transformed cell. Thus, MN proteins and/or polypeptides which have varying amino acid sequences including without limitation, amino acid substitutions, extensions, deletions, truncations and combinations thereof, fall within the scope of this invention. It can also be appreciated that a protein extant within body fluids is subject to degradative processes, such as, proteolytic processes; thus, MN proteins that are significantly truncated and MN polypeptides may be found in body fluids, such as, sera. The phrase “MN antigen” is used herein to encompass MN proteins and/or polypeptides.</div>
    <div num="p-0136" class="description-paragraph style-scope patent-text">It will further be appreciated that the amino acid sequence of MN proteins and polypeptides can be modified by genetic techniques. One or more amino acids can be deleted or substituted. Such amino acid changes may not cause any measurable change in the biological activity of the protein or polypeptide and result in proteins or polypeptides which are within the scope of this invention, as well as, MN muteins.</div>
    <div num="p-0137" class="description-paragraph style-scope patent-text">The MN proteins and polypeptides of this invention can be prepared in a variety of ways according to this invention, for example, recombinantly, synthetically or otherwise biologically, that is, by cleaving longer proteins and polypeptides enzymatically and/or chemically. A preferred method to prepare MN proteins is by a recombinant means. Particularly preferred methods of recombinantly producing MN proteins are described below. A representative method to prepare the MN proteins shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> or fragments thereof would be to insert the full-length or an appropriate fragment of MN cDNA into an appropriate expression vector as exemplified in the Materials and Methods section.</div>
    <heading class="style-scope patent-text">MN Gene</heading>
    <div num="p-0138" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-C</figref> provides the nucleotide sequence for a full-length MN cDNA clone [SEQ ID NO: 1] isolated as described in Zavada et al., WO 95/34650. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A-F</figref> provides a complete MN genomic sequence [SEQ ID NO: 3].</div>
    <div num="p-0139" class="description-paragraph style-scope patent-text">The ORF of the MN cDNA shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> has the coding capacity for a 459 amino acid protein with a calculated molecular weight of 49.7 kd. The overall amino acid composition of the MN/CA IX protein is rather acidic, and predicted to have a pl of 4.3. Analysis of native MN/CA IX protein from CGL3 cells by two-dimensional electrophoresis followed by immunoblotting has shown that in agreement with computer prediction, the MN/CA IX is an acidic protein existing in several isoelectric forms with pls ranging from 4.7 to 6.3.</div>
    <div num="p-0140" class="description-paragraph style-scope patent-text">The CA domain is essential for induction of anchorage independence, whereas the TM anchor and IC tail are dispensable for that biological effect. The MN protein is also capable of causing plasma membrane ruffling in the transfected cells and appears to participate in their attachment to the solid support. The data evince the involvement of MN in the regulation of cell proliferation, adhesion and intercellular communication.</div>
    <heading class="style-scope patent-text">Enzymatic Screening Assays</heading>
    <div num="p-0141" class="description-paragraph style-scope patent-text">Assays are provided herein for the screening of compounds for inhibition of the enzymatic activity of the MN protein. Such assays comprise the incubation of said compound with said MN protein and with a substrate selected from the group consisting of saturated CO<sub class="style-scope patent-text">2 </sub>and 4-nitrophenylacetate, preferably saturated CO<sub class="style-scope patent-text">2</sub>, and determination of the inhibition constant K<sub class="style-scope patent-text">I </sub>of said compound, wherein said enzymatic activity of the MN protein is measured by the pH change of an indicator by stopped flow spectrophotometer.</div>
    <div num="p-0142" class="description-paragraph style-scope patent-text">Screening of representative heterocyclic and aromatic sulfonamides for inhibition of MN protein: From Example 1, it was found that the inhibition profile of isozyme CA IX is very different from that of the classical isozymes CA I and II (cytosolic) as well as CA IV (membrane-bound). The following particular features may be noted: (i) all the 32 sulfonamides investigated in Example 1 act as CA IX inhibitors, with inhibition constants in the range of 14-285 nM (the corresponding affinities for the other three isozymes vary in a much wider range, as seen from data of Table 1). Based on these data, it can be noted that CA IX is a sulfonamide avid CA, similarly to CA II, the isozyme considered up to now to be responsible for the majority of pharmacological effect of sulfonamides [22, 29, 83, 93, 94, 95, 102]. Still, many other differences are observed between CA IX and other isozymes for which inhibitors were developed for clinical use; (ii) for CA I, II and IV, generally, aromatic sulfonamides behave as weaker inhibitors as compared to heterocyclic derivatives (compare 1-6, or DCP), as aromatic compounds, with 15, 21, AAZ, MZA, EZA, DZA or BRZ among others (as heterocyclic sulfonamides). In the case of CA IX, such a fine distinction is rather difficult to be made, since both aromatic (such as 1, 6, 11, 12, 17, 18, 22-26) derivatives, as well as heterocyclic compounds (such as 14, 15, 21, and the clinically used sulfonamides—except dichlorophenamide) possess rather similar inhibition constants, in the range of 14-50 nM; (iii) orthanilamide derivatives (such as 1, 17 and 22) behave as very potent CA IX inhibitors (K<sub class="style-scope patent-text">I</sub>-s in the range of 20-33 nM), although they are weak or medium-weak inhibitors of CA I, II and IV; (iv) 1,3-benzene-disulfonamide derivatives (such as 11, 12 and DCP) are again strong CA IX inhibitors, with K<sub class="style-scope patent-text">I</sub>-s in the range of 24-50 nM, although their CA II, I and IV inhibition profile is not particularly strong; (v) metanilamide 2, sulfanilamide 3, and 4-hydrazino-benzenesulfonamide 4 show CA IX inhibition data quite similar with those against CA II, whereas homosulfanilamide 5 and 4-aminoethyl-benzensulfonamide 6 act as better CA IX inhibitors as compared to CA II inhibition; (vi) the halogenosulfanilamides 7-10 are much weaker inhibitors of CA IX than of CA II, a finding difficult to interpret at this moment; (vii) the strongest CA II inhibitor among the investigated compounds, 4-aminobenzolamide 15 (K<sub class="style-scope patent-text">I </sub>of 2 nM) is not the strongest CA IX inhibitor (K<sub class="style-scope patent-text">I </sub>of 38 nM). Instead, the best CA IX inhibitor detected so far is the ethoxzolamide phenol 21 (K<sub class="style-scope patent-text">I </sub>of 14 nM). It is interesting to note that 21 and EZA have the same affinity for CA II, whereas their affinity for CA IX is rather different, with the phenol more active than the ethoxy-derivative; (viii) among the clinically used compounds, the best inhibitor is acetazolamide, followed by methazolamide, ethoxzolamide and brinzolamide. The most ineffective (but appreciably inhibiting the isozyme IX) are dichlorophenamide and dorzolamide; (ix) <figure-callout id="20" label="sulfonamides" filenames="US07833737-20101116-D00012.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">sulfonamides</a></figure-callout> 20 and 22-26 behave as very good CA IX inhibitors, with K<sub class="style-scope patent-text">I</sub>-s in the range of 16-32 nM, being slightly more effective than the clinically used CAIs mentioned above, and among the best CA IX inhibitors detected so far. It is thus envisageable that such compounds may be used as lead molecules for obtaining more potent and eventually specific CA IX inhibitors, with applications as antitumor agents.</div>
    <div num="p-0143" class="description-paragraph style-scope patent-text">Screening of representative pyridinium derivatives of aromatic sulfonamides for inhibition of MN protein: From Example 2, wherein membrane-impermeant pyridinium derivatives of sulfonamides were tested for their ability to inhibit the enzymatic activity of CA IX, the following conclusions were drawn from data of Table 2: (i) for a given substitution pattern of the pyridinium ring, the 4-aminoethyl-benzenesulfonamide derivatives 55-70 were more active than the corresponding homosulfanilamide derivatives 39-54, which in turn were more active than the corresponding sulfanilamides 27-38. This behavior has also been observed for the other three investigated isozymes [96]; (ii) some of the derivatives possessing bulky substitutents at the pyridinium ring (mainly phenyls, tert-butyls; n-butyl, n-propyl or iso-propyl), such as 34-37, 51 and 67, were very ineffective CA IX inhibitors, showing inhibition constants &gt;500 nM; (iii) another group of compounds, including 27, 30-33, 44, and 60 showed a moderate inhibitory power towards the tumor-associated isozyme IX, showing K<sub class="style-scope patent-text">I </sub>values in the range of 160-450 nM. Most of these compounds are sulfanilamide derivatives (except 44 and 60), and the substitution pattern at the pyridinium ring includes (with one exception, 27) at least one phenyl group in 4, or two phenyls in the 2 and 4 positions. It should be noted that the corresponding homosulfanilamides and 4-aminoethylbenzene-sulfonamides incorporating the same substitution pattern as the compounds mentioned above (sulfanilamides), lead to much better CA IX inhibitors (see later in the text); (iv) a third group of derivatives, including 38, 45-50, 52, 53, 61, 63-66, 68 and 69, showed good CA IX inhibitory properties, with K<sub class="style-scope patent-text">I </sub>values in the range of 64-135 nM. As mentioned above, except for the tetramethyl-pyridinium-substituted derivative 38, most of these compounds incorporate 4-phenyl-pyridinium or 2,4-diphenylpyridinium moieties, whereas the group in <figure-callout id="6" label="position" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">position</a></figure-callout> 6 is generally quite variable (alkyls or phenyl are tolerated). The most interesting observation regarding this subtype of CA IX inhibitors is constituted by the fact that the 2,4,6-triphenyl-pyridinium-and 2,6-diphenyl-pyridinium derivatives of homosulfanilamide and 4-aminoethylbenzenesulfonamide (52-53 and 68-69) efficiently inhibit isozyme IX, although they act as very weak inhibitors for isozymes I, II and IV (Table 2). As it will be discussed shortly, this may be due to the fact that the hCA IX active site is larger than that of the other investigated isozymes, notably CA II, I and IV; (v) a last group of derivatives (28-29; 39-43; 54; 55-59; 62 and 70) showed very good CA IX inhibitory properties, these compounds possessing K<sub class="style-scope patent-text">I </sub>values in the range of 6-54 nM, similarly to the clinically used inhibitors acetazolamide, methazolamide, dichlorophenamide and indisulam, for which the inhibition data are provided for comparison. It should be noted that three derivatives 58, 59 and 70 showed inhibition constants &lt;10 nM, these being the most potent CA IX inhibitors ever reported up to now. Correlated with their membrane-impermeability [96, 85], it may be assumed that in vivo such compounds may lead for the first time to a selective CA IX inhibition. Thus, the best substitution pattern at the pyridinium ring includes either only compact alkyls (39-41, 54, 55 and 70), or 2,6-dialkyl-4-phenyl-pyridinium moieties (all compounds mentioned above except 62, which incorporates a 2-methyl-4,6- diphenylpyridinium ring); (vi) the number of the substitutents at the pyridinium ring seems to be less important for the activity of this series of CAIs, since both di-, tri-or tetrasubstituted derivatives showed good inhibitory potency. The nature of these groups on the other hand—as discussed in detail above—is the most important parameter influencing CA inhibitory properties (together with the linker between the benzenesulfonamide moiety and the substituted pyridinium ring); (vii) the isozyme most similar to hCA IX regarding the affinity for these inhibitors was hCA II (which has 33% homology with hCA IX) [Pastorek et al. (1994), supra] whereas the affinities of isozymes I and IV were rather different.</div>
    <div num="p-0144" class="description-paragraph style-scope patent-text">Screening of representative pyridinium derivatives of heterocyclic sulfonamides for inhibition of MN protein, and comparison with inhibition of other CA isozymes: Isozyme I. As seen from data of Table 3, all derivatives 71-91 reported here act as very efficient CAIs against this isozyme which is generally the most “resistant” to inhibitors of this type [30, 31, 100, 102]. Indeed, aminobenzolamide is already a highly potent CA I inhibitor (K<sub class="style-scope patent-text">I </sub>of 6 nM), whereas inhibitors 71-91 show inhibition constants in the range of 3-12 nM, in contrast to the clinically used sulfonamide CAIs which are much less effective inhibitors, with K<sub class="style-scope patent-text">I </sub>values in the range of 30-1200 nM (Table 3). Thus, derivatives possessing several bulky groups (i-Pr; t-Bu; n-Pr; n-Bu; Ph, etc) substituting the pyridinium moiety, such as 73, 74, 77, 78, 82, 84, 85 showed a decreased inhibitory activity as compared to aminobenzolamide, with K<sub class="style-scope patent-text">I </sub>values in the range of 7-12 nM (aminobenzolamide has a K<sub class="style-scope patent-text">I </sub>of 6 nM against hCA I). The rest of the compounds were more efficient as compared to aminobenzolamide in inhibiting this isozyme, with K<sub class="style-scope patent-text">I </sub>values in the range of 3-5 nM. Best CA I inhibitors were 75, and 89-91 (K<sub class="style-scope patent-text">I </sub>of 3 nM), all of which containing either only alkyl moieties or 4-Ph and other alkyl moieties substituting the pyridinium ring. These are probably the best CA I inhibitors ever reported up to now, since the clinically used CAIs show much higher inhibition constants against isozyme I (Table 3).</div>
    <div num="p-0145" class="description-paragraph style-scope patent-text">Isozyme II. Aminobenzolamide is already a very potent CA II inhibitor, with an inhibition constant around 2 nM. Several of the new inhibitors, such as 74, 77, 78, 82-88 act as weaker CA II inhibitors as compared to aminobenzolamide, with K<sub class="style-scope patent-text">I </sub>values in the range of 3.13-5.96 nM (but all these compounds act as potent inhibitors, being much more effective than the clinically used CAIs acetazolamide, methazolamide, dichlorophenamide or indisulam—see Table 3). Again the substitution pattern at the pyridinium ring is the main discriminator of activity for these compounds: all the less active derivatives mentioned above incorporate at least two bulky/long aliphatic groups, mainly in positions 2-and 6-of the pyridinium ring (n-Pr; t-Bu; n-Bu; and Ph). The best CA II inhibitors among derivatives 71-91 were those incorporating more compact 2,6-substituents at the pyridinium ring (such as Me, Et) together with a 4-Me or 4-Phe moiety, or those incorporating only aliphatic such groups, such as 71-73, 75, 76, 79-81, 89-91, which showed K<sub class="style-scope patent-text">I </sub>values in the range of 0.20-1.61 nM (thus, for the best inhibitors a factor of 10 increase in inhibitory power as compared to aminobenzolamide). It should be mentioned that iso-propyl-substituted compounds (73, 79) are active as CA II inhibitors, although their activity against CA I was not so good.</div>
    <div num="p-0146" class="description-paragraph style-scope patent-text">Isozyme IV. Most sulfonamides show inhibitory activity against CA IV intermediate between those towards CA I (less susceptible) and CA II (very high affinity for sulfonamides). This is also the trend observed with the sulfonamides investigated here, derivatives of aminobenzolamide. Thus, the parent sulfonamide (shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>) is a potent CA IV inhibitor, with a K<sub class="style-scope patent-text">I </sub>value around 5 nM. The new derivatives of general formula (B) incorporating bulky pyridinium-ring substituents (such as 74, 77, 78, 82, 84-88, 90) were less effective than aminobenzolamide, showing K<sub class="style-scope patent-text">I </sub>values in the range of 5.2-10.3 nM, whereas the compounds showing the other substitution pattern mentioned above were better CA IV inhibitors, showing K<sub class="style-scope patent-text">I </sub>values in the range of 2.0-4.7 nM.</div>
    <div num="p-0147" class="description-paragraph style-scope patent-text">Isozyme IX. Aminobenzolamide is less inhibitory against this isozyme (K<sub class="style-scope patent-text">I </sub>of 38 nM) as compared to other isozymes discussed above. This behavior is difficult to explain at this point, since no X-ray crystal structure of this isozyme has been reported. A very encouraging result obtained with the new derivatives of general formula (B) reported here, was the observation that several of them show very high affinity for CA IX, with K<sub class="style-scope patent-text">I </sub>values in the range of 3-9 nM (<figure-callout id="76" label="derivatives" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">derivatives</a></figure-callout> 71, 72, 75, 76, and 89). It may be seen that all of them incorporate aliphatic moieties (Me, Et and i-Pr) in positions 2-and 6-of the pyridinium ring, and either 4-Me or 4-Ph moieties. Only one compound is tetrasubstituted (89), again possessing only methyl moieties. The best CA IX inhibitor (and the best ever reported up to now) was 71, which is almost 13 times more effective than benzolamide in inhibiting this isozyme. Another group of new derivatives, such as 73, 74, 77, 79, 80, 81, 83, 86-88, 90, 91, showed effective CA IX inhibition, with K<sub class="style-scope patent-text">I </sub>values in the range of 12-35 nM, being thus more effective than aminobenzolamide. They incorporate slightly bulkier groups as compared to the previously discussed ones. Again the less effective inhibitors (K<sub class="style-scope patent-text">I </sub>values in the range of 40-43 nM) were those incorporating several bulky pyridinium substituents, such as 78, 84, 85 which contained either two n-Bu or one Ph and n-Bu/t-Bu in positions 2-and 6-of the pyridinium ring. Thus, SAR is now rather clear for this type of CAIs: best CA IX inhibitors should contain either only small, compact aliphatic moieties substituting the pyridinium ring, or they tolerate a 4-Ph moiety, but the 2,6-substituents should again be small, compact aliphatic moieties. In this particular case, 2,4,6-trisubstituted-pyridinium derivatives were more effective CA IX inhibitors as compared to the tetrasubstituted derivatives.</div>
    <div num="p-0148" class="description-paragraph style-scope patent-text">Membrane impermeability of Heterocyclic Sulfonamide Inhibitors of CA IX. As seen from data of Table 4 of Example 3, incubation of human red cells (which contain high concentrations of isozymes I and II, i.e., 150 μM hCA I and 20 μM hCA II, but not the membrane-bound CA IV or CA IX) [118] with millimolar concentrations of different sulfonamide inhibitors, such as acetazolamide, or methazolamide, led to saturation of the two isozymes present in erythrocytes with inhibitor, already after short periods of incubation (30 min), whereas for benzolamide or aminobenzolamide, a similar effect is achieved after somehow longer periods (60 min) (Table 4). This is obviously due to the high diffusibility through membranes of the first three inhibitors, whereas benzolamide/aminobenzolamide with a pK<sub class="style-scope patent-text">a </sub>of 3.2 for the second sulfonamido group [58] being present mainly as an (di)anion at the pH at which the experiment has been done (7.4), is already less diffusible and penetrates membranes in a longer time. Different cationic sulfonamides synthesized by us here, such as 71, 76, 89, 91, in the same conditions, were detected only in very small amounts within the blood red cells, proving that they were unable to penetrate through the membranes, obviously due to their cationic nature. Even after incubation times as long as one hour (and longer, data not shown), only traces of such cationic sulfonamides were present inside the blood red cells, as proved by the three assay methods used for their identification in the cell lysate, which were in good agreement with each other (Table 4). This demonstrates that the proposed approach for achieving membrane impermeability works well for the designed positively-charged sulfonamide CAIs of the general formula (B) (shown above), since the very small amount of sulfonamide detected may be due to contamination of the lysates with very small amount of membranes.</div>
    <heading class="style-scope patent-text">Design of Membrane-Impermeant Sulfonamide Inhibitors of CA IX</heading>
    <div num="p-0149" class="description-paragraph style-scope patent-text">No X-ray crystal structure of isozyme IX is available up to now, in strong contrast with hCA II, for which many X-ray crystal structures are available (alone or in complexes with inhibitors and activators) [1, 2, 14, 15, 19a, 19b, 37, 38]. Examining the active site residues of these two isozymes and the architecture of hCA II, may help explain the above inhibition data and their relevance for CA IX specific inhibitors.</div>
    <div num="p-0150" class="description-paragraph style-scope patent-text">First of all, the zinc ligands and the proton shuttle residue of these two isozymes are identical [33, 43, 72, 100, 101, 102, 114, 115, 117]. An important difference is constituted by the amino acid in <figure-callout id="131" label="position" filenames="US07833737-20101116-D00017.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">position</a></figure-callout> 131, which is Phe for hCA II and Val for hCA IX. <figure-callout id="131" label="Phe" filenames="US07833737-20101116-D00017.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Phe</a></figure-callout> 131 is known to be very important for the binding of sulfonamide inhibitors to hCA II [2, 46, 47]: in many cases this bulky side chain limits the space available for the inhibitor aromatic moieties, or it may participate in stacking interactions with groups present in it (for recent examples see refs. [2, 46, 47]. Thus, the presence of a less bulky such residue in hCA IX (i.e., a valine) which is also unavailable for participation to stacking interactions has as a consequence the fact that the hCA IX active site is larger than that of hCA II. A second potentially important residue is 132, which is Gly in hCA II and Asp in hCA IX. This residue is situated on the rim of the hydrophilic half of the entrance to the active site of hCA II (and presumably also of hCA IX) and it is critical for the interaction with inhibitors possessing elongated molecules, as recently shown by us [19b]. Strong hydrogen bonds involving the CONH moiety of Gly 132 were shown to stabilize the complex of this isozyme with a p-aminoethylbenzenesulfonamide derived inhibitor [19b]. In the case of hCA IX, the presence of aspartic acid in this position at the entrance of the active site may signify that: (i) stronger interactions with polar moieties of the inhibitor bound within the active site should be possible, since the COOH moiety possesses more donor atoms; (ii) this residue may have flexible conformations, fine-tuning in this way the interaction with inhibitors. Thus, the stronger hCA IX inhibition with some of these inhibitors (as compared to their affinity for isozyme II), such as for example 46-50, 52, 53, 55, 58, 62 and 68-70, might be explained just by the different interactions with the two active site residues mentioned above.</div>
    <heading class="style-scope patent-text">Therapeutic Use of MN-Specific Inhibitors</heading>
    <div num="p-0151" class="description-paragraph style-scope patent-text">The MN-specific inhibitors of this invention, organic and/or inorganic, preferably organic, and as outlined above, may be used therapeutically in the treatment of neoplastic and/or pre-neoplastic disease, either alone or in combination with other chemotherapeutic drugs.</div>
    <div num="p-0152" class="description-paragraph style-scope patent-text">The MN-specific inhibitors can be administered in a therapeutically effective amount, preferably dispersed in a physiologically acceptable, non-toxic liquid vehicle.</div>
    <div num="p-0153" class="description-paragraph style-scope patent-text">The MN-specific inhibitors used according to the methods of the invention may exploit activation of CA IX under hypoxia, to specifically target hypoxic conditions, acidic conditions or both conditions.</div>
    <div num="p-0154" class="description-paragraph style-scope patent-text">In addition to targeting hypoxia, CA IX selective inhibitors may be used therapeutically to increase pHe in order to reduce tumor aggressiveness and drug uptake. It is known that the atypical pH gradient of tumor cells (acidic extracellular pH, neutral-to-basic intracellular pH) acts to exclude weak base drugs such as the anthracyclines and vinca alkaloids. In two different mouse tumor models, alkalinization of tumor extracellular pH (using bicarbonate pretreatment) enhanced the anti-tumor activity of the weak base chemotherapeutic agents doxorubicin and mitoxantrone [126, 137]. Most combination chemotherapy regimens include at least one weak base drug, and it may be possible to enhance the efficacy of such drugs with the co-administration of CA IX-specific inhibitors.</div>
    <heading class="style-scope patent-text">Diagnostic/Prognostic and Therapeutic Use of MN-Specific Inhibitors which Selectively Bind Activated CA Domain of CA IX</heading>
    <div num="p-0155" class="description-paragraph style-scope patent-text">As used herein, “normoxia” is defined as oxygen tension levels in a specific vertebrate tissue that are within the normal ranges of physiological oxygen tension levels for that tissue. As used herein, “hypoxia” is defined as an oxygen tension level necessary to stabilize HIF-1α in a specific tissue or cell. Experimentally-induced hypoxia is generally in the range of 2% pO<sub class="style-scope patent-text">2 </sub>or below, but above anoxia (0% pO<sub class="style-scope patent-text">2</sub>, as anoxia would be lethal). The examples described herein that concern hypoxia were performed at 2% pO<sub class="style-scope patent-text">2 </sub>which is an exemplary hypoxic condition. However, ones of skill in the art would expect other oxygen tension levels to be understood as “hypoxic” and to produce similar experimental results. For example, Wykoff et al. [121] used a condition of 0.1% pO<sub class="style-scope patent-text">2 </sub>as representative of hypoxia to induce HIF-1α-dependent expression of CA9. Tomes et al. has demonstrated varying degrees of HIF-1α stabilization and CA9 expression in HeLa cells or primary human breast fibroblasts under exemplary in vitro hypoxic conditions of 0.3%, 0.5% and 2.5% pO<sub class="style-scope patent-text">2 </sub>[Tomes et al., <i class="style-scope patent-text">Br. Cancer Res. Treat., </i>81(1): 61-69 (2003)]. Alternatively, Kaluz et al. has used the exemplary hypoxic condition of 0.5% pO<sub class="style-scope patent-text">2 </sub>for experimental induction of CA9 [Kaluz et al., <i class="style-scope patent-text">Cancer Res., </i>63: 917-922 (2003)] and referred to “experimentally-induced ranges” of hypoxia as 0.1-1% pO<sub class="style-scope patent-text">2 </sub>[129].</div>
    <div num="p-0156" class="description-paragraph style-scope patent-text">Oxygen tension levels above 2% pO<sub class="style-scope patent-text">2 </sub>may also be hypoxic, as shown by Tomes et al., supra. One of skill in the art would be able to determine whether a condition is hypoxic as defined herein, based on a determination of HIF-1α stabilization. Exemplary ranges of hypoxia in a specific tissue or cell may be, for example, between about 3% to about 0.05% pO<sub class="style-scope patent-text">2</sub>, between about 2% to about 0.1% pO<sub class="style-scope patent-text">2</sub>, between about 1% to about 0.1% pO<sub class="style-scope patent-text">2</sub>, and between about 0.5% to about 0.1% pO<sub class="style-scope patent-text">2</sub>.</div>
    <div num="p-0157" class="description-paragraph style-scope patent-text">“Mild hypoxia” is defined herein as an oxygen tension level in a specific vertebrate tissue that does not stabilize HIF-1a and is below normoxia. Mild hypoxia would be understood by those of skill in the art to be below normoxia but still above hypoxia.</div>
    <div num="p-0158" class="description-paragraph style-scope patent-text">As has been previously reported by the inventors and others, CA IX can be expressed by alternative mechanisms, at least in vitro: a hypoxia-regulated pathway which requires HIF-1α stabilization, and a <figure-callout id="3" label="phosphatidylinositol" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phosphatidylinositol</a></figure-callout> 3′ kinase (PI3K) pathway occurring at high cell density, which requires a minimal level of HIF-1α and a lowered oxygen concentration that is, however, above that necessary for HIF-1α stabilization [129]. Cell crowding may lead to pericellular mild hypoxia; for example, in dense LNCaP human <figure-callout id="48" label="prostate carcinoma cells" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">prostate carcinoma cells</a></figure-callout> 48 hours after plating, oxygen tension was 9% pO<sub class="style-scope patent-text">2 </sub>above the cell surface, compared with 13% pO<sub class="style-scope patent-text">2 </sub>above sparse cells, and compared with 0.1-1% pO<sub class="style-scope patent-text">2 </sub>frequently used in experimentally induced hypoxic responses [Sheta et al., <i class="style-scope patent-text">Oncogene, </i>20: 7624-7634 (2001)]. The cell density-dependent induction of CA IX may explain CA IX expression in areas adjacent to hypoxic regions in solid tumors, and the selectivity of the CA IX-specific inhibitors for hypoxically-induced CA IX may be exploited to differentiate between the two mechanisms diagnostically, prognostically and therapeutically.</div>
    <div num="p-0159" class="description-paragraph style-scope patent-text">The CA IX-specific inhibitors which selectively bind the activated form of CA IX can be used, for example, in laboratory diagnostics, using fluorescence microscopy or histochemical staining; as a component in assays for detecting and/or quantitating MN antigen in, for example, clinical samples; in electron microscopy with colloid gold beads for localization of MN proteins and/or polypeptides in cells; and in genetic engineering for cloning the MN gene or fragments thereof, or related cDNA. Such activated CA IX-specific inhibitors can be used as components of diagnostic/prognostic kits, for example, for in vitro use on histological sections; such inhibitors can be labeled appropriately, as with a suitable radioactive isotope, and used in vivo to locate metastases by scintigraphy. Further such inhibitors may be used in vivo therapeutically to treat cancer patients with or without toxic and/or cytostatic agents attached thereto. Further, such inhibitors can be used in vivo to detect the presence of neoplastic and/or pre-neoplastic disease. Still further, such inhibitors can be used to affinity purify MN proteins and polypeptides.</div>
    <div num="p-0160" class="description-paragraph style-scope patent-text">Such CA IX-specific inhibitors which selectively bind activated CA IX could be used in combination with other compounds which bind to any forms of CA IX, in order to differentiate between hypoxic and nonhypoxic expression of CA IX. For example, such methods could comprise the immunohistochemical use of a CA IX-specific sulfonamide, such as <figure-callout id="92" label="compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">compound</a></figure-callout> 92, and an antibody which binds to the PG domain of CA IX, such as the M75 Mab. If a tissue overexpresses CA IX, as indicated by M75 Mab binding, but such CA IX is not activated, as indicated by lack of CAI sulfonamide binding, it would indicate that the CA IX expression is induced by a nonhypoxic condition which elevates CA IX levels, such as by cell density-dependent induction of CA IX mediated by <figure-callout id="3" label="phosphatidylinositol" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phosphatidylinositol</a></figure-callout> 3′-kinase (P13K). Alternatively, the methods of the invention could comprise the use of an antibody which specifically binds the activated form of the CA domain of CA IX, in combination with an antibody which binds to another domain of CA IX, such as the Mab M75 which binds to the PG domain, in order to differentiate between hypoxic and nonhypoxic expression of CA IX.</div>
    <div num="p-0161" class="description-paragraph style-scope patent-text">Such information may be useful as a method of indicating degrees of lowered oxygen tension; for example, at intermediate oxygen tension levels (for example, such as between 9% and 5% pO<sub class="style-scope patent-text">2</sub>), CA IX may be induced, but not activated, and may be detected only by the MAb M75; whereas at hypoxic pO<sub class="style-scope patent-text">2 </sub>levels (such as 2% or less), CA IX protein/polypeptide may be both expressed and activated, and detectable by both the Mab M75 and by a CAI sulfonamide which specifically binds the activated CA domain of CA IX. Thus, detection of both the presence of CA IX and its specific binding by CA IX-specific CAIs can be used in combination as a noninvasive method to determine pO<sub class="style-scope patent-text">2 </sub>levels of a tissue. Such information may be useful diagnostically/prognostically or in patient therapy selection, depending upon which CA IX functions are targeted. For example, in in vitro RNA interference studies, expression of CA IX under both normoxia and hypoxia promoted tumor growth, in additive effects [138]. Those data along with the present invention implicate more than one CA IX function as promoting tumor growth. Radiobiologically relevant tumor hypoxia appears to occur at lower oxygen tension levels, such as at 2% pO<sub class="style-scope patent-text">2 </sub>or lower, which oxygen tension levels may induce activated CA IX expression that is detectable by CA IX-specific inhibitors. It is possible that tumors that express CA IX constitutively because of deregulation [such as deregulated PI3K activity; 129] may be distinguished by the CA IX being detectable by the Mab M75 but not by CA IX-specific inhibitors (because the CA domain is overexpressed but not activated).</div>
    <heading class="style-scope patent-text">Materials and Methods</heading>
    <div num="p-0162" class="description-paragraph style-scope patent-text">General. Melting points: heating plate microscope (not corrected); IR spectra: KBr pellets, 400-4000 cm<sup class="style-scope patent-text">−1 </sup>Perkin-Elmer 16PC FTIR spectrometer; <sup class="style-scope patent-text">1</sup>H-NMR spectra: Varian 300CXP apparatus (chemical shifts are expressed as δ values relative to Me<sub class="style-scope patent-text">4</sub>Si as standard); Elemental analysis: Carlo Erba Instrument CHNS Elemental Analyzer, Model 1106. All reactions were monitored by thin-layer chromatography (TLC) using 0.25-mm precoated silica gel plates (E. Merck). Pyrylium salts were prepared by literature procedures, generally by olefin (or their precursors) bisacylation, as described in the literature [6, 26, 108], whereas aminobenzolamide as described earlier [97]. Other sulfonamides used as standards were commercially available.</div>
    <heading class="style-scope patent-text">General Procedure for the Preparation of Compounds 71-91</heading>
    <heading class="style-scope patent-text">Pyridinium Derivatives of Aminobenzolamide</heading>
    <div num="p-0163" class="description-paragraph style-scope patent-text">An amount of 2.9 mM of aminobenzolamide [97] and 2.9 mM of pyrylium salt II (depicted in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref>) were suspended in 5 mL of anhydrous methanol and poured into a stirred mixture of 14.5 mM of triethylamine and 5.8 mM of acetic anhydride. After five minutes of stirring, another 10 mL of methanol were added to the reaction mixture, which was heated to reflux for 15 min. Then 14.5 mM of acetic acid was added and heating was continued for 2-5 hours. The role of the acetic anhydride is to react with the water formed during the condensation reaction between the pyrylium salt and the aromatic amine, in order to shift the equilibrium towards the formation of the pyridinium salts of the general formula (B) (shown above). In the case of aminobenzolamide, this procedure is the only one which gave acceptable yields in pyridinium salts, probably due to the deactivating effect of the sulfamoylaminothiadiazole moiety on the amine group, which becomes poorly nucleophilic and unreactive towards these reagents. The precipitated pyridinium salts obtained were purified by treatment with concentrated ammonia solution (which also converts the eventually unreacted pyrylium salt to the corresponding pyridine which is soluble in acidic medium), reprecipitation with perchloric acid and recrystallization from water with 2-5% HClO<sub class="style-scope patent-text">4</sub>.</div>
    <div num="h-0027" class="description-paragraph style-scope patent-text">Purification of Catalytic Domain of CA IX</div>
    <div num="p-0164" class="description-paragraph style-scope patent-text">The cDNA of the catalytic domain of hCA IX (isolated as described by Pastorek et al. [72]) was amplified by using PCR and specific primers for the vector pCAL-n-FLAG (from Stratagene). The obtained construct was inserted in the pCAL-n-FLAG vector and then cloned and expressed in <i class="style-scope patent-text">Escherichia coli </i>strain BL21-GOLD(DE3) (from Stratagene). The bacterial cells were lysed and homogenated in a buffered solution (pH 8) of 4 M urea and 2% Triton X-100, as described by Wingo et al. [116]. The homogenate thus obtained was extensively centrifuged in order to remove soluble and membrane associated proteins as well as other cellular debris. The resulting pellet was washed by repeated homogenation and centrifugation in water, in order to remove the remaining urea and Triton X-100. Purified CA IX inclusion bodies were denatured in 6 M guanidine hydrochloride and refolded into the active form by snap dilution into a solution of 100 mM MES (pH 6), 500 mM L-arginine, 2 mM ZnCl<sub class="style-scope patent-text">2</sub>, 2 mM EDTA, 2 mM reduced glutathione, 1 mM oxidized glutathione. Active hCA IX was extensively dialysed into a solution of 10 mM Hepes (pH 7.5), 10 mM Tris HCl, 100 mM Na<sub class="style-scope patent-text">2</sub>SO<sub class="style-scope patent-text">4 </sub>and 1 mM ZnCl<sub class="style-scope patent-text">2</sub>. The amount of protein was determined by spectrophometric measurements and its activity by stopped-flow measurements, with CO<sub class="style-scope patent-text">2 </sub>as substrate [44]. Optionally, the protein was further purified by sulfonamide affinity chromatography [44], the amount of enzyme was determined by spectrophometric measurements and its activity by stopped-flow measurements, with CO<sub class="style-scope patent-text">2 </sub>as substrate [44].</div>
    <div num="h-0028" class="description-paragraph style-scope patent-text">CA I, II and IV Purification</div>
    <div num="p-0165" class="description-paragraph style-scope patent-text">Human CA I and CA II cDNAs were expressed in <i class="style-scope patent-text">Escherichia coli </i>strain BL21 (DE3) from the plasmids pACA/hCA I and pACA/hCA II described by Lindskog's group [54]. Cell growth conditions were those described in ref. [12], and enzymes were purified by affinity chromatography according to the method of Khalifah et al. [45]. Enzyme concentrations were determined spectrophotometrically at 280 nm, utilizing a molar absorptivity of 49 mM<sup class="style-scope patent-text">−1</sup>·cm<sup class="style-scope patent-text">−1 </sup>for <figure-callout id="1" label="CA" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">CA</a></figure-callout> 1 and 54 mM<sup class="style-scope patent-text">−1</sup>·cm<sup class="style-scope patent-text">−1 </sup>for CA II, respectively, based on M<sub class="style-scope patent-text">r</sub>=28.85 kDa for CA I, and 29.3 kDa for CA II, respectively [53, 84]. CA IV was isolated from bovine lung microsomes as described by Maren et al, and its concentration has been determined by titration with ethoxzolamide [59].</div>
    <heading class="style-scope patent-text">Enzyme Assays</heading>
    <div num="h-0030" class="description-paragraph style-scope patent-text">CA CO2 Hydrase Activity Assay</div>
    <div num="p-0166" class="description-paragraph style-scope patent-text">An SX.18MV-R Applied Photophysics stopped-flow instrument has been used for assaying the CA CO<sub class="style-scope patent-text">2 </sub>hydration activity assays [44]. A stopped flow variant of the Poker and Stone spectrophotometric method [76] has been employed, using an SX.18MV-R Applied Photophysics stopped flow instrument, as described previously [43]. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5) as buffer, 0.1 M Na<sub class="style-scope patent-text">2</sub>SO<sub class="style-scope patent-text">4 </sub>(for maintaining constant the ionic strength), following the CA-catalyzed CO<sub class="style-scope patent-text">2 </sub>hydration reaction for a period of 10-100 s. Saturated CO<sub class="style-scope patent-text">2 </sub>solutions in water at 20° C. were used as substrate [44]. Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10-20% (v/v) DMSO (which is not inhibitory at these concentrations) and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 10 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results.</div>
    <div num="h-0031" class="description-paragraph style-scope patent-text">CA Esterase Activity Assay</div>
    <div num="p-0167" class="description-paragraph style-scope patent-text">Initial rates of 4-nitrophenylacetate hydrolysis catalysed by different CA isozymes were monitored spectrophotometrically, at 400 nm, with a <figure-callout id="3" label="Cary" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Cary</a></figure-callout> 3 instrument interfaced with an IBM compatible PC [76]. Solutions of substrate were prepared in anhydrous acetonitrile; the substrate concentrations varied between 2.10<sup class="style-scope patent-text">−2 </sup>and 1.10<sup class="style-scope patent-text">−6 </sup>M, working at 25° C. A molar absorption coefficient ε of 18,400 M<sup class="style-scope patent-text">−1</sup>·cm<sup class="style-scope patent-text">−1 </sup>was used for the 4-nitrophenolate formed by hydrolysis, in the conditions of the experiments (pH 7.40), as reported in the literature [76]. Non-enzymatic hydrolysis rates were always subtracted from the observed rates. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results. Stock solutions of inhibitor (1-3 mM) were prepared in distilled-deionized water with 10-20% (v/v) DMSO (which is not inhibitory at these concentrations) and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 10 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constant K<sub class="style-scope patent-text">I </sub>was determined as described in references [44, 76].</div>
    <heading class="style-scope patent-text">Membrane Permeance Assay</heading>
    <heading class="style-scope patent-text">Ex Vivo Penetration through Red Blood Cells</heading>
    <div num="p-0168" class="description-paragraph style-scope patent-text">An amount of 10 mL of freshly isolated human red cells thoroughly washed several times with Tris buffer (pH 7.40, 5 mM) and centrifuged for 10 min were treated with 25 mL of a 2 mM solution of sulfonamide inhibitor. Incubation has been done at 37° C. with gentle stirring, for periods of 30-120 min. After the incubation times of 30, 60 and 120 min., respectively, the red cells were centrifuged again for 10 min, the supernatant discarded, and the cells washed three times with 10 mL of the above mentioned buffer, in order to eliminate all unbound inhibitor [81, 96, 98]. The cells were then lysed in 25 mL of distilled water, centrifuged for eliminating membranes and other insoluble impurities. The obtained solution was heated at 100° C. for 5 minutes (in order to denature CA-s) and sulfonamides possibly present have been assayed in each sample by three methods: a HPLC method [36]; spectrophotometrically [4] and enzymatically [76].</div>
    <div num="p-0169" class="description-paragraph style-scope patent-text">HPLC: A variant of the methods of Gomaa [36] has been developed by us, as follows: a commercially available 5 μm Bondapak C-18 column was used for the separation, with a mobile phase made of acetonitrile-methanol-phosphate buffer (pH 7.4) 10:2:88 (v/v/v), at a flow rate of 3 mL/min, with 0.3 mg/mL sulphadiazine (Sigma) as internal standard. The retention times were: 12.69 min for acetazolamide; 4.55 min for sulphadiazine; 10.54 min for benzolamide; 12.32 min for aminobenzolamide; 3.15 min for 71; 4.41 min for 76; 3.54 min for 89; and 4.24 min for 91. The eluent was monitored continuously for absorbance (at 254 nm for acetazolamide, and wavelength in the range of 270-310 nm in the case of the other sulfonamides.</div>
    <div num="p-0170" class="description-paragraph style-scope patent-text">Spectrophotometrically. A variant of the pH-induced spectrophotometric assay of Abdine et al. [4] has been used, working for instance at 260 and 292 nm, respectively, for acetazolamide; at 225 and 265 nm, respectively, for sulfanilamide, etc. Standardized solutions of each inhibitor have been prepared in the same buffer as the one used for the membrane penetrability experiments.</div>
    <div num="p-0171" class="description-paragraph style-scope patent-text">Enzymatically: the amount of sulfonamide present in the lysate has been evaluated based on hCA II inhibition measured with the esterase method, as described above [76]. Standard inhibition curves have been obtained previously for each sulfonamide, using the pure compound, which were used thereafter for determining the amount of inhibitor present in the lysate. Mention should be made that the three methods presented above led to results in good agreement, within the limits of the experimental errors.</div>
    <div num="p-0172" class="description-paragraph style-scope patent-text">Statistical analysis: Values are expressed ± standard error of measurement. Statistical significance was determined using an unpaired t-test with p&lt;0.05 considered significant.</div>
    <div num="p-0173" class="description-paragraph style-scope patent-text">The following materials and methods were used for Examples 4-8.</div>
    <heading class="style-scope patent-text">Cell Culture</heading>
    <div num="p-0174" class="description-paragraph style-scope patent-text">MDCK, SiHa, HeLa cells and their transfected derivatives were grown in DMEM with 10% FCS and buffered with 22.3 mM bicarbonate [103]. To maintain the standard conditions, the cells were always plated in 3 ml of culture medium at a density of 0.8-1×10<sup class="style-scope patent-text">6 </sup>per 6 cm dish 24 hours before the transfer to hypoxia (2% O<sub class="style-scope patent-text">2 </sub>and 5% CO<sub class="style-scope patent-text">2 </sub>balanced with N<sub class="style-scope patent-text">2</sub>) generated in a Napco 7000 incubator. Parallel normoxic dishes were incubated in air with 5% CO<sub class="style-scope patent-text">2</sub>. At the end of each experiment, the pH of the culture medium was immediately measured, the medium was harvested for the determination of the lactic acid content with the standard assay kit (Sigma), the cells were counted to ensure that the resulting cultures were comparable, and then processed either for immunofluorescence or extracted for immunoprecipitation and/or immunoblotting.</div>
    <heading class="style-scope patent-text">Sulfonamide Synthesis and Treatment of Cells</heading>
    <div num="p-0175" class="description-paragraph style-scope patent-text"> <figure-callout id="6" label="Compound" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 6 sulfonamide [4-(2-aminoethyl)-benzenesulfonamide] was from Sigma-Aldrich. The membrane-impermeable Compound 39 [4-(2,4,6-trimethylpyridinium-N-methylcarboxamido)-benzenesulfonamide perchlorate] was prepared by reaction of homosulfanilamide with 2,4,6-trimethyl pyrilium perchlorate [81]. Compound 92 [the fluorescent derivative of <figure-callout id="5" label="Compound" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 5 sulfonamide] was obtained from homosulfanilamide and fluorescein isothiocyanate [142]. CAIs showed the following K<sub class="style-scope patent-text">I </sub>values assessed by CO<sub class="style-scope patent-text">2 </sub>hydration methods using the purified CA domain of CA IX: Compound 636 nM, Compound 3938 nM and Compound 9224 nM. The sulfonamides were dissolved in PBS with 20% DMSO at 100 mM concentration and diluted in a culture medium to a required final concentration just before their addition to cells. The cells were incubated for 48 hours in hypoxia and normoxia, respectively, the pH of the culture medium was measured and the binding of the FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 to living cells, washed three times with PBS, was viewed by a Nikon E400 epifluorescence microscope.</div>
    <heading class="style-scope patent-text">Cloning of CA IX Mutants and Transfection</heading>
    <div num="p-0176" class="description-paragraph style-scope patent-text">Cloning of CA IX deletion mutants lacking either the N-terminal PG domain or the central CA domain was performed as described [73, 145]. MDCK and HeLa cell lines constitutively expressing CA IX protein or its mutants were obtained by cotransfection of recombinant plasmids pSG5C-CA IX, pSG5C-ΔCA and pSG5C-ΔPG with pSV2neo plasmid in 10:1 ratio using a GenePorter II transfection kit from Gene Therapy Systems. The transfected cells were subjected to selection in 500-1000 μg/ml G418, cloned, tested for CA IX and expanded. At least three clonal cell lines expressing each CA IX form were analyzed to eliminate the effect of clonal variation. The cells cotransfected with empty pSG5C and pSV2 neo were used as negative controls.</div>
    <heading class="style-scope patent-text">Indirect Immunofluorescence and Immunoblotting</heading>
    <div num="p-0177" class="description-paragraph style-scope patent-text">Cells grown on glass coverslips were fixed in ice-cold methanol at −20° C. for 5 min and stained with CA IX-specific MAb M75 directed to the PG domain or V/10 directed to the CA domain followed by FITC-labeled secondary antibodies [73, 145]. For immunoblotting, cells were rinsed with PBS and extracted in RIPA buffer for 30 min on ice. Protein concentrations were quantified using the BCA kit (Pierce). The proteins (50 μg/lane) were resolved in 10% SDS-PAGE under reducing and non-reducing conditions, respectively, transferred to PVDF membrane and CA IX was detected with the specific MAbs as described [73].</div>
    <heading class="style-scope patent-text">Cell Biotinylation and Immunoprecipitation</heading>
    <div num="p-0178" class="description-paragraph style-scope patent-text">Cells were washed with ice-cold buffer A (20 mM sodium hydrogen carbonate, 0.15 M NaCl, pH 8.0), incubated for 60 min at 4° C. with buffer A containing 1 mg of NHS-LC-Biotin (Pierce), then washed 5 times with buffer A and extracted in RIPA as described above. MAb V/10 (deposited at the BCCM™/LMBP Plasmid Collection Laboratorium, Gent, Belgium under Accession No. LMBP 6009CB) in 1 ml of hybridoma medium was bound to 25 μI 50% suspension of Protein-A Sepharose (Pharmacia) for 2 h at RT. Biotinylated extract (200 μI) was pre-cleared with 20 μl of 50% suspension of Protein-A Sepharose and then added to the bound MAb. Immunocomplexes collected on the Protein-A Sepharose were separated by SDS-PAGE, transferred to a PVDF membrane and revealed with peroxidase-conjugated streptavidin ( 1/1000, Pierce) followed by enhanced chemoluminiscence.</div>
    <div num="p-0179" class="description-paragraph style-scope patent-text">The following examples are for purposes of illustration only and are not meant to limit the invention in any way.</div>
    <heading class="style-scope patent-text">EXAMPLE 1</heading>
    <heading class="style-scope patent-text">Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides</heading>
    <div num="p-0180" class="description-paragraph style-scope patent-text">The inhibition of the tumor-associated transmembrane carbonic anhydrase IX (CA IX) isozyme has been investigated with a series of aromatic and heterocyclic sulfonamides, including the six clinically used derivatives acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide and brinzolamide. Inhibition data for the physiologically relevant isozymes I and II (cytosolic forms) and IV (membrane-bound) were also provided for comparison.</div>
    <div num="p-0181" class="description-paragraph style-scope patent-text">Chemistry. Sulfonamides investigated for the inhibition of the tumor-associated isozyme CA IX, of types 1-26 are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4A-B</figref>. Compounds 1-6, 11-12, 20 and 26 are commercially available, whereas 7-10 [43], 13-19 [24, 79, 90, 97] and 21-25 [79] were prepared as reported earlier. The six clinically used compounds were also assayed, since no such data are available in the literature.</div>
    <div num="p-0182" class="description-paragraph style-scope patent-text">CA inhibition data. Inhibition data against four CA isozymes, CA I, II, IV and IX [44, 72, 116], with the above mentioned compounds 1-26 and the six clinically used inhibitors, are shown in Table 1.</div>
    <div num="p-0183" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00005" num="00005" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 1</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA I, II, IV and IX inhibition data with sulfonamides</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">1-26 and clinically used inhibitors.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K<sub class="style-scope patent-text">I</sub>* (nM)</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Inhibitor</td>
                <td class="description-td style-scope patent-text">hAC I<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">hCA II<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">bCA IV<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">hCA IX<sup class="style-scope patent-text">c</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">45400</td>
                <td class="description-td style-scope patent-text">295</td>
                <td class="description-td style-scope patent-text">1310</td>
                <td class="description-td style-scope patent-text">33</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">25000</td>
                <td class="description-td style-scope patent-text">240</td>
                <td class="description-td style-scope patent-text">2200</td>
                <td class="description-td style-scope patent-text">238</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">28000</td>
                <td class="description-td style-scope patent-text">300</td>
                <td class="description-td style-scope patent-text">3000</td>
                <td class="description-td style-scope patent-text">294</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">78500</td>
                <td class="description-td style-scope patent-text">320</td>
                <td class="description-td style-scope patent-text">3215</td>
                <td class="description-td style-scope patent-text">305</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">25000</td>
                <td class="description-td style-scope patent-text">170</td>
                <td class="description-td style-scope patent-text">2800</td>
                <td class="description-td style-scope patent-text">103</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">21000</td>
                <td class="description-td style-scope patent-text">160</td>
                <td class="description-td style-scope patent-text">2450</td>
                <td class="description-td style-scope patent-text">33</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">8300</td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">180</td>
                <td class="description-td style-scope patent-text">245</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">9800</td>
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">320</td>
                <td class="description-td style-scope patent-text">264</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">6500</td>
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">66</td>
                <td class="description-td style-scope patent-text">269</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">6000</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">125</td>
                <td class="description-td style-scope patent-text">285</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">11</td>
                <td class="description-td style-scope patent-text">5800</td>
                <td class="description-td style-scope patent-text">63</td>
                <td class="description-td style-scope patent-text">154</td>
                <td class="description-td style-scope patent-text">24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">8400</td>
                <td class="description-td style-scope patent-text">75</td>
                <td class="description-td style-scope patent-text">160</td>
                <td class="description-td style-scope patent-text">39</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">13</td>
                <td class="description-td style-scope patent-text">8600</td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">540</td>
                <td class="description-td style-scope patent-text">41</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">14</td>
                <td class="description-td style-scope patent-text">9300</td>
                <td class="description-td style-scope patent-text">19</td>
                <td class="description-td style-scope patent-text">355</td>
                <td class="description-td style-scope patent-text">30</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">15</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">38</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">16</td>
                <td class="description-td style-scope patent-text">164</td>
                <td class="description-td style-scope patent-text">46</td>
                <td class="description-td style-scope patent-text">129</td>
                <td class="description-td style-scope patent-text">34</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">17</td>
                <td class="description-td style-scope patent-text">185</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">144</td>
                <td class="description-td style-scope patent-text">20</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">18</td>
                <td class="description-td style-scope patent-text">109</td>
                <td class="description-td style-scope patent-text">33</td>
                <td class="description-td style-scope patent-text">72</td>
                <td class="description-td style-scope patent-text">31</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">19</td>
                <td class="description-td style-scope patent-text">95</td>
                <td class="description-td style-scope patent-text">30</td>
                <td class="description-td style-scope patent-text">72</td>
                <td class="description-td style-scope patent-text">24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">690</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">154</td>
                <td class="description-td style-scope patent-text">16</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">55</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">17</td>
                <td class="description-td style-scope patent-text">14</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">22</td>
                <td class="description-td style-scope patent-text">21000</td>
                <td class="description-td style-scope patent-text">125</td>
                <td class="description-td style-scope patent-text">415</td>
                <td class="description-td style-scope patent-text">32</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">23</td>
                <td class="description-td style-scope patent-text">23000</td>
                <td class="description-td style-scope patent-text">133</td>
                <td class="description-td style-scope patent-text">438</td>
                <td class="description-td style-scope patent-text">30</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">24</td>
                <td class="description-td style-scope patent-text">24000</td>
                <td class="description-td style-scope patent-text">125</td>
                <td class="description-td style-scope patent-text">560</td>
                <td class="description-td style-scope patent-text">21</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">25</td>
                <td class="description-td style-scope patent-text">18000</td>
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">450</td>
                <td class="description-td style-scope patent-text">22</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">26</td>
                <td class="description-td style-scope patent-text">135</td>
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">86</td>
                <td class="description-td style-scope patent-text">26</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AAZ</td>
                <td class="description-td style-scope patent-text">250</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">25</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MZA</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">14</td>
                <td class="description-td style-scope patent-text">36</td>
                <td class="description-td style-scope patent-text">27</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EZA</td>
                <td class="description-td style-scope patent-text">25</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">13</td>
                <td class="description-td style-scope patent-text">34</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="1200" label="DCP" filenames="US07833737-20101116-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">DCP</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">1200</td>
                <td class="description-td style-scope patent-text">38</td>
                <td class="description-td style-scope patent-text">380</td>
                <td class="description-td style-scope patent-text">50</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DZA</td>
                <td class="description-td style-scope patent-text">50000</td>
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">43</td>
                <td class="description-td style-scope patent-text">52</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">BRZ</td>
                <td class="description-td style-scope patent-text">—</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">45</td>
                <td class="description-td style-scope patent-text">37</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="left" id="FOO-00001" class="description-td style-scope patent-text" colspan="5"> <sup class="style-scope patent-text">a</sup>Human cloned isozymes, esterase assay method [76];</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="left" id="FOO-00002" class="description-td style-scope patent-text" colspan="5"> <sup class="style-scope patent-text">b</sup>Isolated from bovine lung microsomes, esterase assay method [76];</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="left" id="FOO-00003" class="description-td style-scope patent-text" colspan="5"> <sup class="style-scope patent-text">c</sup>Human cloned isozyme, CO<sub class="style-scope patent-text">2 </sub>hydrase assay method [44, 72, 116].</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0184" class="description-paragraph style-scope patent-text">We report here the first inhibition study of the tumor-associated, transmembrane isozyme CA IX with a series of aromatic and heterocyclic sulfonamides, including also the six clinically used derivatives acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide and brinzolamide. Inhibition data for the physiologically relevant isozymes I and II (cytosolic forms) and IV (membrane-bound) are also provided for comparison. Very interesting inhibition profile against CA IX with these sulfonamides has been detected, which is a promising discovery for the potential design of CA IX-specific inhibitors, with applications as antitumor agents. Several nanomolar CA IX inhibitors have been detected, both among the aromatic (such as orthanilamide, homosulfanilamide, 4-carboxy-benzenesulfonamide, 1-naphthalene-sulfonamide and 1,3-benzenedisulfonamide derivatives) as well as the heterocyclic (such as 1,3,4-thiadiazole-2-sulfonamide, benzothiazole-2-sulfonamide, etc.) sulfonamides investigated.</div>
    <heading class="style-scope patent-text">EXAMPLE 2</heading>
    <heading class="style-scope patent-text">The First Selective, Membrane-Impermeant Inhibitors Targeting the Tumor-Associated Isozyme IX</heading>
    <div num="p-0185" class="description-paragraph style-scope patent-text">Up to now no CA IX inhibition studies with this type of membrane-impermeant CAIs have been reported. Thus, we decided to explore some of the pyridinium derivatives of general formula (A) for their interaction with the catalytic domain of tumor-associated isozyme IX, recently cloned and purified by the inventors [33, 43, 114, 115, 117], as well as the cytosolic, physiologically relevant isozymes CA I, II and the membrane-anchored isozyme CA IV [88, 96].</div>
    <div num="p-0186" class="description-paragraph style-scope patent-text">The inhibition of the tumor-associated transmembrane carbonic anhydrase IX (CA IX) isozyme has been investigated with a series of positively-charged, pyridinium derivatives of sulfanilamide, homosulfanilamide and 4-aminoethyl-benzenesulfonamide. Inhibition data for the physiologically relevant isozymes I and II (cytosolic forms) and IV (membrane-bound) were also provided for comparison. This is the first report of inhibitors that may selectively target CA IX, due to their membrane-impermeability and high affinity for this clinically relevant isozyme.</div>
    <div num="h-0043" class="description-paragraph style-scope patent-text">CA Inhibition</div>
    <div num="p-0187" class="description-paragraph style-scope patent-text">Data of Table 2 clearly show that most of the compounds 27-70 act as efficient CA IX inhibitors, and that their affinity for this isozyme differs considerably as compared to affinities for the cytosolic isozymes CA I and II, and the other membrane-associated isozyme investigated, CA IV.</div>
    <div num="p-0188" class="description-paragraph style-scope patent-text">In a series of substituted-pyridinium derived sulfanilamides, homosulfanilamides and p-aminoethylbenzenesulfonamides, a large number of effective hCA IX inhibitors were detected. Some low nanomolar CA IX inhibitors were reported for the first time. Since these compounds are membrane-impermeant due to their salt-like character, and as hCA IX is present on the extracellular side of many tumors with poor clinical prognosis, compounds of this type target specifically this tumor-associate CA isozyme without affecting the cytosolic CAs known to play important physiological functions. Thus, compounds of this type may constitute the basis of new anticancer therapies based on CA inhibitors.</div>
    <div num="p-0189" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00006" num="00006" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 2</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Inhibition of isozymes hCA I, hCA II, bCA IV and hCA IX with the</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">pyridinium salts 27-70.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">A</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">
                  <chemistry id="CHEM-US-00005" num="00005" class="style-scope patent-text">
                    <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cc/78/4c/41692c0630d6fb/US07833737-20101116-C00005.png" class="style-scope patent-text"><img id="EMI-C00005" he="24.89mm" wi="61.04mm" file="US07833737-20101116-C00005.TIF" alt="Figure US07833737-20101116-C00005" img-content="table" img-format="tif" width="244" height="100" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cc/78/4c/41692c0630d6fb/US07833737-20101116-C00005.png"></a></div>
                    <attachments class="style-scope patent-text">
                      <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US07833737-20101116-C00005.CDX" class="style-scope patent-text"> </attachment>
                      <attachment idref="CHEM-US-00005" attachment-type="mol" file="US07833737-20101116-C00005.MOL" class="style-scope patent-text"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K<sub class="style-scope patent-text">I</sub>*</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">hCA I<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">hCA II<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">bCA IV<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">hCA IX<sup class="style-scope patent-text">c</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Compound</td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">2</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">3</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">4</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">6</sup> </td>
                <td class="description-td style-scope patent-text">(μM)</td>
                <td class="description-td style-scope patent-text">(nM)</td>
                <td class="description-td style-scope patent-text">(nM)</td>
                <td class="description-td style-scope patent-text">(nM)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="9"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">27</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">150</td>
                <td class="description-td style-scope patent-text">290</td>
                <td class="description-td style-scope patent-text">165</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">28</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">211</td>
                <td class="description-td style-scope patent-text">48</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">29</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">182</td>
                <td class="description-td style-scope patent-text">43</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">30</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">120</td>
                <td class="description-td style-scope patent-text">194</td>
                <td class="description-td style-scope patent-text">178</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">31</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">90</td>
                <td class="description-td style-scope patent-text">160</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">32</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">210</td>
                <td class="description-td style-scope patent-text">852</td>
                <td class="description-td style-scope patent-text">280</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">33</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">43</td>
                <td class="description-td style-scope patent-text">400</td>
                <td class="description-td style-scope patent-text">1300</td>
                <td class="description-td style-scope patent-text">450</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">34</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">140</td>
                <td class="description-td style-scope patent-text">580</td>
                <td class="description-td style-scope patent-text">1483</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">35</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">125</td>
                <td class="description-td style-scope patent-text">440</td>
                <td class="description-td style-scope patent-text">2102</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">36</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">305</td>
                <td class="description-td style-scope patent-text">620</td>
                <td class="description-td style-scope patent-text">2155</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">37</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">290</td>
                <td class="description-td style-scope patent-text">510</td>
                <td class="description-td style-scope patent-text">2500</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">38</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">61</td>
                <td class="description-td style-scope patent-text">72</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">39</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">92</td>
                <td class="description-td style-scope patent-text">38</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">80</td>
                <td class="description-td style-scope patent-text">42</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">41</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">11</td>
                <td class="description-td style-scope patent-text">80</td>
                <td class="description-td style-scope patent-text">144</td>
                <td class="description-td style-scope patent-text">54</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">42</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">26</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">43</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">52</td>
                <td class="description-td style-scope patent-text">29</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">44</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">24</td>
                <td class="description-td style-scope patent-text">90</td>
                <td class="description-td style-scope patent-text">163</td>
                <td class="description-td style-scope patent-text">230</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">45</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">61</td>
                <td class="description-td style-scope patent-text">101</td>
                <td class="description-td style-scope patent-text">100</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">46</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">32</td>
                <td class="description-td style-scope patent-text">121</td>
                <td class="description-td style-scope patent-text">161</td>
                <td class="description-td style-scope patent-text">64</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">47</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">42</td>
                <td class="description-td style-scope patent-text">314</td>
                <td class="description-td style-scope patent-text">983</td>
                <td class="description-td style-scope patent-text">79</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">48</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">130</td>
                <td class="description-td style-scope patent-text">390</td>
                <td class="description-td style-scope patent-text">1260</td>
                <td class="description-td style-scope patent-text">85</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">49</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">112</td>
                <td class="description-td style-scope patent-text">370</td>
                <td class="description-td style-scope patent-text">1214</td>
                <td class="description-td style-scope patent-text">80</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">300</td>
                <td class="description-td style-scope patent-text">595</td>
                <td class="description-td style-scope patent-text">2104</td>
                <td class="description-td style-scope patent-text">135</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">51</td>
                <td class="description-td style-scope patent-text">t-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">321</td>
                <td class="description-td style-scope patent-text">1070</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">52</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">280</td>
                <td class="description-td style-scope patent-text">472</td>
                <td class="description-td style-scope patent-text">1956</td>
                <td class="description-td style-scope patent-text">120</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">53</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">280</td>
                <td class="description-td style-scope patent-text">493</td>
                <td class="description-td style-scope patent-text">1954</td>
                <td class="description-td style-scope patent-text">106</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">54</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">30</td>
                <td class="description-td style-scope patent-text">51</td>
                <td class="description-td style-scope patent-text">35</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">55</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">14</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">56</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">15</td>
                <td class="description-td style-scope patent-text">32</td>
                <td class="description-td style-scope patent-text">31</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">57</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">49</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">58</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">59</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">42</td>
                <td class="description-td style-scope patent-text">82</td>
                <td class="description-td style-scope patent-text">205</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">61</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">89</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">62</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">18</td>
                <td class="description-td style-scope patent-text">103</td>
                <td class="description-td style-scope patent-text">144</td>
                <td class="description-td style-scope patent-text">37</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">63</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">40</td>
                <td class="description-td style-scope patent-text">220</td>
                <td class="description-td style-scope patent-text">761</td>
                <td class="description-td style-scope patent-text">70</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">64</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">112</td>
                <td class="description-td style-scope patent-text">270</td>
                <td class="description-td style-scope patent-text">1055</td>
                <td class="description-td style-scope patent-text">84</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">65</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">94</td>
                <td class="description-td style-scope patent-text">350</td>
                <td class="description-td style-scope patent-text">864</td>
                <td class="description-td style-scope patent-text">78</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">66</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">290</td>
                <td class="description-td style-scope patent-text">544</td>
                <td class="description-td style-scope patent-text">2008</td>
                <td class="description-td style-scope patent-text">120</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">67</td>
                <td class="description-td style-scope patent-text">t-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">92</td>
                <td class="description-td style-scope patent-text">275</td>
                <td class="description-td style-scope patent-text">1000</td>
                <td class="description-td style-scope patent-text">&gt;500</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">68</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">270</td>
                <td class="description-td style-scope patent-text">419</td>
                <td class="description-td style-scope patent-text">1830</td>
                <td class="description-td style-scope patent-text">95</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">69</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">265</td>
                <td class="description-td style-scope patent-text">420</td>
                <td class="description-td style-scope patent-text">1905</td>
                <td class="description-td style-scope patent-text">81</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">acetazolamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0.25</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">25</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">methazolamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0.05</td>
                <td class="description-td style-scope patent-text">14</td>
                <td class="description-td style-scope patent-text">36</td>
                <td class="description-td style-scope patent-text">27</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">dichlorophenamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1.2</td>
                <td class="description-td style-scope patent-text">38</td>
                <td class="description-td style-scope patent-text">380</td>
                <td class="description-td style-scope patent-text">50</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">indisulam</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0.03</td>
                <td class="description-td style-scope patent-text">15</td>
                <td class="description-td style-scope patent-text">65</td>
                <td class="description-td style-scope patent-text">24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="9"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="left" id="FOO-00004" class="description-td style-scope patent-text" colspan="9"> <sup class="style-scope patent-text">a</sup>Human (cloned) isozymes;</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="left" id="FOO-00005" class="description-td style-scope patent-text" colspan="9"> <sup class="style-scope patent-text">b</sup>From bovine lung microsomes;</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="left" id="FOO-00006" class="description-td style-scope patent-text" colspan="9"> <sup class="style-scope patent-text">c</sup>Catalytic domain of the human, cloned isozyme.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="left" id="FOO-00007" class="description-td style-scope patent-text" colspan="9">*errors in the range of ±10% of the reported value, from three different determinations.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="9" align="left" id="FOO-00008" class="description-td style-scope patent-text" colspan="9">For compunds 27-38: n = 0; 39-54: n = 1; 55-70: n = 2</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">EXAMPLE 3</heading>
    <heading class="style-scope patent-text">Design of Selective, Membrane-Impermeant Heterocyclic Sulphonamide Inhibitors Targeting the Human Tumor-Associated Isozyme IX</heading>
    <div num="p-0190" class="description-paragraph style-scope patent-text">A series of positively-charged sulfonamides were obtained by reaction of aminobenzolamide (5-(4-aminobenzenesulfonylamino)-1,3,4-thiadiazole-2-sulfonamide) with tri-/tetra-substituted pyrilium salts possessing alkyl-, aryl-or combinations of alkyl and aryl groups at the pyridinium ring. These new compounds are membrane-impermeant due to their salt-like character and were assayed for the inhibition of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes, the cytosolic hCA I and II, the membrane-anchored bCA IV and the membrane-bound, tumor associated isozyme hCA IX. The high affinity of these new derivatives for the tumor associated isozyme CA IX and their membrane impermeability, make this type of CA inhibitors interesting candidates for the selective inhibition of only the tumor associated isozyme and not the cytosolic ones, for which they also show high potency.</div>
    <div num="h-0046" class="description-paragraph style-scope patent-text">Results</div>
    <div num="p-0191" class="description-paragraph style-scope patent-text">CA inhibition. Inhibition data against isozymes I, II, IV and IX with compounds 71-91 reported here are shown in Table 3.</div>
    <div num="p-0192" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00007" num="00007" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 3</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Inhibition of isozymes hCA I, hCA II, bCA IV and hCA IX with the</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">pyridinium salts 71-91.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">B</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">
                  <chemistry id="CHEM-US-00006" num="00006" class="style-scope patent-text">
                    <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5f/44/8e/37bf04a3f6875f/US07833737-20101116-C00006.png" class="style-scope patent-text"><img id="EMI-C00006" he="23.28mm" wi="74.25mm" file="US07833737-20101116-C00006.TIF" alt="Figure US07833737-20101116-C00006" img-content="table" img-format="tif" width="297" height="93" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5f/44/8e/37bf04a3f6875f/US07833737-20101116-C00006.png"></a></div>
                    <attachments class="style-scope patent-text">
                      <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US07833737-20101116-C00006.CDX" class="style-scope patent-text"> </attachment>
                      <attachment idref="CHEM-US-00006" attachment-type="mol" file="US07833737-20101116-C00006.MOL" class="style-scope patent-text"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K<sub class="style-scope patent-text">I</sub>* (nm)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="10" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">1</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">2</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">3</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">4</sup> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">5</sup> </td>
                <td class="description-td style-scope patent-text">hCA I<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">hCA II<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">bCA IV<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">hCA IX<sup class="style-scope patent-text">c</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="9" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="10"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="10" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">71</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">0.26</td>
                <td class="description-td style-scope patent-text">2.1</td>
                <td class="description-td style-scope patent-text">3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">72</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">0.39</td>
                <td class="description-td style-scope patent-text">3.0</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">73</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">7</td>
                <td class="description-td style-scope patent-text">1.54</td>
                <td class="description-td style-scope patent-text">4.7</td>
                <td class="description-td style-scope patent-text">16</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">74</td>
                <td class="description-td style-scope patent-text">t-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">t-Bu</td>
                <td class="description-td style-scope patent-text">11</td>
                <td class="description-td style-scope patent-text">3.13</td>
                <td class="description-td style-scope patent-text">9.4</td>
                <td class="description-td style-scope patent-text">34</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">75</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">0.20</td>
                <td class="description-td style-scope patent-text">2.0</td>
                <td class="description-td style-scope patent-text">6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">76</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">0.21</td>
                <td class="description-td style-scope patent-text">2.3</td>
                <td class="description-td style-scope patent-text">9</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">77</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">9</td>
                <td class="description-td style-scope patent-text">3.45</td>
                <td class="description-td style-scope patent-text">8.1</td>
                <td class="description-td style-scope patent-text">35</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">78</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">10</td>
                <td class="description-td style-scope patent-text">4.62</td>
                <td class="description-td style-scope patent-text">10.3</td>
                <td class="description-td style-scope patent-text">40</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">79</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">1.61</td>
                <td class="description-td style-scope patent-text">4.1</td>
                <td class="description-td style-scope patent-text">30</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">80</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">4</td>
                <td class="description-td style-scope patent-text">1.21</td>
                <td class="description-td style-scope patent-text">3.0</td>
                <td class="description-td style-scope patent-text">24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">81</td>
                <td class="description-td style-scope patent-text">Et</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">1.14</td>
                <td class="description-td style-scope patent-text">3.8</td>
                <td class="description-td style-scope patent-text">29</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">82</td>
                <td class="description-td style-scope patent-text">n-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">3.90</td>
                <td class="description-td style-scope patent-text">6.0</td>
                <td class="description-td style-scope patent-text">40</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">83</td>
                <td class="description-td style-scope patent-text">i-Pr</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">3.74</td>
                <td class="description-td style-scope patent-text">4.5</td>
                <td class="description-td style-scope patent-text">32</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">84</td>
                <td class="description-td style-scope patent-text">n-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">8</td>
                <td class="description-td style-scope patent-text">4.95</td>
                <td class="description-td style-scope patent-text">8.4</td>
                <td class="description-td style-scope patent-text">45</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">85</td>
                <td class="description-td style-scope patent-text">t-Bu</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">4.11</td>
                <td class="description-td style-scope patent-text">7.0</td>
                <td class="description-td style-scope patent-text">43</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">86</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">4.78</td>
                <td class="description-td style-scope patent-text">5.8</td>
                <td class="description-td style-scope patent-text">12</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">87</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">5.96</td>
                <td class="description-td style-scope patent-text">5.6</td>
                <td class="description-td style-scope patent-text">12</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">88</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">5</td>
                <td class="description-td style-scope patent-text">4.93</td>
                <td class="description-td style-scope patent-text">5.4</td>
                <td class="description-td style-scope patent-text">16</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">89</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">0.30</td>
                <td class="description-td style-scope patent-text">2.4</td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">90</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">Ph</td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">1.24</td>
                <td class="description-td style-scope patent-text">5.2</td>
                <td class="description-td style-scope patent-text">15</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">3</sup>, R<sup class="style-scope patent-text">5</sup> =</td>
                <td class="description-td style-scope patent-text">Me</td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">1.37</td>
                <td class="description-td style-scope patent-text">4.6</td>
                <td class="description-td style-scope patent-text">12</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">(CH<sub class="style-scope patent-text">2</sub>)<sub class="style-scope patent-text">9</sub>;</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">R<sup class="style-scope patent-text">4</sup> = Me</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">aminobenzolamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">2.04</td>
                <td class="description-td style-scope patent-text">5.1</td>
                <td class="description-td style-scope patent-text">38</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">acetazolamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">250</td>
                <td class="description-td style-scope patent-text">12</td>
                <td class="description-td style-scope patent-text">70</td>
                <td class="description-td style-scope patent-text">25</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">methazolamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">14</td>
                <td class="description-td style-scope patent-text">36</td>
                <td class="description-td style-scope patent-text">27</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">dichlorophenamide</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1200</td>
                <td class="description-td style-scope patent-text">38</td>
                <td class="description-td style-scope patent-text">380</td>
                <td class="description-td style-scope patent-text">50</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">indisulam</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">30</td>
                <td class="description-td style-scope patent-text">15</td>
                <td class="description-td style-scope patent-text">65</td>
                <td class="description-td style-scope patent-text">24</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="8"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="left" id="FOO-00009" class="description-td style-scope patent-text" colspan="8"> <sup class="style-scope patent-text">a</sup>Human (cloned) isozymes, esterase assay method [76].</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="left" id="FOO-00010" class="description-td style-scope patent-text" colspan="8"> <sup class="style-scope patent-text">b</sup>From bovine lung microsomes, esterase assay method [76].</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="left" id="FOO-00011" class="description-td style-scope patent-text" colspan="8"> <sup class="style-scope patent-text">c</sup>Catalytic domain of the human, cloned isozyme, CO<sub class="style-scope patent-text">2 </sub>hydrase assay method [44].</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="left" id="FOO-00012" class="description-td style-scope patent-text" colspan="8">*Errors in the range of ±10% of the reported value, from three different determinations.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0193" class="description-paragraph style-scope patent-text">Ex vivo penetration through red blood cells. Levels of sulfonamides in red blood cells after incubation of human erythrocytes with millimolar solutions of inhibitor for 30-60 min (both classical as well as positively-charged sulfonamides were used in such experiments) are shown in Table 4 [4, 12, 36, 45, 53, 54, 58, 59, 84, 116, 118].</div>
    <div num="p-0194" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00008" num="00008" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 4</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Levels of sulfonamide CA inhibitors (μM) in red blood cells</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">at 30 and 60 min, after exposure of 10 mL of blood to solutions</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">of sulfonamide (2 mM sulfonamide in 5 mM Tris buffer, pH 7.4).</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">The concentrations of sulfonamide has been determined by three</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">methods: HPLC; electronic spectroscopy (ES) and the enzymatic</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">method (EI) - see Experimental for details.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">[sulfonamide], μM*</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">t = 30 min</td>
                <td class="description-td style-scope patent-text">t = 60 min</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Inhibitor</td>
                <td class="description-td style-scope patent-text">HPLC<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">ES<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">EI<sup class="style-scope patent-text">c</sup> </td>
                <td class="description-td style-scope patent-text">HPLC<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">ES<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">EI<sup class="style-scope patent-text">c</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="7"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">AAZ</td>
                <td class="description-td style-scope patent-text">136</td>
                <td class="description-td style-scope patent-text">139</td>
                <td class="description-td style-scope patent-text">140</td>
                <td class="description-td style-scope patent-text">160</td>
                <td class="description-td style-scope patent-text">167</td>
                <td class="description-td style-scope patent-text">163</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MZA</td>
                <td class="description-td style-scope patent-text">170</td>
                <td class="description-td style-scope patent-text">169</td>
                <td class="description-td style-scope patent-text">165</td>
                <td class="description-td style-scope patent-text">168</td>
                <td class="description-td style-scope patent-text">168</td>
                <td class="description-td style-scope patent-text">167</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Benzolamide</td>
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">108</td>
                <td class="description-td style-scope patent-text">112</td>
                <td class="description-td style-scope patent-text">148</td>
                <td class="description-td style-scope patent-text">146</td>
                <td class="description-td style-scope patent-text">149</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="125" label="Aminobenzolamide" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Aminobenzolamide</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">125</td>
                <td class="description-td style-scope patent-text">127</td>
                <td class="description-td style-scope patent-text">122</td>
                <td class="description-td style-scope patent-text">154</td>
                <td class="description-td style-scope patent-text">156</td>
                <td class="description-td style-scope patent-text">158</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">71</td>
                <td class="description-td style-scope patent-text">0.3</td>
                <td class="description-td style-scope patent-text">0.5</td>
                <td class="description-td style-scope patent-text">0.5</td>
                <td class="description-td style-scope patent-text">0.4</td>
                <td class="description-td style-scope patent-text">0.5</td>
                <td class="description-td style-scope patent-text">0.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">76</td>
                <td class="description-td style-scope patent-text">1.0</td>
                <td class="description-td style-scope patent-text">1.1</td>
                <td class="description-td style-scope patent-text">1.0</td>
                <td class="description-td style-scope patent-text">1.1</td>
                <td class="description-td style-scope patent-text">1.2</td>
                <td class="description-td style-scope patent-text">1.1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">89</td>
                <td class="description-td style-scope patent-text">0.3</td>
                <td class="description-td style-scope patent-text">0.2</td>
                <td class="description-td style-scope patent-text">0.5</td>
                <td class="description-td style-scope patent-text">0.3</td>
                <td class="description-td style-scope patent-text">0.6</td>
                <td class="description-td style-scope patent-text">0.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">0.4</td>
                <td class="description-td style-scope patent-text">0.3</td>
                <td class="description-td style-scope patent-text">0.5</td>
                <td class="description-td style-scope patent-text">0.3</td>
                <td class="description-td style-scope patent-text">0.6</td>
                <td class="description-td style-scope patent-text">0.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="7"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="left" id="FOO-00013" class="description-td style-scope patent-text" colspan="7">*Standard error (from 3 determinations) &lt;5% by:</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="left" id="FOO-00014" class="description-td style-scope patent-text" colspan="7"> <sup class="style-scope patent-text">a</sup>the HPLC method [36];</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="left" id="FOO-00015" class="description-td style-scope patent-text" colspan="7"> <sup class="style-scope patent-text">b</sup>the electronic spectroscopic method [4];</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="7" align="left" id="FOO-00016" class="description-td style-scope patent-text" colspan="7"> <sup class="style-scope patent-text">c</sup>the enzymatic method [76].</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0195" class="description-paragraph style-scope patent-text">The new compounds reported in the present work were characterized by standard chemical and physical methods (elemental analysis, within ±0.4% of the theoretical values; IR and NMR spectroscopy) that confirmed their structure (see Materials and Methods and Table 5 below for details) and were assayed for the inhibition of isozymes hCA I, hCA II, bCA IV and hCA IX.</div>
    <div num="p-0196" class="description-paragraph style-scope patent-text"> <tables id="TABLE-US-00009" num="00009" class="style-scope patent-text"> <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text"> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <thead class="style-scope patent-text"> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 5</td> </tr> </thead>  <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Elemental analysis data for the</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">compounds described in Example 3</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td> <td class="description-td style-scope patent-text">Elemental analysis data (calc./found)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">No</td> <td class="description-td style-scope patent-text">Formula</td> <td class="description-td style-scope patent-text">% C</td> <td class="description-td style-scope patent-text">% H</td> <td class="description-td style-scope patent-text">% N</td> </tr> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">71</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">16</sub>H<sub class="style-scope patent-text">18</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">35.59/35.32</td> <td class="description-td style-scope patent-text">3.36/3.62</td> <td class="description-td style-scope patent-text">12.97/12.93</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">72</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">18</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">38.06/37.95</td> <td class="description-td style-scope patent-text">3.90/4.16</td> <td class="description-td style-scope patent-text">12.33/12.18</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">73</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">20</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">40.30/39.99</td> <td class="description-td style-scope patent-text">4.40/4.54</td> <td class="description-td style-scope patent-text">11.75/11.63</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">74</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">22</sub>H<sub class="style-scope patent-text">30</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">42.34/42.56</td> <td class="description-td style-scope patent-text">4.84/4.76</td> <td class="description-td style-scope patent-text">11.22/11.03</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">75</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">21</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">41.89/42.02</td> <td class="description-td style-scope patent-text">3.35/3.03</td> <td class="description-td style-scope patent-text">11.63/11.48</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">76</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">23</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">43.84/43.88</td> <td class="description-td style-scope patent-text">3.84/3.62</td> <td class="description-td style-scope patent-text">11.11/10.95</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">77</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">45.62/45.60</td> <td class="description-td style-scope patent-text">4.29/4.36</td> <td class="description-td style-scope patent-text">10.64/10.50</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">78</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">27</sub>H<sub class="style-scope patent-text">32</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">47.26/47.45</td> <td class="description-td style-scope patent-text">4.70/4.89</td> <td class="description-td style-scope patent-text">10.21/10.14</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">79</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">45.62/45.49</td> <td class="description-td style-scope patent-text">4.29/4.18</td> <td class="description-td style-scope patent-text">10.64/10.61</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">80</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">26</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">47.02/46.79</td> <td class="description-td style-scope patent-text">3.34/3.33</td> <td class="description-td style-scope patent-text">10.55/10.23</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">81</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">27</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">47.82/47.73</td> <td class="description-td style-scope patent-text">3.57/3.73</td> <td class="description-td style-scope patent-text">10.33/10.40</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">82</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">28</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">48.59/48.83</td> <td class="description-td style-scope patent-text">3.79/3.91</td> <td class="description-td style-scope patent-text">10.12/10.24</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">83</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">28</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">48.59/48.27</td> <td class="description-td style-scope patent-text">3.79/3.82</td> <td class="description-td style-scope patent-text">10.12/10.05</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">84</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">29</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">49.32/49.59</td> <td class="description-td style-scope patent-text">4.00/4.23</td> <td class="description-td style-scope patent-text">9.92/9.67</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">85</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">29</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">49.32/49.16</td> <td class="description-td style-scope patent-text">4.00/3.94</td> <td class="description-td style-scope patent-text">9.92/9.71</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">86</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">26</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">47.02/47.25</td> <td class="description-td style-scope patent-text">3.34/3.18</td> <td class="description-td style-scope patent-text">10.55/10.46</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">87</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">31</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">51.27/51.50</td> <td class="description-td style-scope patent-text">3.33/3.60</td> <td class="description-td style-scope patent-text">9.64/9.67</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">88</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">46.19/46.28</td> <td class="description-td style-scope patent-text">3.10/2.95</td> <td class="description-td style-scope patent-text">10.77/10.67</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">89</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">17</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">36.86/36.72</td> <td class="description-td style-scope patent-text">3.64/3.53</td> <td class="description-td style-scope patent-text">12.64/12.45</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">90</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">22</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">42.89/42.70</td> <td class="description-td style-scope patent-text">3.60/3.84</td> <td class="description-td style-scope patent-text">11.37/11.15</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">91</td> <td class="description-td style-scope patent-text">C<sub class="style-scope patent-text">24</sub>H<sub class="style-scope patent-text">32</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup> ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> </td> <td class="description-td style-scope patent-text">44.34/44.57</td> <td class="description-td style-scope patent-text">4.96/4.99</td> <td class="description-td style-scope patent-text">10.77/10.51</td> </tr> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td> </tr>  </tbody></table> </patent-tables> </tables> <br class="style-scope patent-text">
Conclusions
</div>
    <div num="p-0197" class="description-paragraph style-scope patent-text">We report here a general approach for the preparation of positively-charged, membrane-impermeant sulfonamide CA inhibitors with high affinity for the cytosolic isozymes CA I and CA II, as well as for the membrane-bound ones CA IV and CA IX. They were obtained by attaching substituted-pyridinium moieties to aminobenzolamide, a very potent CA inhibitor itself. Ex vivo studies showed the new class of inhibitors reported here to discriminate for the membrane-bound versus the cytosolic isozymes. Correlated with the low nanomolar affinity of some of these compounds for the tumor-associated isozyme CA IX, this report constitutes the basis of selectively inhibiting only the target, tumor-associated CA IX in vivo, whereas the cytosolic isozymes would remain unaffected.</div>
    <div num="h-0047" class="description-paragraph style-scope patent-text">Characterization of Compounds 71-91 (for Preparation, see Materials and Methods Section)</div>
    <div num="p-0198" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,4,6-trimethyl-pyridinium perchlorate 71: white crystals, mp &gt;300° C.; IR (KBr), cm<sup class="style-scope patent-text">−1 </sup>(bands in italics are due to the anion): 595, 625, 664, 787, 803, 884, 915, 1100, 1150, 1190, 1200, 1285, 1360, 1495, 1604, 3065; <sup class="style-scope patent-text">1</sup>H-NMR (D<sub class="style-scope patent-text">2</sub>O), δ, ppm: 3.08 (s, 6H, 2,6-Me<sub class="style-scope patent-text">2</sub>); 3.11 (s, 3H, 4-Me), 7.30-8.06 (m, AA′BB′, 4H, ArH from phenylene); 9.05 (s, 2H, ArH, 3,5-H from pyridinium); in this solvent the sulfonamido protons are not seen, being in fast exchange with the solvent. Anal C<sub class="style-scope patent-text">16</sub>H<sub class="style-scope patent-text">18</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0199" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-iso-propyl-4,6-dimethylpyridinium perchlorate 72, colorless crystals, mp 29o-1° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 680, 720, 1100, 1165, 1330, 1640, 3020, 3235; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.50 (d, 6H, 2Me from i-Pr); 2.80 (s, 3H, 6-Me); 2.90 (s, 3H, 4-Me); 3.49 (heptet, 1H, CH from i-Pr); 7.25-8.43 (m, AA′BB′, 4H, ArH from 1,4-phenylene); 7.98 (s, 2H, ArH, 3,5-H from pyridinium). Anal C<sub class="style-scope patent-text">18</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0200" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-di-iso-propyl-4-methylpyridinium perchlorate 73, tan crystals, mp 278-9° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 685, 820, 1100, 1165, 1340, 1635, 3030, 3250; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.51 (d, 12H, 4Me from 2 i-Pr); 2.83 (s, 3H, 4-Me); 3.42 (heptet, 2H, 2CH from 2 i-Pr); 7.31-8.51 (m, AA′BB′, 4H, ArH from 1,4-phenylene); 8.05 (s, 2H, ArH, 3,5-H from pyridinium). Anal C<sub class="style-scope patent-text">20</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0201" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-dimethyl-4-phenylpyridinium perchlorate 75, white crystals, mp &gt;300° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 690, 770, 1100, 1170, 1330, 1635, 3030, 3260, 3330; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 2.62 (s, 6H, 2,6-(Me)<sub class="style-scope patent-text">2</sub>); 8.10-9.12 (m, 11H, ArH from 1,4-phenylene, pyridinium and 4-Ph). Anal C<sub class="style-scope patent-text">21</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0202" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-diethyl-4-<figure-callout id="76" label="phenylpyridinium perchlorate" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phenylpyridinium perchlorate</a></figure-callout> 76, tan crystals, mp 267-8° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 695, 765, 1100, 1180, 1340, 1630, 3040, 3270, 3360; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.43 (t, 6H, 2 Me from ethyl); 2.82 (q, 4H, 2 CH<sub class="style-scope patent-text">2 </sub>from Et); 7.68-8.87 (m, 11H, ArH from 1,4-phenylene, pyridinium and 4-Ph). Anal C<sub class="style-scope patent-text">23</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0203" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-di-n-propyl-4-<figure-callout id="77" label="phenylpyridinium perchlorate" filenames="US07833737-20101116-D00001.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phenylpyridinium perchlorate</a></figure-callout> 77, colorless crystals, mp 235-7° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 695, 770, 1100, 1180, 1340, 1630, 3050, 3220, 3315; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.06 (t, 6H, 2 Me from propyl); 1.73 (sextet, 4H, 2CH<sub class="style-scope patent-text">2 </sub>(β) from n-Pr); 2.84 (t, 4H, 2 CH<sub class="style-scope patent-text">2 </sub>(α) from n-Pr); 7.55-8.71 (m, 11H, ArH from 1,4-phenylene, pyridinium and 4-Ph). Anal C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0204" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-di-isopropyl-4-phenylpyridinium perchlorate 79, white crystals, mp 278-9° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 690, 765, 1100, 1180, 1340, 1625, 3040, 3270, 3315; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.45 (d, 12H, 4 Me from i-Pr); 2.95 (heptet, 2H, 2 CH from i-Pr); 7.92-8.97 (m, 11H, ArH from 1,4-phenylene, pyridinium and 4-Ph). Anal C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0205" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-methyl-4,6-diphenylpyridinium perchlorate 80, white crystals, mp 298-99° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 710, 770, 1100, 1170, 1345, 1625, 3040, 3245, 3350; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 2.75 (s, 3H, 2-Me); 7.53-8.70 (m, 16H, ArH from 1,4-phenylene, pyridinium and 4,6-Ph<sub class="style-scope patent-text">2</sub>). Anal C<sub class="style-scope patent-text">26</sub>H<sub class="style-scope patent-text">22</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0206" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-ethyl-4,6-diphenylpyridinium perchlorate 81, white crystals, mp 254-5° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 700, 770, 1100, 1180, 1340, 1620, 3040, 3250, 3350; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.52 (t, 3H, Me from ethyl); 2.97 (q, 2H, CH<sub class="style-scope patent-text">2</sub>); 7.40-8.57 (m, 16H, ArH from 1,4-phenylene, pyridinium and 4,6-Ph<sub class="style-scope patent-text">2</sub>). Anal C<sub class="style-scope patent-text">27</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0207" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-n-propyl-4,6-diphenylpyridinium perchlorate 82, white crystals, mp 214-5° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 700, 770, 1100, 1180, 1340, 1620, 3030, 3270, 3350; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.03 (t, 3H, Me from propyl); 1.95 (sextet, 2H, β-CH<sub class="style-scope patent-text">2 </sub>from n-Pr); 2.88 (t, 2H, α-CH<sub class="style-scope patent-text">2 </sub>from n-Pr); 7.39-8.55 (m, 16H, ArH from 1,4-phenylene, pyridinium and 4,6-Ph<sub class="style-scope patent-text">2</sub>). Anal C<sub class="style-scope patent-text">28</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0208" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-iso-propyl-4,6-diphenylpyridinium perchlorate 83, white crystals, mp 186-8° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 700, 770, 1100, 1170, 1340, 1620, 3040, 3250, 3360; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.51 (d, 6H, 2 Me from i-propyl); 2.50-3.27 (m, 1H, CH from i-Pr); 7.32-8.54 (m, 16H, ArH from 1,4-phenylene, pyridinium and 4,6-Ph<sub class="style-scope patent-text">2</sub>). Anal C<sub class="style-scope patent-text">28</sub>H<sub class="style-scope patent-text">26</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0209" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-n-butyl-4,6-diphenylpyridinium perchlorate 84, white crystals, mp 241-3° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 710, 770, 1100, 1180, 1335, 1625, 3040, 3260, 3345; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 0.93 (t, 3H, Me from butyl); 1.12-2.14 (m, 4H, CH<sub class="style-scope patent-text">3</sub>—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2</sub>—CH<sub class="style-scope patent-text">2 </sub>from n-Bu); 2.96 (t, 2H, α-CH<sub class="style-scope patent-text">2 </sub>from n-Bu); 7.21-8.50 (m, 16H, ArH from 1,4-phenylene, pyridinium and 4,6-Ph<sub class="style-scope patent-text">2</sub>). Anal C<sub class="style-scope patent-text">29</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0210" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2-tert-butyl-4,6-diphenylpyridinium perchlorate 85, white crystals, mp 203-5° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 705, 765, 1100, 1160, 1310, 1620, 3060, 3270; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 1.91 (s, 9H, t-Bu); 6.80-8.74 (m, 16H, ArH from 1,4-phenylene, 4,6-Ph<sub class="style-scope patent-text">2 </sub>and 3,5-H from pyridinium). Anal C<sub class="style-scope patent-text">29</sub>H<sub class="style-scope patent-text">28</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0211" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,4,6-triphenhyl-pyridinium perchlorate 87: pale yellow crystals, mp &gt;300° C.; IR (KBr), cm<sup class="style-scope patent-text">−1 </sup>(bands in italics are due to the anion): 625, 635, 703, 785, 896, 1100, 1150, 1204, 1355, 1410, 1520, 1600, 3065; <sup class="style-scope patent-text">1</sup>H-NMR (D<sub class="style-scope patent-text">2</sub>O), δ, ppm: 7.50-8.60 (m, 19H, ArH, 3Ph+C<sub class="style-scope patent-text">6</sub>H<sub class="style-scope patent-text">4</sub>); 9.27 (s, 2H, ArH, 3,5-H from pyridinium); in this solvent the sulfonamido protons are not seen, being in fast exchange with the solvent. Anal C<sub class="style-scope patent-text">31</sub>H<sub class="style-scope patent-text">24</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0212" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-diphenylpyridinium perchlorate 88, yellow crystals, mp 218-20° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 705, 765, 1100, 1160, 1335, 1615, 3050, 3260; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 6.75-8.43 (m, 17H, ArH from 1,4-phenylene, 2,6-Ph<sub class="style-scope patent-text">2 </sub>and 3,4,5-H from pyridinium). Anal C<sub class="style-scope patent-text">25</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <div num="p-0213" class="description-paragraph style-scope patent-text">1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,3,4,6-tetramethylpyridinium perchlorate 89, tan crystals, mp &gt;300° C.; IR (KBr), cm<sup class="style-scope patent-text">−1</sup>: 625, 800, 1100, 1165, 1330, 1630, 3030, 3305; <sup class="style-scope patent-text">1</sup>H-NMR (TFA), δ, ppm: 2.62 (s, 3H, 4-Me); 2.74 (s, 3H, 3-Me); 2.88 (s, 6H, 2,6-(Me)<sub class="style-scope patent-text">2</sub>); 7.21-8.50 (m, AA′BB′, 4H, ArH from 1,4-phenylene); 7.93 (s, 1H, ArH, 5-H from pyridinium). Anal C<sub class="style-scope patent-text">17</sub>H<sub class="style-scope patent-text">20</sub>N<sub class="style-scope patent-text">5</sub>O<sub class="style-scope patent-text">4</sub>S<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text">+</sup>ClO<sub class="style-scope patent-text">4</sub> <sup class="style-scope patent-text">−</sup> (C, H, N).</div>
    <heading class="style-scope patent-text">EXAMPLE 4</heading>
    <heading class="style-scope patent-text">Ectopic Expression of CA IX Leads to Increased Acidification of Extracellular pH in Hypoxia</heading>
    <div num="p-0214" class="description-paragraph style-scope patent-text">Expression of CA IX in tumor cells is induced by hypoxia simultaneously with various components of anaerobic metabolism and acid extrusion pathways. Such simultaneous induction complicates the determination of the contribution of CA IX to the overall change in pHe. Therefore, the inventors used MDCK immortalized canine kidney epithelial cells that do not express endogenous CA IX, but were stably transfected to express the human CA IX protein in a constitutive manner. Levels of CA IX in MDCK-CA IX transfectants were comparable between the hypoxic cells maintained for 48 hours in 2% O<sub class="style-scope patent-text">2 </sub>and the normoxic cells incubated in 21% O<sub class="style-scope patent-text">2 </sub>(data not shown). Immunofluorescence analysis indicated that CA IX was predominantly localized at the cell surface, although the membrane staining in hypoxic cells was less pronounced due to hypoxia-induced perturbation of intercellular contacts [103]. Hypoxic incubation led to the expected extracellular acidification in the CA IX-positive as well as CA IX-negative cell cultures when compared to their normoxic counterparts (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A</figref>). However, upon mutual comparison of the hypoxic cells it was evident that pHe was significantly decreased in the cells containing CA IX. Taking into account a steady, hypoxia-independent level of CA IX in MDCK-CA IX cells, that finding indicated that hypoxia activated the catalytic performance of CA IX, which resulted in enhanced pHe acidification.</div>
    <div num="p-0215" class="description-paragraph style-scope patent-text">To exclude the possibility that hypoxia-induced acidification was caused by an increased production of lactic acid, the inventors determined the corresponding lactate concentrations in the media from both CA IX-negative and CA IX-positive transfectants (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7B</figref>). In accord with the literature, production of lactic acid was significantly higher in the cells maintained in hypoxia than in the normoxic cells. However, there were practically no differences between the lactate production in cultures of CA IX-positive and CA IX-negative cells, suggesting that the excessive pHe decrease observed in hypoxia could be explained by the activation of CA IX.</div>
    <heading class="style-scope patent-text">EXAMPLE 5</heading>
    <heading class="style-scope patent-text">Sulfonamides Inhibit CA IX-Mediated Acidification of pHe and Bind to Hypoxic MDCK-CA IX Cells</heading>
    <div num="p-0216" class="description-paragraph style-scope patent-text">The three representative CA IX-selective inhibitors shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8A</figref> were tested in accordance with the concepts of the subject invention. <figure-callout id="6" label="Compound" filenames="US07833737-20101116-D00010.png,US07833737-20101116-D00011.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 6 is a strong inhibitor of CA IX, whereas it is less efficient against the widely distributed cytoplasmic CA II and the plasma membrane-anchored CA IV [114], <figure-callout id="39" label="Compound" filenames="US07833737-20101116-D00015.png,US07833737-20101116-D00016.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 39 is practically membrane-impermeable [81] and Compound 92 [FITC derivative of homosulfanilamide (Compound 5)] has a big moiety favoring its interaction with the CA IX active site, which is assumed to form a larger cavity than in CA II [135]. All three sulfonamides were able to reduce the extracellular acidification of MDCK-CA IX cells in hypoxia and their effect on the normoxic pHe was negligible (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8B</figref>). Moreover, in fluorescence analysis (treated MDCK-CA IX cells incubated in normoxia or hypoxia for 48 hours), FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 was detected only in hypoxic MDCK-CA IX cells, but was absent from their normoxic counterparts and from the mock-transfected controls (data not shown). Cytoplasmic accumulation of <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 was possibly related to a hypoxia-induced internalization of CA IX described earlier [103]. Lack of the fluorescence signal in CA IX-negative MDCK cells confirmed the selectivity of the inhibitor, which did not bind to other potentially present CA isoforms and indicated that only the hypoxic MDCK-CA IX cells contain the catalytically active CA IX with the enzyme center accessible to inhibitor.</div>
    <heading class="style-scope patent-text">EXAMPLE 6</heading>
    <heading class="style-scope patent-text">Intact CA IX Catalytic Domain is Required for the Extracellular Acidification in Hypoxia</heading>
    <div num="p-0217" class="description-paragraph style-scope patent-text">In addition to the enzyme domain (CA), the extracellular part of CA IX contains an N-terminal proteoglycan-related region (PG) that is absent from the other CAs and seems implicated in cell adhesion [146]. To examine involvement of those CA IX domains in pHe control, the inventors produced deletion variants of CA IX, in which either the PG region (ΔPG) or a large portion of the CA domain (ΔCA) was removed [<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9A</figref>]. Immunofluorescence analysis using two MAbs, namely the PG-specific M75 for ΔCA and CA-specific V/10 for ΔPG, has shown that both deleted proteins were transported to the plasma membrane (data not shown). The mutants were expressed at levels comparable with the wild-type CA IX, as analyzed by immunoblotting of ΔCA and ΔPG proteins under both reducing and non-reducing conditions for their molecular weight and a capacity to form oligomers (data not shown). Interestingly, ΔCA was unable to form oligomers possibly due to the absence of two out of four cysteines (C174 and C336) required for the proper S—S bonding. As judged from the molecular weights, ΔPG mutant appeared to assemble into dimeric and tetrameric complexes, rather then into trimers.</div>
    <div num="p-0218" class="description-paragraph style-scope patent-text">Elimination of a large part of the CA domain perturbed the acidification capacity of CA IX, whereas removal of the PG region had no such effect (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9B</figref>). That differential behavior could be reasonably assigned to the absence versus presence of the catalytic activity of CA IX, because the cells expressing these variants produced similar levels of lactic acid (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9B</figref>). It also indicates that the CA domain is both necessary and sufficient for the enzyme activity, and that the PG and CA portions of CA IX can be functionally separated, although they may still cooperate in response to diverse physiological factors. Based on the knowledge that the extracellular acidosis interferes with the cell adhesion, the enzyme activity carried out by the CA domain might influence the adhesion-related properties of PG region and vice versa. Indeed, CA IX was shown to destabilize E cadherin-mediated intercellular adhesion in transfected MDCK cells, which was particularly dramatic in the hypoxic monolayer [103] in conditions accompanied by CA IX-mediated extracellular acidosis described herein.</div>
    <heading class="style-scope patent-text">EXAMPLE 7</heading>
    <heading class="style-scope patent-text">FITC-Labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 Sulfonamide Binds to and Increases pHe of Hypoxic Tumor Cells</heading>
    <div num="p-0219" class="description-paragraph style-scope patent-text">To see whether the phenomenon of CA IX-mediated acidification is applicable to tumor cells with endogenous CA IX, the effect of FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 sulfonamide [FITC derivative of homosulfanilamide, Compound 5] on the pHe of the cervical carcinoma cells HeLa and SiHa, respectively, was examined. Under hypoxia, tumor cells coordinately express elevated levels of multiple HIF-1 targets, including CA IX [139]. In addition, activity of many components of the hypoxic pathway and related pH control mechanisms, such as ion transport across the plasma membrane, are abnormally increased in order to maintain the neutral intracellular pH [86]. This explains the considerably decreased pHe of the hypoxic versus normoxic HeLa and SiHa cells (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref>). The acidosis was partially reduced by <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 inhibitor, in support of the idea that activation of CA IX is just one of many consequences of hypoxia. Moreover, FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 accumulated in the hypoxic HeLa and SiHa cells that contained elevated levels of CA IX, but not in the normoxic cells with a diminished CA IX expression. [HeLa and SiHa cells plated on coverslips were treated with FITC-labeled <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 sulfonamide during 48 hour incubation in normoxia and hypoxia, washed with PBS and inspected under the fluorescence microscope (data not shown). CA IX expression levels were measured by immunoblotting analysis with M75 MAb.] As indicated by CA IX's ability to bind <figure-callout id="92" label="Compound" filenames="US07833737-20101116-D00001.png,US07833737-20101116-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Compound</a></figure-callout> 92 and mediate its accumulation in hypoxia, CA IX expressed in the hypoxic tumor cells was catalytically active.</div>
    <heading class="style-scope patent-text">EXAMPLE 8</heading>
    <heading class="style-scope patent-text">Expression of ΔCA Mutant in HeLa Cells Reduces pHe Acidification in Hypoxia</heading>
    <div num="p-0220" class="description-paragraph style-scope patent-text">Based on the assumption that the enzyme-dead ΔCA mutant could abolish the function of the endogenous CA IX, the inventors generated HeLa-ΔCA transfectants. As determined by immunofluorescence and immunoblotting analysis (using V/10 MAb to detect endogenous CA IX protein or M75 MAb to visualize both CA IX and ΔCA mutant), the HeLa-ΔCA cells contained ΔCA but not CA IX under normoxia, expressed both proteins under hypoxia, and under non-reducing conditions exhibited an atypical band presumably corresponding to mixed oligomers composed of both CA IX and ΔCA (data not shown). No significant differences in pHe were observed between the normoxic HeLa-mock and HeLa-ΔCA cells. On the other hand, HeLa-ΔCA transfectants treated by hypoxia produced less acidic medium than the control HeLa-mock cells (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11</figref>), suggesting that the inactive ΔCA deletion variant interfered with the activity of the wild-type protein, and further supporting the role of CA IX. Altogether, the data strongly implies that the acidification of the extracellular pH in hypoxic tumor cells does involve CA activity, and that CA IX directly participates in the phenomenon.</div>
    <div num="h-0058" class="description-paragraph style-scope patent-text">Discussion</div>
    <div num="p-0221" class="description-paragraph style-scope patent-text">In the context of the experimental results described herein that place CA IX among the direct contributors to the hypoxic microenvironment, it is tempting to propose possible means of CA IX's action. MN/CA IX is considered to participate in this phenomenon by catalyzing hydration of carbon dioxide to generate bicarbonate ions that are then transported into cell interior and protons that acidify extracellular pH. There are some indications given by the data obtained with the physiologically relevant CA isoforms II and IV that physically interact with anion exchangers (AE) to form a metabolon that facilitates bicarbonate transport in differentiated cells [140, 141]. It seems plausible that CA IX could work as an extracellular component of the similar metabolon in tumor cells. Assembly and/or activation of such metabolon would be especially meaningful in low oxygen conditions, because a highly efficient transport of bicarbonate is required particularly in hypoxic cells for the buffering of intracellular pH and biosynthetic reactions. According to such a model, enhanced conversion of CO<sub class="style-scope patent-text">2 </sub>to bicarbonate by the hypoxia-activated CA IX would be coupled with the increased production of extracellular protons contributing to acidosis. Data obtained as disclosed herein fit well with such a proposal. Further supportive hints come from the studies of von Hippel-Lindau tumor suppressor protein (pVHL), the main negative regulator of HIF-1, which can down-regulate CA IX (obviously as a direct HIF-1 target) and can also reduce the transport activity of AEs [128, 131].</div>
    <div num="p-0222" class="description-paragraph style-scope patent-text">Downstream effects of CA IX can be at least partially anticipated on the basis of the known connections between the acidic pHe and certain features of the tumor phenotype [86, 124, 125, 126, 130, 132]. Moreover, as a part of the hypoxic acidification machinery, CA IX might facilitate a nucleolar sequestration of pVHL and activation of HIF, which is a recently described pH-dependent mechanism proposed to serve a protective role in reoxygenated cells [Mekhail et al., 2004]. In such case, HIF-mediated increase in the level and activity of CA IX resulting in enhanced acidification might create a feedback loop leading to a prolonged HIF activation, which is certainly an attractive possibility requiring experimental proof.</div>
    <div num="p-0223" class="description-paragraph style-scope patent-text">In conclusion, the instant disclosure provides the first direct evidence for the role of CA IX in acidification of the extracellular pH. The findings of the inventors significantly improve the view of CA IX as a molecule, whose levels and catalytic activity are regulated by the oxygen availability, and open new possibilities for its better understanding and clinical exploitation. Inhibition of the MN/CA IX catalytic activity resulting in reduced extracellular acidification may have direct anticancer effects or may modulate efficiency of those conventional chemotherapeutic drugs whose uptake is pH-dependent.</div>
    <heading class="style-scope patent-text">Budapest Treaty Deposits</heading>
    <div num="p-0224" class="description-paragraph style-scope patent-text">The hybridoma VU-M75 was deposited on Sep. 17, 1992 with the American Type Culture Collection (ATCC) now at 10810 University Blvd., Manassus, Va. 20110-2209 (USA) and assigned Accession No. HB 11128. The deposit was made under the provisions of the Budapest Treaty on the International Recognition of Deposited Microorganisms for the Purposes of Patent Procedure and Regulations thereunder (Budapest Treaty). Maintenance of a viable culture is assured for thirty years from the date of deposit. The hybridoma will be made available by the ATCC under the terms of the Budapest Treaty, and subject to an agreement between the Applicants and the ATCC which assures unrestricted availability of the deposited hybridoma to the public upon the granting of a patent from the instant application. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any Government in accordance with its patent laws.</div>
    <div num="p-0225" class="description-paragraph style-scope patent-text">Similarly, the hybridoma cell line V/10-VU which produces the V/10 monoclonal antibodies was deposited on Feb. 19, 2003 under the Budapest Treaty at the International Depository Authority (IDA) of the Belgian Coordinated Collections of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Biologie-Plasmidencollectie (LMBP) at the Universeit Gent, K. L. Ledeganckstraat 35, is B-9000 Gent, Belgium [BCCM/LMBP] under the Accession No. LMBP 6009CB.</div>
    <div num="p-0226" class="description-paragraph style-scope patent-text">The description of the foregoing embodiments of the invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teachings. The embodiments were chosen and described in order to explain the principles of the invention and its practical application to enable thereby others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated.</div>
    <div num="p-0227" class="description-paragraph style-scope patent-text">All references cited herein are hereby incorporated by reference.</div>
    
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(23)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM33534169" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <div class="claim style-scope patent-text"> <div id="CLM-00001" num="00001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A diagnostic/prognostic method for a preneoplastic/neoplastic disease associated with abnormal MN/CA IX expression, comprising determining whether MN/CA IX is activated in a vertebrate sample, comprising:
<div class="claim-text style-scope patent-text">(a) determining whether MN/CA IX is overexpressed in said vertebrate sample, at a level above that for a control sample; and if so,</div>
<div class="claim-text style-scope patent-text">(b) contacting said vertebrate sample with a membrane-impermeant, potent specific inhibitor of activated MN/CA IX, wherein said membrane-impermeant, potent specific inhibitor of activated MN/CA IX is selected from the group consisting of organic heterocyclic sulfonamides and aromatic sulfonamides, and</div>
<div class="claim-text style-scope patent-text">(c) detecting or detecting and quantifying binding of said specific inhibitor of activated MN/CA IX in said vertebrate sample;</div>
<div class="claim-text style-scope patent-text">wherein binding of said inhibitor to MN/CA IX indicates that MN/CA IX is activated;</div>
<div class="claim-text style-scope patent-text">wherein said inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay comprising determining the inhibition constant K<sub class="style-scope patent-text">I</sub>, of said inhibitor, wherein if said inhibition constant K<sub class="style-scope patent-text">I</sub>, is determined to be less than about 50 nanomolar, said inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity;</div>
<div class="claim-text style-scope patent-text">wherein said inhibitor of activated MN/CA IX is determined to be an MN/CA IX-specific inhibitor if said inhibitor is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of at least one of the carbonic anhydrases selected from the group consisting of CA I, CA II and CA IV; and</div>
<div class="claim-text style-scope patent-text">wherein said potent inhibitor of activated MN/CA IX is considered to be membrane-impermeant if it is tested in a membrane permeance assay comprising:</div>
<div class="claim-text style-scope patent-text">(1) incubating a millimolar solution of said potent inhibitor of activated MN/CA IX with human erythrocytes at 37° C. for at least 30 minutes;</div>
<div class="claim-text style-scope patent-text">(2) washing said human erythrocytes;</div>
<div class="claim-text style-scope patent-text">(3) quantitating the levels of said potent inhibitor present in said human erythrocytes; and</div>
<div class="claim-text style-scope patent-text">(4) if said potent inhibitor is present in said human erythrocytes at 1 micromolar or less, then said potent inhibitor is considered to be membrane-impermeant.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00002" num="00002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> wherein said activated MN/CA IX is hypoxia-activated.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00003" num="00003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The method of clam <b class="style-scope patent-text">1</b> wherein said membrane-impermeant, potent specific inhibitor of activated MN/CA IX is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00004" num="00004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> wherein said membrane-impermeant, potent specific sulfonamide inhibitor of activated MN/CA IX is a membrane-impermeant pyridinium derivative of an aromatic sulfonamide or a membrane-impermeant pyridinium derivative of a heterocyclic sulfonamide.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00005" num="00005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> wherein said MN/CA IX-specific sulfonamide is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of at least two of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00006" num="00006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> wherein said MN/CA IX-specific sulfonamide is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of each of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00007" num="00007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The method of <claim-ref idref="CLM-00004" class="style-scope patent-text">claim 4</claim-ref> wherein said MN/CA IX-specific sulfonamide is positively-charged.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00008" num="00008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref> wherein said inhibitor is labeled.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00009" num="00009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. A method for imaging tumors and/or metastases that express activated MN/CA IX in a patient comprising:
<div class="claim-text style-scope patent-text">(a) determining whether MN/CA IX is overexpressed in a sample taken from said tumor or from one of said metastases, at a level above that for a control sample; and if so,</div>
<div class="claim-text style-scope patent-text">(b) administering a membrane-impermeant, potent specific inhibitor of activated MN/CA IX conjugated to a label or imaging agent to said patient, wherein said specific inhibitor of activated MN/CA IX is an organic heterocyclic sulfonamide or aromatic sulfonamide;</div>
<div class="claim-text style-scope patent-text">wherein said specific inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay comprising determining the inhibition constant K<sub class="style-scope patent-text">I</sub>, of said inhibitor, wherein if said inhibition constant K<sub class="style-scope patent-text">I </sub>is determined to be less than about 50 nanomolar, said labeled specific inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity;</div>
<div class="claim-text style-scope patent-text">wherein said inhibitor of activated MN/CA IX is determined to be an MN/CA IX-specific inhibitor if said inhibitor is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of at least one of the carbonic anhydrases selected from the group consisting of CA I, CA II and CA IV;</div>
<div class="claim-text style-scope patent-text">and wherein said potent specific inhibitor of activated MN/CA IX is considered to be membrane-impermeant if it is tested in a membrane permeance assay comprising:</div>
<div class="claim-text style-scope patent-text">(1) incubating a millimolar solution of said potent MN/CA IX-specific inhibitor with human erythrocytes at 37° C. for at least 30 minutes;</div>
<div class="claim-text style-scope patent-text">(2) washing said human erythrocytes;</div>
<div class="claim-text style-scope patent-text">(3) quantitating the levels of said potent MN/CA IX-specific inhibitor present in said human erythrocytes; and</div>
<div class="claim-text style-scope patent-text">(4) if said potent MN/CA IX-specific inhibitor is present in said human erythrocytes at 1 micromolar or less, then said potent inhibitor is considered to be membrane-impermeant.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00010" num="00010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref>, wherein said imaging agent comprises a radioactive isotope.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00011" num="00011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The method of <claim-ref idref="CLM-00010" class="style-scope patent-text">claim 10</claim-ref>, wherein said inhibitor conjugated to said radioactive imaging agent is used in vivo to locate metastases by scintigraphy.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00012" num="00012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref> wherein said membrane-impermeant, potent specific sulfonamide inhibitor of activated MN/CA IX is a membrane-impermeant pyridinium derivative of an aromatic sulfonamide or a membrane-impermeant pyridinium derivative of a heterocyclic sulfonamide.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00013" num="00013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The method of <claim-ref idref="CLM-00012" class="style-scope patent-text">claim 12</claim-ref>, wherein said membrane-impermeant pyridinium derivative of an aromatic sulfonamide is Compound 39.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00014" num="00014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. A diagnostic/prognostic method for a preneoplastic/neoplastic disease associated with abnormal MN/CA IX expression, comprising determining whether MN/CA IX is activated in a vertebrate sample, comprising:
<div class="claim-text style-scope patent-text">(a) determining whether MN/CA IX is overexpressed in said vertebrate sample, at a level above that for a control sample; and if so,</div>
<div class="claim-text style-scope patent-text">(b) contacting said vertebrate sample with a membrane-permeant, potent specific inhibitor of activated MN/CA IX, wherein said membrane-permeant, potent specific inhibitor of activated MN/CA IX is selected from the group consisting of organic heterocyclic sulfonamides and aromatic sulfonamides, and</div>
<div class="claim-text style-scope patent-text">(c) detecting or detecting and quantifying binding of said specific inhibitor of activated MN/CA IX in said vertebrate sample;</div>
<div class="claim-text style-scope patent-text">wherein binding of said inhibitor to MN/CA IX indicates that MN/CA IX is activated;</div>
<div class="claim-text style-scope patent-text">wherein said inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity in a screening assay comprising determining the inhibition constant K<sub class="style-scope patent-text">I</sub>, of said inhibitor, wherein if said inhibition constant K<sub class="style-scope patent-text">I </sub>is determined to be less than about 50 nanomolar, said inhibitor of activated MN/CA IX is determined to be a potent inhibitor of MN/CA IX enzymatic activity;</div>
<div class="claim-text style-scope patent-text">wherein said membrane-permeant, potent specific sulfonamide inhibitor of activated MN/CA IX is determined to be an MN/CA IX-specific inhibitor if said inhibitor is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of CA II;</div>
<div class="claim-text style-scope patent-text">and wherein said potent inhibitor of activated MN/CA IX is considered to be membrane-permeant if it is tested in a membrane permeance assay comprising:</div>
<div class="claim-text style-scope patent-text">(1) incubating a millimolar solution of said potent inhibitor of activated MN/CA IX with human erythrocytes at 37° C. for at least 30 minutes;</div>
<div class="claim-text style-scope patent-text">(2) washing said human erythrocytes;</div>
<div class="claim-text style-scope patent-text">(3) quantitating the levels of said potent inhibitor present in said human erythrocytes; and</div>
<div class="claim-text style-scope patent-text">(4) if said potent inhibitor is present in said human erythrocytes at more than 1 micromolar, then said potent inhibitor is considered to be membrane-permeant.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00015" num="00015" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref> wherein said activated MN/CA IX is hypoxia-activated.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00016" num="00016" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref> further wherein said MN/CA IX-specific sulfonamide is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of at least one of the carbonic anhydrases in the group consisting of CA I and CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00017" num="00017" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref> wherein said MN/CA IX-specific sulfonamide is a more potent inhibitor of MN/CA IX enzymatic activity than of the enzymatic activity of each of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00018" num="00018" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref> wherein said inhibitor is labeled.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00019" num="00019" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. The method of <claim-ref idref="CLM-00018" class="style-scope patent-text">claim 18</claim-ref> wherein said inhibitor is labeled with fluorescein isothiocyanate.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00020" num="00020" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. The method of <claim-ref idref="CLM-00008" class="style-scope patent-text">claim 8</claim-ref> wherein said inhibitor is labeled with fluorescein isothiocyanate.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00021" num="00021" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref> wherein said membrane-impermeant, potent specific inhibitor of activated MN/CA IX conjugated to a label or imaging agent is a more potent inhibitor of the enzymatic activity of MN/CA IX than of CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00022" num="00022" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref> wherein said membrane-impermeant, potent specific inhibitor of activated MN/CA IX conjugated to a label or imaging agent is a more potent inhibitor of the enzymatic activity of MN/CA IX than of the enzymatic activity of at least two of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00023" num="00023" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref> wherein said membrane-impermeant, potent specific inhibitor of activated MN/CA IX conjugated to a label or imaging agent is a more potent inhibitor of the enzymatic activity of MN/CA IX than of the enzymatic activity of each of the carbonic anhydrases in the group consisting of CA I, CA II and CA IV.</div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (7)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5610304A/en"><a id="link" href="#" class="style-scope state-modifier">US5610304A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-08-20</span>
                    <span class="td style-scope patent-result">1997-03-11</span>
                    <span class="td style-scope patent-result">Eisai Co., Ltd.</span>
                    <span class="td style-scope patent-result">Pyrimidinyl or pyridinyl sulfonamide substituted compounds 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6034099A/en"><a id="link" href="#" class="style-scope state-modifier">US6034099A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-11-24</span>
                    <span class="td style-scope patent-result">2000-03-07</span>
                    <span class="td style-scope patent-result">Cell Pathways, Inc.</span>
                    <span class="td style-scope patent-result">Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6284923B1/en"><a id="link" href="#" class="style-scope state-modifier">US6284923B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-08-22</span>
                    <span class="td style-scope patent-result">2001-09-04</span>
                    <span class="td style-scope patent-result">Tularik Inc</span>
                    <span class="td style-scope patent-result">Substituted benzene compounds as antiproliferative and cholesterol lowering action 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6027887A/en"><a id="link" href="#" class="style-scope state-modifier">US6027887A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2000-02-22</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Solvak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL121041A0/en"><a id="link" href="#" class="style-scope state-modifier">IL121041A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-06-09</span>
                    <span class="td style-scope patent-result">1997-11-20</span>
                    <span class="td style-scope patent-result">Yeda Res &amp; Dev</span>
                    <span class="td style-scope patent-result">Immunogenic compositions for induction of anti-tumor immunity 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2005538682A/en"><a id="link" href="#" class="style-scope state-modifier">JP2005538682A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-03</span>
                    <span class="td style-scope patent-result">2005-12-22</span>
                    <span class="td style-scope patent-result">アブジェニックス・インコーポレーテッド</span>
                    <span class="td style-scope patent-result">
  Antibody against carboxic anhydrase IX (CAIX) tumor antigen
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2496572A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2496572A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-08-23</span>
                    <span class="td style-scope patent-result">2004-03-04</span>
                    <span class="td style-scope patent-result">Chiron Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (76)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Alterio et al., "Carbonic Anhydrase Inhibitors: X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX," J. Am. Chem. Soc., 128: 8329-8335 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Casey et al., "Carbonic Anhydrase Inhibitors. Design of Selective, Membrane-Impermeant Inhibitors Targeting the Human Tumor-Associated Isozyme IX," J. Med Chem., 47: 2337-2347 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Casini et al., "Carbonic Anhydrase Inhibitors: Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects," J. Med. Chem., 43: 4884-4892 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cecchi et al., "Carbonic Anhydrase Inhibitors. Design of Fluorescent Sulfonamides as Probes of Tumor-Associated Carbonic Anhydrase IX That Inhibit Isozyme IX-Mediated Acidification of Hypoxic Tumors," J. Med. Chem., 48: 4834-4841 (2005).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chegwidden et al., "The Roles of Carbonic Anhydrase Isozymes in Cancer," Gene Families: Studies of DNA, RNA, Enzymes and Proteins, Proceedings of the International Isozymes, 10th, Beijing, China, Oct. 5-10, 1999, Meeting Date 1999, 157-169 (Xue, G. ed.: World Scientific Pub. Co.: 2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Clare and Supuran, "Carbonic anhydrase inhibitors. Part 61. Quantum Chemical QSAR of a group of benzenedisulfonamides," Eur. J. Med. Chem., 34: 463-474 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cuthbert et al., "Bicarbonate-dependent chloride secretion in Calu-3 epithelia in response to 7,8-benzoquinoline," J Physiol., 551(Pt 1): 79-92 (Aug. 15, 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dorwald F. A. (Side reactions in organic synthesis, 2005, Wiley, VCH, Weinheim, p. IX of Preface).
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fischer et al., "Acidic pH Inhibits Non-MHC-Restricted Killer Cell Functions," Clin. Immunol., 96(3): 252-263 (Sep. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Franchi et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Lipophillic Sulfonamides," Journal of Enzyme Inhibition and Medicinal Chemistry, 18(4): 333-338 (Aug. 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Fukumura et al., "Hypoxia and Acidosis Independently Up-Regulate Vascular Endothelial Growth Factor Transcription in Brain Tumors in Vivo," Cancer Research, 61: 6020-6024 (Aug. 15, 2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Garaj et al., "Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties," Bioorganic &amp; Medicinal Chemistry Letters, 14: 5427-5433 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gerweck, L.E., "Tumor pH: Implications for Treatment and Novel Drug Design," Seminars in Radiation Oncology, 8(3): 176-182 (Jul. 1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gruneberg et al., "Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation," J. Med. Chem., 45(17): 3588-3602 (Abstract) (Aug. 15, 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Helmlinger et al., "Acid Production in Glycolysis-impaired Tumors Provides New Insights into Tumor Metabolism," Clinical Cancer Research, 8: 1284-1291 (Apr. 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hies et al., "Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide Derivatives," J. Med. Chem., 46: 2187-2196 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Ivanov et al., "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes," PNAS (USA) 95: 12596-12601 (Oct. 1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kaluz et al., "Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hyposia-inducible Factor lalpha Stabilization: A Role for Phosphatidylinositol 3′Kinase," Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kaluz et al., "Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hyposia-inducible Factor lalpha Stabilization: A Role for Phosphatidylinositol 3'Kinase," Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Karumanchi et al., "VHL tumor supressor regulates Cl-/HC03- exchange and Na+/H+ exchange activities in renal carcinoma cells," Physiol. Genomics, 5: 119-128 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Karumanchi et al., "VHL tumor supressor regulates Cl−/HC03− exchange and Na+/H+ exchange activities in renal carcinoma cells," Physiol. Genomics, 5: 119-128 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Kato et al., "Induction of 103-kDa Gelatinase/Type IV Collagenase by Acidic Culture Conditions in Mouse Metastatic Melanoma Cell Lines," J. Biol. Chem., 267(16): 11424-11430 (Jun. 5, 1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Liu et al. "BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities," Nucleic Acids Research, 00 (Database Issue): D1-D4 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Matinez-Zaguilan et al., Acidic pH enhances the invasive behavior of human melanoma cells, Clin. Exp. Metastasis, 14: 176-186 (1996).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Medina et al., "Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells," Bioorg Med Chem Lett., 9(13): 1843-1846 (Jul. 5, 1999) Abstract.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Mekhall et al., "HIF activation of pH-dependent nucleolar sequestration of VHL," Nature Cell Biology, 6(7): 642-647 (Jul. 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Newell et al., "Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity," PNAS  (USA), 90: 1127-1131 (Feb. 1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Newell et al., "Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity," PNAS (USA), 90: 1127-1131 (Feb. 1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein witha domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," Oncogene, 9: 2877-2888 (1994).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pastorekova et al., "Carbonic anhydrase Inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX," Bioorganic &amp; Medicinal Chemistry Letters, 14: 869-873 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Potter and Harris, "Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer," Br. J. Cancer, 89(1): 2-7 (Jul. 7, 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Potter and Harris, "Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumor Hypoxia, Survival Pathway and Therapy Target," Cell Cycle, 3(2): 164-167 (Feb. 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Raghunand and Gillies, "pH and chemotherapy," Noyartis Foundation Symposium, 240: 199-211 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Robertson et al., "Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion," Cancer Research, 64(17): 6160-6165 (Sep. 1, 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Scozzafava and Supuran, "Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholylthiocarbonylsulfenylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II and IV,"Bioorganic &amp; Medicinal Chemistry Letters, 10: 1117-1120 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Scozzafava et al., "Carbonic anhydrase inhibitors and activators and their use in therapy," Expert Opin. Ther. Pat., 16(12): 1627-1664 (2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Scozzafava et al., "Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties: Is the Tail More Important than the Ring?" J. Med. Chem., 42: 2641-2650 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Scozzafava et al., "Carbonic Anhydrase Inhibitors: Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes," J. Med. Chem., 292-300 (Jan. 27, 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sterling et al., "A Transport Metabolon," J. Biol. Chem., 276(51): 47886-47894 (Dec. 21, 2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sterling et al., "The Extracellular Component of a Transport Metabolon," J. Biol. Chem., 277(28): 25239-25246 (Jul. 12, 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sterling et al., "The functional anti physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II," Am. J. Physiol. Cell Phsiol., 283(5): C1522-C1529 (Nov. 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Stubbs et al., "Causes and consequences of tumour acidity and implications for treatment," Mol. Med. Today, 6: 15-19 (Jan. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Clare, "Carbonic anhydrase inhibitors. Part 24. A quantitative structure-activity relationship study of positively charged sulfonamide inhibitors," Eur. J. Med. Chem., 30: 687-696 (1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Clare, "Carbonic anhydrase inhibitors-Part 57: Quantum chemical QSAR of a group of 1,3,4-thladizole- and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties," Eur. J. Med. Chem., 34: 41-50 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Clare, "Carbonic anhydrase inhibitors—Part 57: Quantum chemical QSAR of a group of 1,3,4-thladizole- and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties," Eur. J. Med. Chem., 34: 41-50 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Scozzafava, "Benzolamide is not a Membrane-impermeant Carbonic Anhydrase Inhibitor,"Journal of Enzyme Inhibition and Medicinal Chemistry, 19(3): 269-273 (Jun. 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Scozzafava, "Carbonic Anhydrase Inhibitors: Aromatic Sulfonamides and Disulfonamides Act as Efficient Tumor Growth Inhibitors," J. Enzyme Inhib., 15(6): 597-610 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Scozzafava, "Carbonic anhydrase inhibitors-Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?," Eur. J. Med. Chem., 35(9):867-874 (Sep. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran and Scozzafava, "Carbonic anhydrase inhibitors—Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?," Eur. J. Med. Chem., 35(9):867-874 (Sep. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic Anhydrase Inhibitors," Medicinal Research Reviews, 23(2): 146-189 (Mar. 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents?," Bioorganic &amp; Medicinal Chemistry, 9(3): 703-714 (Mar. 2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors-Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives," Eur. J. Med. Chem., 33: 739-751 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors—Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives," Eur. J. Med. Chem., 33: 739-751 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors-Part 49**: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I," Eur. J. Med. Chem., 33: 83-93 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors—Part 49**: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I," Eur. J. Med. Chem., 33: 83-93 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors-Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV," Eur. J. Med. Chem., 33: 577-594 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic anhydrase inhibitors—Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV," Eur. J. Med. Chem., 33: 577-594 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran et al., "Carbonic Anhydrase: Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and In Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes," J. Enzyme Inhibition, 15(4): 381-401 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran, Casini and Scozzafava, "Development of Sulfonamide Carbonic Anhydrase Inhibitors," "Selective Inhibitors for Membrane-Associated CAs," Carbonic Anhydrase-Its Inhibitors and Activators, Supuran, C.T., Scozzafava, A., Conway, J.; Eds., CRC Press, Boca Raton (FL), USA (2004); pp. 121-124.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Supuran, Casini and Scozzafava, "Development of Sulfonamide Carbonic Anhydrase Inhibitors," "Selective Inhibitors for Membrane-Associated CAs," Carbonic Anhydrase—Its Inhibitors and Activators, Supuran, C.T., Scozzafava, A., Conway, J.; Eds., CRC Press, Boca Raton (FL), USA (2004); pp. 121-124.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Svastova et al., "Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular p11," FEBS Letters, 577(3): 439-445 (Nov. 19, 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tanaka et al., "In situ detection of activated caspase-3 in apoptotic granule neurons in the developing cerebellum in slice cultures and in vivo," Developmental Brain Research, 121(2): 223-228 (2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Taylor et al., "Ligand discovery and virtual screening using the program LIDAEUS," British Journal of Pharmacology, 153: S55-S67 (2008).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Teicher et al., "A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies," Anticancer Research, 13: 1549-1556 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vullo et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Anions," Journal of Enzyme Inhibition and Medicinal Chemistry, 18(5): 403-406 (Oct. 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vullo et al., "Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides," Bioorganic Medicinal Chemistry Letters, 13(6): 1005-1009 (Mar. 24, 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wingo et al., "The Catalytic Properties of Human Carbonic Anhydrase IX," Biochemical and Biophysical Research Communications, 288: 666-669 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Winnum et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors," J. Med. Chem. , 46(11): 2197-2204 (May 22, 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Winum et al., "Carbonic Anhydrase IX: A New Druggable Target for the Design of Antitumor Agents," Medicinal Research Reviews, 28(3): 445-463 (2008).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase-From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase—From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Workman and Stratford, "The experimental development of bioreductive drugs and their role in cancer therapy," Cancer and Matastasis Reviews, 12: 73-82 (1993).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Ciliary Epithelium, J. Membrane Biol., 162: 31-38 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wykoff et al., "Hypoxia-inducible Expression of Tumor-associated Carbonic Anhydrases," Cancer Research, 60: 7075-7083 (Dec. 15, 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Yamagata et al., "The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase," British Journal of Cancer, 77(11): 1726-1731 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Zatovicova et al., "Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX," Journal of Immunological Methods, 282: 117-134 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (16)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102702057A/en"><a id="link" href="#" class="style-scope state-modifier">CN102702057A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-06-15</span>
                    <span class="td style-scope patent-result">2012-10-03</span>
                    <span class="td style-scope patent-result">华东理工大学</span>
                    <span class="td style-scope patent-result">Sulfonamide compound and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012154885A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2012154885A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-05-09</span>
                    <span class="td style-scope patent-result">2012-11-15</span>
                    <span class="td style-scope patent-result">Visen Medical, Inc.</span>
                    <span class="td style-scope patent-result">Carbonic anhydrase targeting agents and methods of using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20130190396A1/en"><a id="link" href="#" class="style-scope state-modifier">US20130190396A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-07-09</span>
                    <span class="td style-scope patent-result">2013-07-25</span>
                    <span class="td style-scope patent-result">Metasignal Therapeutics Inc.</span>
                    <span class="td style-scope patent-result">Novel sulfonamide compounds for inhibition of metastatic tumor growth 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013148319A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013148319A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-03-30</span>
                    <span class="td style-scope patent-result">2013-10-03</span>
                    <span class="td style-scope patent-result">Visen Medical, Inc.</span>
                    <span class="td style-scope patent-result">Bacterial imaging agents and methods of using same 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090162382A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090162382A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2009-06-25</span>
                    <span class="td style-scope patent-result">Bernett Matthew J</span>
                    <span class="td style-scope patent-result">Optimized ca9 antibodies and methods of using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080124274A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080124274A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-06-07</span>
                    <span class="td style-scope patent-result">2008-05-29</span>
                    <span class="td style-scope patent-result">James Edward Summerton</span>
                    <span class="td style-scope patent-result">Compositions and methods for detecting and treating tumors containing acidic areas 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BRPI0906797A2/en"><a id="link" href="#" class="style-scope state-modifier">BRPI0906797A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-01-09</span>
                    <span class="td style-scope patent-result">2015-07-14</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharm Inc</span>
                    <span class="td style-scope patent-result">
  Ix carbonic anhydrase inhibitors
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2539565C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2539565C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-05</span>
                    <span class="td style-scope patent-result">2015-01-20</span>
                    <span class="td style-scope patent-result">Моликьюлар Инсайт Фармасьютикалз, Инк.</span>
                    <span class="td style-scope patent-result">Ca-ix specific radiopharmaceutical agents for treating and imaging malignant tumours 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2706057B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2706057B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-05</span>
                    <span class="td style-scope patent-result">2016-04-20</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Bis(imidazolyl)compounds and radionuclide complexes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010065906A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2010065906A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-12-05</span>
                    <span class="td style-scope patent-result">2010-06-10</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112012000209B8/en"><a id="link" href="#" class="style-scope state-modifier">BR112012000209B8</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-06-15</span>
                    <span class="td style-scope patent-result">2021-07-27</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharm Inc</span>
                    <span class="td style-scope patent-result">
  glutamic acid heterodimers and their preparation processes
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2800471A4/en"><a id="link" href="#" class="style-scope state-modifier">EP2800471A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-06</span>
                    <span class="td style-scope patent-result">2015-11-04</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharm Inc</span>
                    <span class="td style-scope patent-result">Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2998307A1/en"><a id="link" href="#" class="style-scope state-modifier">FR2998307A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-19</span>
                    <span class="td style-scope patent-result">2014-05-23</span>
                    <span class="td style-scope patent-result">Centre Nat Rech Scient</span>
                    <span class="td style-scope patent-result">
  CHEMICAL MODEL OF NEURODEGENERATIVE DISEASE, PREPARATION METHOD AND USES
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HUE035739T2/en"><a id="link" href="#" class="style-scope state-modifier">HUE035739T2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-01-14</span>
                    <span class="td style-scope patent-result">2018-05-28</span>
                    <span class="td style-scope patent-result">Molecular Insight Pharm Inc</span>
                    <span class="td style-scope patent-result">Triazine based radiopharmaceuticals and radioimaging agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3424537B1/en"><a id="link" href="#" class="style-scope state-modifier">EP3424537B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-02-03</span>
                    <span class="td style-scope patent-result">2021-01-13</span>
                    <span class="td style-scope patent-result">Eidgenössiche Technische Hochschule Zürich</span>
                    <span class="td style-scope patent-result">Small molecule drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP7285537B2/en"><a id="link" href="#" class="style-scope state-modifier">JP7285537B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-16</span>
                    <span class="td style-scope patent-result">2023-06-02</span>
                    <span class="td style-scope patent-result">オン ターゲット ラボラトリーズ エルエルシー</span>
                    <span class="td style-scope patent-result">
  CA IX Targeted NIR Dyes and Their Use
 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier">US7833737B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-16</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7829065B2/en"><a id="link" href="#" class="style-scope state-modifier">US7829065B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-09</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/18161516227229668881"><a id="link" href="#" class="style-scope state-modifier">Puccetti et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005</span>
                    <span class="td style-scope patent-result">Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff’s bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080138291A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080138291A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-06-12</span>
                    <span class="td style-scope patent-result">Sulfonamide Derivatives Having Carbonic Anhydrase Inhibiting Activity and their Use as Therapeutic and Diagnostic Agents 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/1449593366684631951"><a id="link" href="#" class="style-scope state-modifier">Garaj et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004</span>
                    <span class="td style-scope patent-result">Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1, 2, 4-triazine moieties</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/13849468930266444184"><a id="link" href="#" class="style-scope state-modifier">Linkuvienė et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016</span>
                    <span class="td style-scope patent-result">Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080038251A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080038251A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-02-14</span>
                    <span class="td style-scope patent-result">MN/CA IX and MAPK inhibition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2012211499B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2012211499B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-07-24</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2010200368B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2010200368B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-05-10</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20100056611A1/en"><a id="link" href="#" class="style-scope state-modifier">US20100056611A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-03-04</span>
                    <span class="td style-scope patent-result">MN/CA9 Splice Variants 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/3091263399447824585"><a id="link" href="#" class="style-scope state-modifier">Hoang</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007</span>
                    <span class="td style-scope patent-result">c12) United States Patent</span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            
            <h3 id="parentApplications" class="scroll-target style-scope patent-result">
              Parent Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Relation</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7833734B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/222,986</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2002-11-26</span>
                    <span class="td nowrap style-scope patent-result">2005-09-08</span>
                    <span class="td nowrap style-scope patent-result">
                        Continuation<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="applicationPriorityApps" class="scroll-target style-scope patent-result">
              Priority Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/929,536</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2002-11-26</span>
                    <span class="td nowrap style-scope patent-result">2007-10-30</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        CA IX-specific inhibitors 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (7)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US42908902P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2002-11-26</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US48947303P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-07-22</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US51510403P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-10-28</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7550424B2/en"><a id="link" href="#" class="style-scope state-modifier">US10/723,795</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-11-26</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US60910304P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7833734B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/222,986</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-09-08</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7833737B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/929,536</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2007-10-30</span>
                    <span class="td style-scope patent-result">CA IX-specific inhibitors 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2009-11-01</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2013-12-02</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES,</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: NUNC PRO TUNC ASSIGNMENT;ASSIGNORS:PASTOREK, JAROMIR, DR.;PASTOREKOVA, SILVIA, DR.;REEL/FRAME:031696/0302</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20131128</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2014-05-16</span>
                    <span class="td nowrap style-scope patent-result">FPAY</span>
                    <span class="td nowrap style-scope patent-result">Fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 4</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-07-02</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-12-24</span>
                    <span class="td nowrap style-scope patent-result">LAPS</span>
                    <span class="td nowrap style-scope patent-result">Lapse for failure to pay maintenance fees</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-12-24</span>
                    <span class="td nowrap style-scope patent-result">STCH</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent discontinuation</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-01-15</span>
                    <span class="td nowrap style-scope patent-result">FP</span>
                    <span class="td nowrap style-scope patent-result">Lapsed due to failure to pay maintenance fee</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20181116</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2010775166" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2010775166" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=404641551" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>